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Abstract 
Background: Data on the burden of severe Staphylococcus aureus disease, a significant 
cause of invasive bacterial infections among children aged <5 years in The Gambia and Africa 
at large, are lacking. The work in this thesis estimates the burden (cases and deaths) of 
severe S. aureus disease in Africa, the incidence of S. aureus bacteraemia (SAB) in children 
aged <5 years and assesses the risk factors for neonatal S. aureus acquisition in rural Gambia.  
Methods: This thesis includes three separate studies. First, following a systematic literature 
review and meta-analysis, raw and processed data were synthesised to estimate the 
numbers of cases and deaths due to severe S. aureus diseases in children aged <5 years in 
Africa. Second, the incidence and case fatality ratio (CFR) of SAB in <5 years Gambian 
children were estimated from a population-based study. Lastly, a longitudinal study of 
newborn-contact pairs was used to evaluate the risk factors associated with neonatal S. 
aureus carriage at birth as well as with its acquisition at one-week of age. 
Results: In Africa, an estimated 392,066 cases and 46,467 deaths due to severe S. aureus 
disease occurred among children aged <5 years with 20.4% and 58.4% of these occurring 
among neonates, respectively in 2015. The incidence of SAB among Gambian children aged 
<5 years and neonates was 78/100,000 person-years (95%CI 67–91) and 3.5/1,000 live-
births (95%CI 2.9–4.7), respectively. The CFR was 14.1% (95%CI 9.6-19.8). S. aureus 
carriage at birth was associated with the midwife’s report of handwashing before delivery 
while carriage acquisition one week after delivery was associated with maternal and 
household child nasal carriage.  
Conclusion: The burden of severe S. aureus disease among children aged <5 years in Africa 
is substantial. Developing new, and implementing existing, strategies urgently to tackle this 
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Chapter 1: Introduction 
1.1 Overview of Staphylococcus aureus disease in children  
In 2018, 5.3 million and 2.5 million childhood and neonatal deaths occurred worldwide, 
respectively.1 In the last three decades, there has been a substantial reduction (59%) in 
under-five mortality globally.1 The decline is likely attributable to several interventions 
including exclusive breastfeeding, adequate nutrition, prevention and case management of 
diarrhoea and pneumonia, immunisation and malaria control. Despite the gains, there are 
geographic variations with sub-Saharan Africa and South Asia accounting for about 80% of 
these deaths in 2018.1 
Neonatal mortality rates have declined at a slower pace compared to the overall under-5 
mortality (the neonatal period is defined as the first 28 days of life). As a result, neonatal 
mortality now accounts for two-thirds of deaths in children under one year of age and nearly 
47% of all deaths in children under five years of age.1 Furthermore, the United Nations has 
projected that neonatal mortality rates would continue to increase as a proportion of under-
five deaths over the next ten years1 unless mitigation actions are taken urgently. To meet 
the third Sustainable Development Goal (SDG 3.2), additional interventions are required to 
reduce neonatal and under-5 mortality in Africa, and reliable estimates of cause-specific 
childhood disease burden will be necessary to guide policy. 
Globally, preventable infections are responsible for a third of childhood deaths,2 and all-
cause invasive infections such as pneumonia, meningitis, and sepsis account for 23% of 
neonatal deaths.1,3,4 Neonatal infections are the second leading cause of deaths (after 
pneumonia) among children aged less than five years.3 More neonates die from infections 
than from all childhood deaths from HIV and malaria infections combined.1,3 In sub-Saharan 
Africa (sSA), preventable infections are responsible for about 40% of these childhood 
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deaths.2 Available evidence suggest that in sSA deaths from invasive bacterial infections 
(IBI) (n=500,000) outnumber malaria deaths (n=250,000) among children less than five 
years of age.5 
Until recently, the main bacteria implicated in childhood IBI were Streptococcus pneumoniae 
and Haemophilus influenzae.6-8 However, following the widespread use of conjugate vaccines 
against H. influenzae type b (Hib) and S. pneumoniae in children, the disease burden due to 
Hib has decreased considerably,9,10 and that due to vaccine-serotype S. pneumoniae is 
declining.11-13 The decrease in the incidence of diseases due to these pathogens has led to 
Staphylococcus aureus becoming a relatively more important cause of IBI among children 
aged less than five years.14 
Staphylococcal disease can present in a wide variety of ways ranging from local infections 
of the superficial skin and soft tissues (SSTI) and pyomyositis to toxin-mediated diseases 
such as scalded skin syndrome and food poisoning to systemic and more life-threatening 
diseases like septicaemia, endocarditis, meningitis, brain abscess and toxic-shock syndrome 
(TSS). Worldwide, hospital-based reports rank S. aureus among the top two leading Gram-
positive bacteria causing neonatal sepsis14-19 and a leading cause of IBI in older children.20-
23 
S. aureus carriage, a significant risk factor for S. aureus disease, is highly prevalent in the 
early neonatal period.24,25 Thus, knowledge of the risk factors for S. aureus carriage 
acquisition in newborns is essential in finding ways to reduce the incidence of neonatal S. 
aureus bacteraemia (SAB). However, there is a scarcity of up-to-date population-level data 
on SAB and no data on country-specific estimates of disease burden (number of cases and 
deaths) due to S. aureus diseases in sub-Saharan Africa. Population-level data are important 
because they are representative, demonstrate true disease burden and are less subject to 
bias than hospital-based data. Such data help to inform decision-making, allocation of funds 
and planning processes in the healthcare sector of a nation. It is therefore essential to 
describe the population-based burden of the disease, and associated risk factors in children 
aged less than five years, to inform further research and the design of interventions required 
to reduce childhood and neonatal morbidity and mortality due to S. aureus disease.  
 
1.1.1 The global incidence of S. aureus disease in children 
The global burden of S. aureus disease in children is unknown. Regional variations in 
incidence exist due to differences in the populations studied and unavailability of routinely 
collected high-quality data in most low- and middle-income countries (LMIC). 
 
High-income countries 
Most population-based and hospital-based studies on S. aureus disease burden have been 
conducted in high-income countries (HIC).26-29 These studies reported an increase in the 
incidence of S. aureus disease from 1971 to 2007.26-28 A population-based study in Denmark 
among subjects aged 0 - 20 years reported an increase in the incidence of SAB from 4.6 cases 
annually per 100,000 population in the period 1971 - 1975 to 8.4 cases per 100,000 
population in the period 1996 – 2000 with the highest rates among infants.26 Similarly, a 
hospital-based study in Spain among children aged 0 - 16 years reported an increase in the 
incidence of SAB from 1.3 cases per 1,000 admissions in the period 1995 – 1999 to 3.7 cases 
per 1,000 admissions in the period 2006 – 2008 with the highest rates seen among 
neonates.27 Both studies linked the rise with an increase in the use of central venous 
catheters, increased survival rates of premature and low birth weight infants, children with 
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metabolic disorders, immunodeficiencies and haematological diseases.26,27 The majority of 
cases are nosocomial infections. Since 2008, the incidence of SAB has remained stable in 
Denmark30 or decreased in Spain.27 The decline in Spain is attributable to improved infection 
prevention and control measures.  
In HIC, S. aureus was the third most common cause of neonatal sepsis after group B 
streptococcus and Escherichia coli16,31 and a leading cause of IBI in older children.20-22 In the 
UK, Ladhani and colleagues,31 in a prospective national surveillance study of IBI in infants, 
reported an increase in the incidence from 412 per 100,000 population in 2010 - 2011 to 
552 per 100,000 population in 2016 - 2017 with the highest rates seen in the first week of 
life. S. aureus was the third most common cause of IBI in infants (responsible for 10.8% of 
isolates recovered) after E. coli and group B streptococcus. Although, this study was unable 
to differentiate between community-acquired and hospital-acquired infections or between 
early-onset or late-onset neonatal infections due to lack of access to clinical data, S. aureus 
remained a significant cause of childhood IBI.  
In the USA, hospital-based reports of S. aureus disease among children aged less than 18 
years showed a significant increase in incidence between 2002 and 2007 from 20.8 to 35.8 
annual cases per 1,000 admissions.28 The investigators attributed the increase to a surge in 
the frequency of methicillin-resistant S. aureus (MRSA) disease,28 although an increase in the 
burden of SSTI and other chronic complex conditions could have contributed to the rise.  
Data on infective endocarditis are rare in children, and population-based incidence data are 
even more limited. Retrospective hospital-based studies reported an incidence of 0.05 – 0.78 
per 1,000 paediatric admissions over eight decades with no definite trends.32-34 
Traditionally, Streptococcus viridians was the dominant pathogen recovered from children 
with endocarditis. However, current data suggest that S. aureus is now the leading pathogen 
(32.0% - 51.6% of isolates recovered),35 and this is attributable to the increasing use of 
vascular catheters and prosthetic materials.35  
The incidence of paediatric osteomyelitis ranges between 1.9 and 24.0 cases per 100,000 
person-years36-39 and S. aureus was responsible for 72% of cases.39 In the USA, there was an 
increase in the incidence of SSTI up until 2008 as a result of an epidemic of community-
associated methicillin-resistant S. aureus (CA-MRSA) strains.40  More recently, the incidence 
of SSTI has declined, but the proportion caused by S. aureus remains largely unchanged.40,41  
 
Low- and middle-income countries 
S. aureus disease is also a common cause of IBI in children in low- and middle-income 
countries (LMIC). Two recent reviews of the bacterial causes of neonatal sepsis  - one in 157 
LMIC and another in 26 sub-Saharan African (sSA) countries found that S. aureus was the 
most commonly isolated bacterium.14,19 In Asia, available data from both population-based 
and hospital-based studies indicate that S. aureus is the leading cause of IBI in neonates42,43 
and children aged less than 15 years.44 Unlike in the HIC, these are community-acquired 
infections.  
There are relatively few population-based data on the incidence of SAB in sSA. Available 
studies report an incidence of SAB ranging from 27 to 118 per 100,000 person-years in 
children aged less than five years between 1998 and 2010.6,45,46 This variation may be 
related to the prevalence of HIV in the communities. Similar to the observations in the HIC, 
the highest rates are seen among neonates. Population-based data from Kenya and 
Mozambique showed that S. aureus was the third and first most common Gram-positive 
bacteria among neonates with sepsis, respectively.6,45 Among children aged less than five 
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years, S. aureus ranked the fifth and third most common, respectively. The most common 
causes being S. pneumoniae, non-typhoidal salmonella species, H. influenzae, and E. coli. 
Hospital-based studies show that S. aureus is the principal cause of neonatal sepsis19,47-49 and 
the second leading cause in children aged less than five years in both Nigeria and Ghana 
(after Salmonella spp).50,51  
Data on the aetiology of pneumonia in children in Africa are also limited. Among the cases 
of bacteraemic pneumonia, determined by isolating a bacterial pathogen from blood, in 
children aged less than five years, the prevalence of  S. aureus ranged between 0.8% to 
34.0%.52-54 In contrast, that of non-bacteraemic pneumonia (established by isolation of the 
pathogen from the lung parenchyma) was 2.0% – 45.2%.54-56 In a multi-centre study in Africa 
and Asia, S. aureus was the third most prevalent bacterial cause of pneumonia after S. 
pneumoniae and H. influenzae57 and was more commonly isolated in severe cases.58  
Globally, there is geographical variation in the incidence of meningitis. Data from a 
systematic review reported that between 1980 and 2010, the highest incidence of acute 
bacterial meningitis among children aged 0 - 4 years (143.6 cases per 100,000 child-years) 
was seen in Africa and the lowest (16.6 cases per 100,000 child-years) in the American 
region.59 This review may have over-estimated the incidence of meningitis in Africa because 
it did not differentiate between data collected routinely and those from outbreak 
investigations. However, S. aureus meningitis (patients with clinically suspected meningitis 
from whom S. aureus was isolated from the cerebrospinal fluid) is relatively uncommon, 
representing about 0.6% – 0.9% of the isolates identified from patients aged less than 15 
years60,61 and 12% from newborns.19 No country in Africa has data on the incidence of S. 
aureus meningitis. 
There are few hospital-based studies on endocarditis in African children. However, among 
the studies that have reported data on the epidemiology of endocarditis in children, S. aureus 
was either the leading or second leading pathogen identified.62-64 Hospital-based studies on 
osteoarticular infections among African children65-67 reported S. aureus as the predominant 
pathogen isolated, representing between 36% - 50% of patients investigated. However, 
population-based data on S. aureus endocarditis or osteoarticular infections among African 
children are lacking. Similarly, there are no population-based studies on S. aureus SSTI.  
S. aureus remains a principal causative agent of several clinical syndromes, yet there are few 
population-based studies describing the burden of disease due to the pathogen. 
Furthermore, the burden – the number of cases and deaths - among African children is 
unknown. This information is not only needed for policymakers as they seek to reduce 
neonatal and child mortality, but it also serves as baseline data. 
 
1.1.2 Predisposing factors 
In HIC, the risk of S. aureus disease is significant at the extremes of life; that is newborns, 
infants, and older people are at the most risk.27,68-70 With advances in sophisticated 
supportive care, more premature babies are more likely to survive, and the immature 
immune systems in these babies put them at high risk of infection. Similarly, in LMIC, the 
risk is highest among infants.45,71-73 Apart from their immature immune responses, poor 
hygiene, and high carriage rate of S. aureus may contribute to the increased risk. The 
increased risk in older age groups is attributable to a rise in the ageing population with the 
attending co-morbidities, which increase their exposure to the healthcare facilities. 
Underlying co-morbidities such as cancer,74 diabetes,74 haemodialysis,27,74,75 heart disease 
and stroke76 are known risk factors. 
27 
 
In HIC, ethnicity has been reported as a risk factor for S. aureus disease in a community 
setting77,78, but this is likely to be an indirect effect from overcrowding, poor hygiene, and 
delayed access to health care. Some investigators have related the increased risk in some 
ethnic groups to a higher prevalence of skin lesions.79,80 In both HIC and LMIC, HIV infection 
is a risk factor for S. aureus disease.71,81,82 Other factor associated with S. aureus disease in 
LMIC is sickle cell disease.83 
Other risk factors for S. aureus disease in HIC include male sex,68,70 the use of central venous 
catheters,27,84 previous admission to intensive care,27 administration of parenteral 
nutrition.27 Although the risk factors for S. aureus disease are well described in HIC, there 
are limited data on the risk factors associated with S. aureus disease in African children. 
Knowledge of the risk factors for S. aureus disease will help shape the development of 
effective interventions against this disease. 
 
1.1.3 Carriage as a risk factor for infection  
The relationship between S. aureus carriage and infection was first reported in 1954 when 
Roodyn found that 77% of his patients with stye and 37% of those with boils carried the 
same type of S. aureus in their nose.85 After that, several reports on the S. aureus carrier state 
as a risk factor for disease in hospital and community settings were published.86-88 These 
studies and others have provided further evidence that between 82% and 86% of carriage 
strains are indistinguishable from those causing disease.24 Some studies also showed that 
decolonisation of patients resulted in a reduction in the prevalence of S. aureus disease.89  
More recently, data from a meta-analysis of 38 articles involving 5,596 chronic renal disease 
patients undergoing dialysis reported an 11-fold increase in the risk of developing an 
infection in those who carried S. aureus compared to those who did not.90 Furthermore, 
another meta-analysis reported that participants who carried community-acquired S. 
aureus were twice as likely to progress to disease compared to those who did not.91 
However, prediction of progression of carriers to disease is challenging because of the 
complexity of the interplay between carriage, pathogenesis and host susceptibility.  
1.2 Carriage, acquisition and transmission 
1.2.1 Carriage  
S. aureus is carried on multiple sites on the human body, namely the nares, hands, throat, 
axilla, vagina, skin, groin, and umbilicus.92 S. aureus detection rate varies by site of the body93 
and increases with the number of body sites (maximum three sites) screened.93-95 The most 
frequent carriage site is the anterior nares of the nose.92 In newborns, S. aureus is commonly 
carried on the umbilicus, which leads to an increased risk of superficial and systemic 
infection. 
Carriage rates vary with age and geographical location. Estimates from HIC indicate carriage 
rates between 7.6% in 0 - 40-month-old children in Israel96 and 13.5% in 24-month-olds in 
the Netherlands.97 Carriage rates are higher in LMIC, ranging from 20% in 0 - 23-month-old 
children in The Gambia98 to 35% in 12 - 72-month-old children in India.99 The prevalence of 
S. aureus carriage is typically higher in young compared to older infants96,100 with the highest 
values seen in neonates.25,101 The nares are believed to be pathogen-free at birth, but S. 
aureus is rapidly acquired after birth sometimes as early as two hours after birth.102 In HIC, 
nasal S. aureus carriage in infants peaks at about 40% - 50% between six and eight weeks of 
life100,102 but then drops to about 21% by 24 weeks.100 On the other hand, in low-income 
countries, carriage in infancy peaks much earlier at between 50% – 63% by 6 - 7 days of 
life101,103 then falls to about 21% at 20 weeks.25,101 These differences suggest a higher force 
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of infection (the rate at which susceptible individuals acquire an infection) in LMIC but may 
also be a reflection of the sources and route of acquisition of S. aureus in the infant in the 
two settings. Further research is required to confirm this. 
 
1.2.2 Acquisition and transmission  
Acquisition describes the presence of a pathogen that was previously absent at a site on a 
host while transmission describes the spread of a pathogen from a reservoir or host to 
another host. The transmission pathways, and therefore, acquisition of S. aureus among 
newborns are not well characterised. Still, they have been linked to multiple factors in the 
mother (for example, carriage status and intrapartum antibiotic use).104,105 Transmission 
may be from the mother during delivery, person-to-person contact post-delivery, or through 
exposure to contaminated materials. Transmission by the airborne route is considered less 
likely. In Africa, the sources of S. aureus acquisition by the newborn are not known; 
knowledge of what these are will inform the development of strategies to reduce acquisition 
during the neonatal period.  
 
Mother-to-newborn transmission 
As with other pathogens associated with early-onset sepsis, it is assumed that the most 
significant source of neonatal acquisition of S. aureus is the mother. In particular, it is 
believed that transmission takes place during delivery as the newborn passes through the 
vaginal tract. Maternal vaginal carriage of S. aureus has been associated with neonatal 
carriage using conventional microbiological methods.94,106,107 Furthermore, molecular 
genotyping has shown that among mother-newborn pairs who carried S. aureus at the same 
time points (concordance), about 45% - 84% of them carried the same genotype.94,108   
Maternal S. aureus transmission to her newborn can also occur in the post-natal period 
either during handling94,100 or breastfeeding.100,107 Studies have shown that babies born to 
carrier mothers via caesarean section carried strains with the same genotype as those 
carried by the mother,94,105 and breastfeeding is positively associated with neonatal S. aureus 
carriage.100,107 However, the concordance between a mother and her newborn's carriage 
status and strain typing may also be a reflection of their shared environment or from a 
person who is in close contact with both of them. Additionally, in 23% - 80% of mother-
infant pairs, S. aureus carriage discordance has been reported, in which mothers were non-
carriers, but newborns were carriers.94,105-108 In such discordant S. aureus carrier mother-
infant pairs, potential sources of transmission to the newborn include healthcare workers 
(HCW), other patients or environmental sources such as delivery surfaces. 
In Africa, only two studies (one conducted in Gabon and the other in The Gambia) have 
investigated neonatal S. aureus acquisition.  In The Gambian study, 21% of neonatal carriage 
was attributable to maternal carriage, whereas, in the study conducted in Gabon, only 5.6% 
was attributable to maternal carriage.104,107 The attributable fraction may have been lower 
in the Gabonese study because vaginal samples were not collected or by antibiotic use by 
both the mothers and their newborns in the immediate postpartum period or both.104 
Despite the differences, these studies underscore the fact that there are other sources of 
transmission of S. aureus to the newborn.  
 
Transmission in the healthcare facility 
Transmission of S. aureus in the healthcare facility in outbreak settings is well 
documented.109,110 These studies have shown that many aspects of the hospital environment 
are associated with the risk of transmission including other patients (especially if their 
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carriage status is unknown),111 inanimate objects, body fluids, HCW, and unhygienic 
practices in the health facility.112  
The hands of HCW are the primary source of cross-transmission of carriage and infection in 
the hospital.113 In the absence of optimal hand hygiene, the degree of contamination 
increases as patient care continues,112 and the probability of transmitting also increases. S. 
aureus hand carriage correlates well with nasal carriage.92 Furthermore, S. aureus is 
resistant to desiccation, surviving on surfaces for many months, if not adequately cleaned 
with antiseptics. Overcrowded and understaffed wards and unavailable or unhygienic 
sanitary protocols for managing infections on the ward aid transmission.109 Therefore, 
infection-control measures, including optimal hand hygiene and adequate cleaning of 
hospital surfaces, reduce the risk of S. aureus transmission in the hospital.111 
 
Household transmission 
In epidemiology, a reservoir is defined as “one or more epidemiologically connected 
populations or environments in which the pathogen can be maintained, and from which 
carriage or infection is transmitted to the defined target population”.114 The household plays 
an insidious role as a reservoir in the transmission, acquisition, and persistence of successful 
clones of S. aureus in a community.86,95,115, Clustering of S. aureus carriage and infection are 
observed in households and can often be traced to carriage in an index member.95,116  These 
carriers are usually asymptomatic and serve as reservoirs for S. aureus transmission to the 
rest of the household.  
Transmission between household members can occur through the sharing of contaminated 
fomites,117-119 direct skin-to-skin contact or indirect contact with an individual who is a 
carrier or infected.95, 120 The most common route of transmission in the household is direct 
contact with the carrier or infected person.121 The ability of S. aureus to survive for months 
on surfaces, lack of personal and environmental hygiene, and the ubiquitous nature of S. 
aureus propagate environmental contamination.122 In particular, domestic pets and 
livestock have been associated with S. aureus transmission in the household. Strain 
similarities between pets and their owners have been demonstrated;119,123 however, most of 
these studies have been unable to ascertain the direction of transmission.  
Personal hygiene such as regular baths, hand hygiene (including handwashing and use of 
alcohol-based hand gels), regular laundering of bed linen and clothes, and environmental 
cleaning has been shown to reduce household transmission of S. aureus.124 In HIC, the risk 
of transmission of S. aureus increases with family size (≥ 5 members)125 and the presence of 
a child aged less than five years in the household.117 In LMIC, household transmission maybe 
even more common than in HIC due to poor hygiene, overcrowding and high ambient 
temperatures and humidity.  
 
1.3 Microbiology and pathogenesis of S. aureus diseases 
1.3.1 History of S. aureus 
In 1880, a Scottish surgeon, Alexander Ogston (1844 – 1929) was concerned by the alarming 
rate of postoperative deaths due to the suppuration of surgical wounds. The contemporary 
theory that suppuration was necessary for wound healing did not convince him.126 He 
therefore stained and examined pus from the abscess of one of his patients under a 
microscope. He observed: 
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“My delight may be conceived when there were revealed to me beautiful 
tangles, tufts and chains of round organisms in great numbers, which stood 
out clear and distinct among the pus cells and debris...”127  
He concluded that micrococci caused abscesses. He further went on to inject pus from 
abscesses into guinea pigs and demonstrated the formation of new abscesses; the guinea 
pigs later developed features of septicaemia. He named the micrococci “Staphylococci” from 
a Greek word “staphyle” which means a bunch of grapes. 
In 1884, a German surgeon, Anton J. Rosenbach (1842-1923), isolated two types of 
staphylococci which he named according to the pigmentation of their colonies – 
Staphylococcus aureus (from the Latin word “aurum” which means gold) and Staphylococcus 
albus (from the Latin word “albus” which means white).128 
 
1.3.2 The bacterium – Staphylococcus aureus  
Staphylococcus aureus is a Gram-positive, non-motile, non-spore-forming, catalase-positive, 
oxidase-negative, facultative anaerobe belonging to the Staphylococcaceae family.129 The 
bacterium has a cell wall which consists of proteins, teichoic acid and a thick layer of 
peptidoglycan, outside of which lies a polysaccharide layer called the capsule. The bacteria 
are approximately 0.5 - 1.5 µm in diameter and occur singly, in pairs or irregular clusters. 
On nutritive media, the colonies are well defined, yellow, smooth, opaque, convex with a 
diameter of about 1 to 3 mm and they are haemolytic on blood agar. S. aureus grows between 
150C and 450C, in a pH range of 4.2 – 9.5 and a maximum sodium chloride concentration of 
15%.129 Incubation at room temperature in daylight for about 24 to 48 hours will enhance 
pigment production. S. aureus appears as mucoid, sticky colonies when encapsulated. It is 
differentiated from other Staphylococcus species by its gold pigmentation and positive 
reactions to the coagulase test, mannitol fermentation test and deoxyribonuclease test.129 
Positive reaction to mannitol fermentation test differentiates it from 
Staphylococcus epidermidis while sensitivity to novobiocin differentiates from 
Staphylococcus saprophyticus. 
 
1.3.3 Host defense mechanisms  
Typically, carriage and colonisation are used interchangeably and refers to the 
establishment of S. aureus at the portal of entry of disease. However, some investigators 
believe that they are separate entities. Carriage is usually defined as the presence of S. aureus 
on the body surface without causing tissue invasion or symptoms. By contrast, during 
colonisation, there is tissue invasion eliciting host immune responses without causing 
symptoms.130 Disease is said to occur when there is an invasion of the body eliciting host 
immune responses and causing symptoms. 
 
Intact skin and mucosa of body tracts 
The body’s first lines of defense against infection are the epithelial surfaces of the skin and 
the mucosal linings of the body tracts. The outer layer of the intact skin, the stratum 
corneum, forms a physical and chemical barrier between the body’s internal milieu and the 
external environment.131 Tight junctions connect the epithelial cells of the skin, respiratory, 
gastrointestinal, and urogenital tracts and form a seal against pathogens. 
Furthermore, the linings of these tracts secrete mucus containing immunoglobulins and 
lysozyme that prevent adherence of pathogens to the epithelium.132 The epithelia of the 
respiratory tract have cilia which move to expel mucus and pathogens from the tract and the 
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mucosal epithelia of the stomach produce acid and digestive enzymes which degrade 
pathogens.132 As long as these defense mechanisms are not interrupted, the pathogen is 
carried on the skin or epithelium asymptomatically. 
 
1.3.4 Pathogenesis of disease 
Anti-staphylococcal antibodies are produced during colonisation episodes. However, most 
are not capable of killing the bacteria or neutralising their toxins.133,134 Therefore, colonised 
persons and carriers are not protected from disease;135-137 at best, they are protected against 
the severe types of the disease.134 The reason for less severe disease in colonised persons is 
not known, although they tend to have higher anti-staphylococcal antibodies than non-
colonised.138  
S. aureus usually enters the human body where there is a breach in the integrity of the skin 
or mucosal lining of the respiratory or urinary tract. Subsequently, there may be 
haematogenous spread of S. aureus from a localised infection to other tissues. This exposure 
of the human tissues to S. aureus may initiate the up-regulation of bacterial virulence 
genes.139 Host pattern recognition molecules “sense” the bacteria and peptidoglycan on their 
cell wall, causing both the human host and the pathogen to release chemokines and 
exotoxins, respectively. The exotoxins released by S. aureus include enterotoxin A, 
enterotoxin B, and toxic shock syndrome toxin (TSST-1) which induce human monocytes 
and endothelial cells to produce interleukin-8 (IL-8), a potent chemoattractant.140 
The host cytokines (granulocyte chemotactic protein 2,  IL-8 and complement component 
5a) attract neutrophils and phagocytes from the blood and bone marrow to the site of 
infection. Some of these host chemokines and cytokines prime neutrophils for reduced 
mobility, firm adhesion to the endothelium, facilitate migration through the endothelial 
junction out of the blood vessel (diapedesis) to the infection site and stimulate phagocytosis, 
degranulation and bactericidal activity (Figure 1.1).141,142 Anti-staphylococcal antibodies 
produced by plasmablasts initiate the complement systems leading to the production of C3 
convertases.142 These convertases lead to a cascade of reactions in the complement systems 
causing opsonisation of the bacteria. Additionally, anti-staphylococcal antibodies also cause 
opsonisation of the bacteria.142 At the infection site, neutrophils quickly engulf opsonised S. 
aureus by releasing a host of antimicrobial substances such as lysozyme, proteases, and 
reactive oxygen species.143 These antimicrobial substances also cause the non-specific host 
tissue destruction leading to the formation of necrotic tissue which may be walled off with 
the development of an abscess. This process of infection and consolidation of the disease 




Figure 1.1: Movement of neutrophils to infection site and phagocytosis of S. aureus 
AMP=Antimicrobial proteins; CR=complement receptors; FcyR=Fcγ receptors; NADPH=Nicotinamide adenine dinucleotide phosphate hydrogen; 
ROS=reactive oxygen species; NETosis=expulsion of DNA by neutrophils 
Source: Spaan et al. Neutrophil versus Staphylococcus aureus: A biological tug of war. Annual Review of Microbiology. 2013. Used with permission from 
Science Direct142 
 
Apart from causing disease by tissue invasion, S. aureus release exotoxins such as 
enterotoxins, exfoliating, and toxic shock syndrome toxins leading to gastroenteritis, 
scalded skin syndrome and toxic shock syndrome, respectively. 
 
1.3.5 Host immune evasion pathways 
Neutrophil evasion 
All stages of neutrophil recruitment and functions are targeted by S. aureus in an attempt to 
evade human immune responses. S. aureus prevents neutrophil chemotaxis by secreting 
chemotactic inhibitory proteins and staphylococcal superantigen-like substances. These 
substances inhibit the reduced mobility of neutrophils before adhesion to the endothelium, 
which is an essential step of neutrophil migration. Additionally, S. aureus reduces or 
prevents opsonisation by targeting the complement pathways and blocking C3 
convertases.144 S. aureus also prevents opsonisation by antibodies by up-regulating proteins 
such as staphylococcal protein A which block the effector domain of the opsonising 
antibodies.144 It evades reactive oxygen substances by converting hydrogen peroxide to 
water and oxygen through the activities of catalase and staphyloxanthin.145 Apart from 
avoiding innate immunity, S. aureus also secretes pore-forming toxins which cause cellular 
destruction leading to the disruption of the endothelial and epithelial linings and lyse 
phagocytic cells.146  
 
Formation of biofilm 
Development of biofilms is another way by which S. aureus evades the host immune systems. 
S. aureus biofilms are adherent sessile communities of bacteria embedded in an extracellular 
polymeric matrix attached to a host cell surface. Biofilms are formed on damaged host 
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epithelium like heart valves and fitted medical devices and are capable of manipulating and 
evading host immune responses. The matrix inhibits cytokine production and the ability of 
macrophages to penetrate the matrix and phagocytose bacteria.147 
Additionally, pro-inflammatory Th1/Th17 responses are up-regulated early in S. aureus 
infections and promote the development of biofilms and chronic infections.148,149 In the 
absence of nutrients and oxygen, S. aureus enter a dormant state evading the host immune 
system and also becoming intolerant of antibiotics.150 S. aureus may also act as an 
intracellular pathogen in osteoblasts and epithelial cells, effectively concealing itself from 
immune detection.151,152  
 
1.4 Classification of S. aureus diseases 
S. aureus diseases can be classified according to its focus of infection, place of acquisition, 
antibiotic susceptibility, the clinical syndrome, and severity (see Box 1). 
 
1.5 Diagnosis 
1.5.1 Conventional microbiological method 
Early detection or identification of the pathogen from human specimens, especially in severe 
cases, is crucial to the management of S. aureus disease. Pathogen identification is usually 
not required for mild cases as they may resolve spontaneously without treatment. Available 





















Box 1: Definition of terms 
Community-acquired disease refers to a patient who is culture positive for S. aureus at 
admission (that is, culture positive on a sample obtained within 48 hours of hospital admission)a.  
Healthcare-associated disease refers to a patient who is culture positive for S. aureus at 
admission and has had prior contact with the healthcare environment in the previous 2 - 30 days, 
for example, attended a hospital-based clinic or an Accident and Emergency department. 
Hospital-acquired disease refers to a patient who is culture positive for S. aureus in a sample 
collected more than 48 hours after hospital admissiona. 
Methicillin-resistant S. aureus (MRSA) are strains of S. aureus resistant to a wide range of β-
lactam antimicrobial agents due to the presence of the mecA gene and detected by testing for 
susceptibility to cefoxitin or oxacillinb while those susceptible to all β-lactam antimicrobial agents 
are methicillin-sensitive S. aureus (MSSA)b, however most MSSA are penicillin-resistant due to 
β-lactamases.  
Vancomycin-resistant S. aureus (VRSA) are strains of S. aureus with a minimum inhibitory 
concentration (MIC) for vancomycin of ≥ 16 µg/mL, those with a MIC between 4 and 8 µg/mL are 
referred to as vancomycin-intermediate S. aureus (VISA) while vancomycin-sensitive S. aureus 
(VSSA) are those with a MIC for vancomycin of ≤ 2 µg/mLb  
S. aureus septicaemia/bacteraemia cases are patients with clinically suspected septicaemia 
from whom S. aureus was isolated from the blood.c  
S. aureus bacteraemic pneumonia cases are patients with clinical, with or without radiological 
signs of pneumonia, from whom S. aureus was isolated from the blood.  
S. aureus non-bacteraemic pneumonia cases are patients with clinical signs of pneumonia and 
radiological evidence of lung consolidation from whom S. aureus was isolated from lung 
parenchyma. 
S. aureus meningitis cases are patients with clinically suspected meningitis from whom S. aureus 
was isolated from the cerebrospinal fluid. 
S. aureus osteomyelitis/osteoarticular infections cases are patients with clinically suspected 
osteomyelitis or septic arthritis from whom S. aureus was isolated from the blood, bone, or joint 
fluid. 
S. aureus endocarditis cases are patients with clinically suspected endocarditis from whom S. 
aureus was isolated from the blood or valve vegetations. 
Uncomplicated S. aureus disease cases are patients with clinical signs of disease and who are 
culture-positive for S. aureus but without endocarditis and implanted prostheses; negative follow-
up cultures after 2 - 4 days, clinical resolution within 72 hour of effective therapy and no evidence 
of metastatic infections. (Infectious Disease Society of America) 
Complicated S. aureus disease refers to any patient who does not meet the criteria for 
uncomplicated disease and who is culture-positive for S. aureus. 
a Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J 
Infect Control 1988, 16(3):128-40. 
bThe Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk 
Susceptibility Tests; Approved Standard. In., Twelfth Edition (M02-A1 edn). Wayne, Pennsylvania, USA.; 2017. 
c Note that in all the above definitions isolation were by conventional microbiological methods. Although the 
sensitivity of conventional microbiology is lower than molecular methods, the latter has a higher probability 




The ideal diagnostic test for S. aureus should have high sensitivity, high specificity, rapid 
time to detection, reliability, and be inexpensive while being less affected by prior antibiotic 
use or blood volume. 
 
1.5.2 Microbiological culture 
Microbiological culture is the gold standard for the diagnosis of S. aureus disease,153,154 and 
also allows antibiotic susceptibility testing. Information on antibiotic susceptibility enables 
modification of empiric antibiotic treatment for the proper management of patients and 
reduces the selection of resistant strains, especially in the era of high rates of antimicrobial 
resistance. However, the turn-around time for culture is two to five days.  
 
Septicaemia 
Blood cultures are positive in 5% – 10% of children with features suggestive of invasive 
infections.155 This figure may be lower in neonates (due to smaller blood volume obtained 
for the test) and in resource-poor settings, especially in sSA.155 Prior antibiotic use, 
laboratory capability, the number of blood cultures done, the volume of blood obtained, the 
ratio of the volume of blood to that of the medium in the culture bottle, blood culture 
sampling technique, blood culture bottle and the system used influence the yield of positive 
blood culture.156-158 The use of automated blood culture systems has improved the yield 
because of their antibiotic-removal resins and charcoal content and also reduced the time 
to detection of pathogens.159 Despite this, the yield of S. aureus in blood cultures is still 
considered low. Sensitivity and specificity of blood cultures concerning S. aureus, or any 




Cerebrospinal fluid (CSF) culture is considered the reference test for the diagnosis of 
bacterial meningitis. The detection rates of CSF culture are over 80% in symptomatic 
patients with no history of antibiotic use before sampling.160 In LMIC, some children with 
meningitis are likely to have received antibiotics before presentation161,162 reducing the 
culture positivity rate.160 In such cases, molecular methods such as polymerase chain 
reaction (PCR)-based tests may be useful for the identification of S. aureus.  
 
Pneumonia 
The diagnosis of pneumonia is discussed in chapter 2. 
 
1.5.3 Molecular detection 
New tools for pathogen identification are being developed to improve on the sensitivity, 
time to detection and clinical benefit to the patients - the prompt administration of 
appropriate antibiotics which improves survival. Molecular methods such as PCR-based 
tests have high sensitivity ranging from 72% to about 100% and specificity ranging from 
80% to 100%; they are rapid and reliable, even with a history of pre-treatment antibiotic 
use.163 In addition, molecular methods may be used to detect antimicrobial resistance which 
makes them attractive. Rapid PCR-based tests have been developed for the detection of 
MRSA and MSSA based on the detection of the mecA gene. Molecular methods might be 
useful in clinical practice, though they are currently not in use. A drawback of these methods 
43 
 
is that they are often too sensitive, detecting deoxyribonucleic acid (DNA) from dead 
microbes, other non-microbial nucleic acid, or contaminant DNA. The presence of PCR 
inhibitors may also influence them. Other limitations of these tests include the cost and skills 
required to perform these tests. Additionally, isolates are not available for further research 
and tests. However, these tests are widely used in research. 
 
1.5.4 Mass spectrometry method 
Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF 
MS) is a new method for pathogen identification. It works by ionisation of the specimen, 
measuring the mass to charge ratio and generating peptide mass fingerprints (PMF) which 
are compared with known PMF stored in a database.164 This method is accurate, fast and 
cost-effective in pathogen (including S. aureus) identification165 up to species level from 
human specimens. Although this method depends on microbiological culture, it is fast 
gaining grounds in clinical use. 
 
1.5.5 Methods for characterising S. aureus strains 
Phenotypic tests 
The most reliable method for the detection of methicillin-resistant strains of S. aureus is the 
detection of mecA gene.166 Most laboratories are unable to perform molecular biology 
techniques, therefore, phenotypic tests (oxacillin or cefoxitin disc diffusion or E test) are the 
most widely used to screen for methicillin resistance. Cefoxitin is preferred above oxacillin 
because it is more stable and accurate.166  
 
Genotyping tests 
Molecular typing methods are essential in the evaluation of the global evolution of S. aureus 
and genetic relatedness of its strains. Based on the detection of the mecA gene, techniques 
such as PCR tests can distinguish between MRSA and MSSA. Other methods used for 
molecular characterisation of S. aureus strains include pulsed-field gel electrophoresis, 
staphylococcal protein A typing, multi-locus sequence type, and SCC mec typing. Pulsed-field 
gel electrophoresis (PGFE) is used to separate large DNA molecules into distinct fragments. 
It is discriminatory, easy to perform, reproducible, relatively cheap; however, it is laborious 
and time-consuming. Staphylococcal protein A (spa) typing relies on a single-locus 
(polymorphic X region of protein A gene) sequencing, therefore prone to misclassification. 
It is, however, portable, rapid, cheap, discriminatory and reproducible.167 Multi-locus 
sequence type (MLST) is a DNA sequence-based typing that depends on seven conserved 
house-keeping genes. It lacks the power to resolve small evolutionary differences as might 
be seen during outbreaks and is more expensive than the spa typing or PGFE. Whole-genome 
sequencing analyses the entire genome of the bacteria, therefore highly discriminatory and 




Biological markers (or biomarkers) are “biological characteristics that can be objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention”.168 They are useful in clinical 
practice as an early diagnostic tool, for monitoring response to therapy and treatment 
outcomes. There is no single biomarker with 100% sensitivity, though combining them has 
the potential to achieve higher sensitivity and specificity. The well-established and 
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commonly used biomarkers in infections are white cell count, C-reactive proteins, and 
procalcitonin. They are useful markers of infections but not specific for S. aureus infections. 
Some biomarkers such as interleukin-10 and interleukin-1β169,170 have been correlated with 
the outcome of S. aureus bacteraemia, but these were small studies, and the results need to 
be validated in larger populations.  
 
1.6 Management 
1.6.1 Specific treatment  
The drug of choice for the treatment of S. aureus depends on the country, the methicillin-
susceptibility type of S. aureus infection, the severity of the infection and the local 
antimicrobial susceptibility patterns. In patients with MSSA infections, the preferred drugs 
include flucloxacillin, amoxicillin, oxacillin, and nafcillin, while vancomycin and daptomycin 
are recommended in patients with MRSA. Vancomycin is not recommended for the 
treatment of MSSA because of the increased risk of relapse, treatment failure171 and death.172 
Other drugs used include linezolid and clindamycin. Uncomplicated cases of systemic 
infections should be treated with at least 14 days of parenteral therapy and complicated 
cases (presence of prostheses, metastatic disease, or deep focus of disease) for 28 days while 
for confirmed endocarditis the standard course of treatment is 42 days.171 Sometimes, these 
patients receive a combination of two or more antibiotics, and they are more likely to receive 
combination therapy if the focus of infection is not removable. New drugs are available for 
the treatment of SSTI; these are semi-synthetic glycopeptides such as dalbavancin, 
oritavancin, and telavancin. Clinical responses to these antibiotics are similar to the 
standard care and have reduced cost compared to standard care.173  
In Africa, the first-line drugs for the treatment of S. aureus diseases include cloxacillin and 
flucloxacillin. The WHO recommends the use of cloxacillin or flucloxacillin for the treatment 
of S. aureus diseases.174 In The Gambia, the drug of choice is flucloxacillin;175 uncomplicated 
cases are treated for 5 – 7 days and complicated cases for longer.175 
 
Antimicrobial resistance (AMR) 
 The World Health Organization (WHO) has deemed antimicrobial resistance to be a 
significant threat to global health.176 Antimicrobial resistance is increasing worldwide and 
threatens the gains of childhood survival programmes that have been established over the 
last three decades. Projections of deaths attributable to AMR will reach 10 million deaths a 
year by the year 2050 if current trends are unchecked.177 The primary drivers of AMR are 
unregulated antibiotic use in human (hospitals and community) as well as veterinary 
medicine.178 In LMIC, scarcity of supportive diagnostic resources, availability of over-the-
counter antibiotics, poverty and ignorance, contribute to the overuse and misuse of these 
drugs. Reports on AMR have shown an association with increased adverse patient outcomes 
such as morbidity, cost of treatment and even mortality.179 Additionally, AMR is associated 
with lost productivity, missed days from school and work by parents. 
The first report of S. aureus antimicrobial resistance was in 1930.180 Today, almost a century 
later, about 90% - 95% of clinical isolates of S. aureus are resistant to penicillin,181 and about 
60% of isolates from intensive care units in the USA are methicillin-resistant.182 Pockets of 
resistance to vancomycin have been reported mainly in high-income countries.183 VRSA 
strains carry the vanA gene and are exceedingly rare; no VRSA transmission between 




Since the isolation of MRSA in 1961, it has been a significant cause of nosocomial infections 
(HA-MRSA),185 and a community-acquired strain (CA-MRSA) emerged 20 - 25 years ago 
causing SSTI.186 Methicillin-resistance has been described in both hospital and community 
strains, but it is reported that HA-MRSA are generally resistant to a wide range of antibiotics 
compared to CA-MRSA. Nowadays, the distinguishing features between the two strains are 
fading with CA-MRSA strains causing nosocomial infections and being resistant to a wide 
variety of antibiotics, just like HA-MRSA.186 A few staphylococcal lineages are responsible 
for both HA-MRSA and CA-MRSA, and they have evolved, by acquiring genetic materials 
through horizontal gene transfer, thus altering the gene expression and function.185 
There are geographical variations in the strains of MRSA. Based on MLST, MRSA population 
structure associated with humans has ten dominant lineages called clonal complexes (CC) 
within which many more minor ones arise.185 Some strains are widespread, while others are 
limited to some countries. For example, CC30 is commonly seen in Australia, Canada, Spain, 
the UK, and USA while Germany, Italy, and the UK have reported CC22.185 The common clonal 
complexes in Africa include CC5, CC30, CC80 and CC88,187 and in The Gambia, CC5 and 
CC15.98 This suggests global dissemination of S. aureus or high adaptation to new 
environments. Despite the broad geographic variations, isolates from the same lineage have 
conserved genes, while those from different lineages differ by hundreds of genes. 
In the USA, the incidence of MRSA bacteraemia declined between 2005 and 2014,188,189 while 
other studies report a stable incidence between 2010 and 2014.190 The converse is the case 
in Australia, Canada and the Scandinavia where Laupland and colleagues191 reported an 
increase in the incidence of MRSA bacteraemia between 2000 and 2008. In LMICs, there is a 
wide variation in the prevalence of MRSA. A prospective multinational surveillance study in 
17 teaching hospitals in eight Asian countries reported that the prevalence of CA-MRSA and 
HA-MRSA was 25.5% and 67.4%, respectively.192 In Africa, the prevalence of MRSA ranges 
from 16% to 44% of all clinical isolates;19,193 the higher rates are seen in areas of high HIV 
prevalence due to repeated exposure of HIV patients to healthcare facilities. In Africa, the 
resistance of S. aureus isolates to penicillin and ampicillin is high, up to 89% or even 100% 
(in the case of penicillin)178 and relatively low to gentamicin.178,194 This high antimicrobial 
resistance rate is not surprising given the unregulated access and use of antibiotics. The 
most frequently prescribed antimicrobial in The Gambia includes amoxicillin195 exerting 
selective pressure on the S. aureus carriage isolates in this country, thus increasing the risk 
of resistance.  
Local AMR patterns usually acquired through continuous surveillance inform the decision 
on the empirical therapy for infections like S. aureus diseases. However, in Africa, where the 
burden of S. aureus community-acquired diseases is high, there is limited information on 
AMR patterns. The WHO recommends the use of ampicillin and gentamicin as empirical 
treatment of suspected neonatal and childhood bacterial infections in the absence of local 
AMR data.174 Given that S. aureus is a significant cause of neonatal and childhood IBI it is, 
therefore, imperative to document the susceptibility of the S. aureus isolates seen in Africa 
to these antibiotics.  
 
1.6.2 Supportive treatment 
In addition to administering antibiotics, the management of S. aureus infection should 
involve repeated cultures and the removal of an identifiable focus of infection in cases where 
this can be identified. The former is important because of the risk of developing endocarditis 
which increases with persistent bacteraemia, and pyelonephritis and renal scarring in S. 
aureus UTI. Other supportive treatments depend on the clinical syndrome and the severity 
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of the disease and include, but are not limited to, resuscitation, the administration of 
intravenous fluid and circulatory support in septic shock,196 supplementary oxygen in 
pneumonia, and control of seizures in meningitis and brain abscess.196 
 
1.7 Morbidity/Mortality 
1.7.1 Length of hospital stay 
S. aureus disease is associated with extended hospital stays. Patients with S. aureus disease 
have, on average, longer hospital stays compared to those with the same clinical syndrome 
due to other pathogens.197 The duration of hospital stay is further increased in patients with 
associated comorbidities and those with hospital-acquired infections (HAI) due to S. 
aureus.74  
It is unclear whether resistance impacts the duration of hospital stay. Some authors have 
reported similar durations in patients with methicillin-resistant S. aureus (MRSA) and those 
with methicillin-susceptible S. aureus (MSSA)198 while others have reported longer 
durations in patients with MRSA.71,199,200  
 
1.7.2 Cost 
In HIC, the cost of treating S. aureus disease varies according to the severity of infection, 
admission status (in-patient or out-patient), the presence of antimicrobial resistance and 
the country. In HIC, the cost ranges from $12,216 to $84,436 per patient201,202 with the cost 
of treating MRSA being particularly high.199 There are no data on the cost of treating S. aureus 
diseases in adults or children in Africa.  
 
1.7.3 Case fatality ratios 
In the pre-antibiotic era, mortality from invasive S. aureus disease was as high as 80%,203 
but this has drastically reduced since the introduction of antibiotics and better protocols for 
S. aureus disease management. In HIC, CFR ranges between 1.4% and 6.0%,27,70,79 and the 
predictors of fatality include older age,27 black/indigenous race,78,79 immunosuppression,204 
the presence of co-morbidities,70,79 and acquisition of the disease in the hospital.27 Fatality 
ratios are higher in patients with MRSA compared with those with MSSA, even after 
adjusting for age and the presence of co-morbidities.200,205 In LMIC, CFR ranges between 6% 
and 32% in children45,47,71,72,206 and the factors associated with fatality include younger age,73 
absence of a focus of infection,73 malnutrition,72,73 not receiving appropriate antibiotics,73  
and HIV infection.72 Patients who present with non-specific symptoms such as a history of 
fever or elicited fever without evidence of localization of the infection in any organ or system 
of the body are usually regarded as not having focus of infection. These patients without 
focus of infection are unlikely to receive appropriate antibiotics because they have not 
presented with other clinical features traditionally associated with S. aureus infections 
which reduces the physician’s suspicion to treat as such. More information on risk factors 
for fatality in LMIC are required.  
 
1.8 Prevention  
1.8.1 Infection prevention and control 
Cross-infection in the hospital settings 
Simple and inexpensive interventions can reduce most staphylococcal hospital-acquired 
infections (HAI) and carriage. These infections occur when patients with no evidence of an 
infection and not incubating infections at the time of admission acquire infections during 
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their hospital stay. Most HAI occur as a result of unhygienic practices in the hospital. These 
aid the transmission of S. aureus or other pathogens from patient to patient via 
contaminated clothing and hospital equipment207 or through the contaminated hands of 
HCW.208 These HAI are associated with high mortality and increased health care costs. 
The burden of HAI in LMIC is significantly higher than reported in HIC.209 Worldwide, the 
leading pathogen responsible for HAI is S. aureus.111 Other pathogens include extended-
spectrum-beta-lactamase-producing Enterobacteriaceae, Klebsiella spp, Pseudomonas 
aeruginosa, and Acinetobacter species amongst others.210  
Carriage in the patient after contact with a contaminated person or environment usually 
precedes the development of diseases. Although strategies to reduce the transmission of 
pathogens and HAI are complex, simple intervention such as hand hygiene (including 
handwashing and the use of alcohol-based hand sanitisers), use of personal protective 
equipment such as gloves, masks and gowns by staff, disinfecting and decontaminating 
hospital equipment, and the isolation of infected patients have been suggested.211 Even 
though there are no data on the effectiveness of personal protective equipment,212 their role 
in the prevention of the spread of carriage and HAI cannot be overlooked.  
Hand washing is a cost-effective intervention for the transmission of carriage and 
prevention of HAI in the hospital setting213 however, compliance with hand hygiene 
practices is variable in both HIC and LMIC.214,215 In HIC, the primary reason for non-
compliance is behavioural.214 In contrast, in most LMIC, non-compliance may also be 
attributable to the scarcity or irregular availability of essential hand hygiene resources such 
as water, soap, alcohol-based hand sanitisers, and single-use towels. Besides, there is often 
a lack of knowledge of infection prevention and control (IPC) by hospital staff and 
inadequate hospital policy on hygiene.216,217 These findings cut across all levels of healthcare 
in Africa.215 Improvement in the compliance of hand hygiene is essential for the reduction of 
the incidence of HAI and carriage in hospital settings.218 
In HIC, apart from hand hygiene, other interventions in the IPC programmes include 
activities such as screening for S. aureus on admission, isolating carriers or patients with the 
disease, contact precautions and decolonisation of patients. These measures are well 
accepted in outbreak settings, and combinations of interventions have been shown to 
prevent transmission.219 However, they have their limitations. Screening has not yet been 
standardised because there is no consensus on the patient population, body sites, frequency 
of screening, and cost-benefits of screening all patients. Additionally, there is no evidence 
for an increase in the incidence of S. aureus infection rates following the cessation of 
isolation and contact precautions in the nursing of infected patients.220 In contrast, isolation 
and contact precautions led to reduced contact times with isolated patients by HCW, causing 
anxiety and depression in such patients or their parents. Good compliance with these 




Standard IPC measures alone may not be 100% effective against S. aureus transmission. 
Autoinfection is the development of a disease in one body site following the transfer of a 
pathogen previously carried in another body site. It can occur in the hospital as well as in 
the community settings. The demonstration of strain similarities between invasive and 
carriage S. aureus isolates from the same patient supports the importance of autoinfection.24  
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Therefore, a review recommended decolonisation of patients to prevent autoinfection,221 
but the evidence for this intervention is weak.222 A potential problem with decolonisation is 
that it leads to the temporary clearance of S. aureus carriage. Repeated decolonisation has 
been proposed to overcome this problem, but the effect of the decolonising agent such as 
mupirocin diminishes over time. There is also the possibility that antimicrobial resistance 
to the decolonising agent may develop. Currently, decolonisation is used for patients with 
recurrent SSTI and when the risk of S. aureus transmission remains high despite optimal 
infection control measures.171 
 
1.8.2 Vaccination 
Vaccination is one of the most effective public health intervention against diseases. 
However, there is no effective vaccine against S. aureus. The high burden of S. aureus disease, 
increasing prevalence of S. aureus antimicrobial resistance, high case fatality ratios and the 
ease of transmissibility of the pathogen in the hospital and community highlight the urgent 
need for an effective vaccine. Various S. aureus proteins have been used as targets for vaccine 
development for passive or active immunisation,223-225 and some have been evaluated in 
early phase clinical trials. However, none of the five vaccine candidates that have progressed 
into clinical trials so far has demonstrated efficacy against disease.226 Possible reasons for 
the failure of these vaccines include the use of a single protein as a target, the absence of 
adjuvants, antibodies not being assessed for functionality or opsonophagocytic activity, and 
critically ill trial participants.  
Barriers to the development of an effective vaccine against S. aureus disease or carriage 
include a lack of information on correlates or surrogates of protection, antigenic variation, 
complex invasion, carriage and disease mechanisms amongst others.226 A vaccine that 
induces both humoral and cellular immune responses will be required. Vaccine 
development is currently focusing on the use of multiple antigens as targets in the same 
vaccine.226 Unfortunately, however, the most recent candidate, SA4Ag vaccine, which 
included four antigens, also failed to demonstrate efficacy against disease.  
Monoclonal antibodies appear to be a promising adjunctive treatment to reduce the 
mortality rates in cases of severe S. aureus infection, especially in immunocompromised 
patients.227 However, to date, none of the five candidate monoclonal antibodies evaluated in 
clinical trials has demonstrated efficacy against the disease.228 In the absence of an effective 
vaccine for active or passive immunisation, efforts should be made to optimise and scale-up 
the other preventive measures. 
 
1.9 The rationale for the studies 
Part of the Sustainable Development Goal 3.2 requires that countries reduce childhood and 
newborn mortality to 25 per 1,000 live births and 12 per 1,000 live births by 2030, 
respectively. The current childhood and neonatal mortality rates in Africa are 78 per 1,000 
live births and 28 per 1,000 live births, respectively. Achieving these targets would entail as 
much as a threefold and two-fold reduction of the current rates in the region. Hence, 
significant and innovative efforts are required to increase the momentum of recent years 
further and achieve better health outcomes in this age group.  
Preventable infections contribute significantly to the unacceptably high childhood and 
neonatal mortality rates in Africa. S.  aureus is a significant cause of IBI (ranking among the 
top two leading gram-positive bacteria) in childhood and neonates with morbidity and 
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mortality worsened by antimicrobial resistance. However, there are limited, recent 
population-based country-representative data on the burden and risk factors for S. aureus 
disease in children aged less than five years in Africa. Furthermore, newborns rapidly 
acquire high carriage rates of S. aureus, a significant risk factor for disease. Besides, there 
are differences in AMR within and between countries driven by antibiotic use, co-
morbidities such as HIV and socioeconomic factors. Information on the burden of S. aureus 
disease among under-5 children in Africa, as well as the risk factors for neonatal carriage 
acquisition and the prevalence of antimicrobial strains of both carriage and invasive isolates 
in The Gambia and Africa at large, will serve as baseline and are necessary for the evidence-
informed allocation of health resources and developing strategies for control, treatment, 
and prevention.  
 
1.10 Aim and objectives 
The collection of studies presented in this thesis aims to estimate the burden of severe S. 
aureus disease in African children and identify the risk factors for carriage acquisition 
among neonates in rural Gambia. 
The specific objectives are to: 
1. Systematically review the literature on the burden of S. aureus disease and 
estimate the number of cases and deaths attributable to S. aureus disease in 
children aged less than five years in Africa. 
2. Estimate the incidence and case fatality ratio of SAB among children aged less 
than five years in rural Gambia using prospective data collected over eight years 
in a health and demographic surveillance system setting.  
3. Assess the risk factors for neonatal carriage acquisition of S. aureus among a 




Chapter 2: The burden of community-acquired Staphylococcus 




This chapter describes the burden (number of cases and deaths) of severe S. aureus disease 
among children aged less than five years in Africa. The first step was to conduct a systematic 
literature review and meta-analysis of the incidence, prevalence, and case fatality ratio of 
childhood S. aureus disease in Africa. Then, the information from this meta-analysis was 
synthesised with country-specific population estimates to estimate the burden (number of 
cases and deaths) of severe S. aureus disease in Africa.  
 
2.1 Introduction 
Credible estimates of cause-specific childhood morbidity and mortality can help to 
formulate regional and national health policy. In LMIC, S. aureus is a significant contributor 
to childhood and neonatal morbidity and mortality; however, it ranks low among diseases 
of public health importance.206 The burden of S. aureus morbidity and mortality is made 
more substantial by the increasing prevalence of antimicrobial resistance and the lack of an 
effective vaccine. Resources geared towards the improvement of child survival are 
increasing, and in the past three decades, much progress has been made in reducing 
childhood morbidity and mortality. However, the reduction of neonatal morbidity and 
mortality has been slower than that in the under-5 years' age group. Although mortality 
rates in African countries are still unacceptably high, the lack of valid estimates of the burden 
(number of cases and deaths) of S. aureus disease in children aged less than five years at 
national and sub-regional levels could account for the low level of attention and priority 
given to S. aureus. Due to considerable geographical variations in cause-specific disease 
burden, national and sub-regional data are required to develop appropriately focused 
interventions. Therefore, knowledge of the burden of S. aureus disease in Africa will serve 
both as the baseline for monitoring trends and to guide policy decisions on the allocation of 
health resources and the development of strategies for treatment, control, and prevention 
at both national and sub-regional levels. This study estimates the number of cases and 
deaths of severe S. aureus disease in children aged less than five years in each sub-region in 
Africa in 2015 to fill the knowledge gap.  
The approach described below is consistent with methods used by others to estimate the 
burden of disease caused by S. pneumoniae in children aged less than five years.229 
 
The road map for the chapter 
This chapter describes two distinct methods sections - one for the systematic literature 
review and meta-analysis (pages 59 – 65) and the other for estimating the burden of severe 
disease (pages 65 – 72).  Then, the results of the systematic literature review (pages 72– 89) 
are presented, followed by the burden of severe disease (pages 89 - 101) results. Finally, the 
last section of the chapter discusses the results of both the systematic review and the disease 

























The burden of community-acquired Staphylococcus aureus disease in children aged less 
than five years in Africa is high. 
2.2 Objectives 
Aim 
Box 2: Definition of terms 
Aetiologic fraction for pneumonia is the proportion of S. aureus-positive cases among patients diagnosed 
with clinical pneumonia who had blood culture or lung aspirate investigation. For septicaemia and 
meningitis, it is the proportion of S. aureus-positive cases among all culture-confirmed bacteraemia and 
meningitis patients, respectively. Different definitions were used because of the case ascertainment methods 
employed to calculate incidence for the clinical syndromes. For septicaemia and meningitis, the cases were 
patients with culture-confirmed disease while for pneumonia they were those with clinical pneumonia. 
Burden is the impact on population health as measured by the number of cases (morbidity) and deaths 
(mortality) attributable to S. aureus disease. 
Case fatality ratio (CFR) is the proportion of cases of S. aureus disease who died of the disease before 
discharge from the hospital. 
Clinical syndrome is a complex of symptoms and signs associated with a specific condition for which the 
cause may not necessarily be known. Those associated with S. aureus include pneumonia, septicaemia, 
meningitis, endocarditis, osteomyelitis, toxic shock syndrome, food poisoning, skin and soft tissue infections 
and urinary tract infection, among others. 
Disease refers to a clinical syndrome with a known causative agent or process. 
Incidence is the number of new cases in a defined population at risk per year. 
Non-pneumonia Non-meningitis Non-septicaemia (NPNMNS) clinical syndromes associated with S. 
aureus other than pneumonia, meningitis, or septicaemia, for example endocarditis, osteomyelitis, urinary 
tract infections, brain abscess, skin and soft tissue infections among others. 
Population-based studies are studies conducted in a well-defined geographical location and everyone in 
the specified age group in the area is followed-up in time for the event of interest. Population-based studies 
are designed to detect all cases that occur in the given geographical location. 
See Box 1 (Chapter 1, section 1.4) for other definitions 
 
To estimate the burden of community-acquired S. aureus disease in children aged less than 
five years in Africa. 
 
Objectives 
• To estimate the number of cases of community-acquired S. aureus disease in children 
aged less than five years in Africa in 2015  
• To estimate the number of deaths due to community-acquired S. aureus disease in 
children aged less than five years in Africa in 2015 and  
• To describe antimicrobial susceptibility patterns of clinical S. aureus isolates 
recovered from children aged less than five years in Africa 
 
2.3 Methods  
This report follows the Guidelines for Accurate and Transparent Health Estimates Reporting 
(GATHER) statements.230 The GATHER statement provides guidelines for the reporting of 
studies synthesising multiple studies or data sources to report on global, regional, or 
national health estimates. The key elements of GATHER include describing (i) the objectives 
and funding, (ii) data inputs, (iii) data analysis, and (iv) results and discussion (Appendix 1).  
 
2.3.1 Methods for the systematic review 
A systematic literature review was conducted to obtain country representative data on the 
estimates of incidence, aetiologic fraction and case fatality ratio (CFR) of each of the clinical 
syndromes caused by S. aureus. These parameters were required for the models for the 




The criteria for inclusion of the studies used the population, intervention or exposure, 
comparison group, outcome, and study design (PICOS/PECOS) framework.231 
Population: Children aged less than five years in Africa 
Outcomes: 1) incidence of meningitis, toxic shock syndrome, neonatal septicaemia, 
septicaemia, peritonitis, scalded skin syndrome, endocarditis, pericarditis, septic arthritis, 
osteomyelitis, empyema, lung abscess, pyomyositis, urinary tract infections, conjunctivitis, 
otitis media, skin infections; 2) aetiologic fraction of community-acquired S. aureus disease 
in cases of meningitis, toxic shock syndrome, neonatal septicaemia, septicaemia, peritonitis, 
scalded skin syndrome, endocarditis, pericarditis, septic arthritis, osteomyelitis, empyema, 
lung abscess, pyomyositis, urinary tract infections, conjunctivitis, otitis media, skin 
infections; 3) case fatality ratio of S. aureus meningitis, toxic shock syndrome, neonatal 
septicaemia, septicaemia, peritonitis, scalded skin syndrome, endocarditis, pericarditis, 
septic arthritis, osteomyelitis, empyema, lung abscess, pyomyositis, urinary tract infections, 
conjunctivitis, otitis media, skin infections; 4) resistance to antibiotics (ampicillin, 
amoxicillin, amoxicillin-clavulanate, cloxacillin, chloramphenicol, cotrimoxazole, 
cefotaxime, cefoxitin or oxacillin, erythromycin, gentamicin, ofloxacin, and penicillin) 




Studies on the aetiologic fraction or incidence of community-acquired S. aureus bacteraemia 
and serious non-bacteraemic illnesses, for example, conjunctivitis, empyema, endocarditis, 
lung abscess, meningitis, osteomyelitis, otitis media, pericarditis, peritonitis, pyomyositis, 
scalded skin syndrome, septic arthritis, skin infections, toxic shock syndrome, urinary tract 
infections were included. Studies conducted among children aged less than five years in an 
African country between January 1980 and May 2019 and published in English or French 
were included.  
Exclusion criteria 
Studies were excluded if they assessed infections in specific risk groups (for example, HIV- 
infection, sickle cell disease, haemodialysis patients, or malnutrition among others), or if 
they were specific to methicillin-resistant S. aureus (MRSA) or methicillin-sensitive S. aureus 
(MSSA) or the identification of molecular clones of clinical isolates. Other studies excluded 
were case reports of less than 50 cases, conference abstracts, outbreak investigations, 
retrospective studies, review articles, editorials, policy statements, and those on secondary 
data analysis of a dataset already described in a comprehensive paper. Studies that did not 
stratify isolates by age or sample type or where the methods of data collection or laboratory 
methods were unclear (for example, the method of selection of participants) were also 
excluded. 
 
Data sources  
A systematic search of articles reported in English and French was undertaken using 
Medline (Medical Literature Analysis and Retrieval System Online), EMBASE (Excerpta 
Medica Database, Amsterdam, The Netherlands), Web of Science, Global Health, and Africa 
Wide Information. In addition, the reference lists of included articles were searched to 
identify additional studies that met the eligibility criteria. 
 
Search strategy 
A combination of both Medical Subject Headings (MeSH) terms and free text terms were 
combined to capture concepts related to clinical syndromes, pathogen, and geographic area 
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for the literature search. The terms included “abscess”, “acute respiratory infection”, 
“bacter(a)emia”, “bloodstream infection (s)”, “cellulitis”, “conjunctivitis”, “empyema“, 
“endocarditis”, “fever”, “meningitis”, “osteomyelitis”, “otitis media”, “pericarditis”, 
“peritonitis”, “pneumonia”, “pyomyositis”, “septic(a)emia”, “septic arthritis”, “skin 
infection”, “toxic shock syndrome”, “urinary tract infection”, “Staphylococcus aureus”, “S 
aureus”, “Staph aureus” and a list of all African countries. See Appendix 2 for the search 
strategy for Medline, EMBASE, and Global Health which was undertaken through Ovid®. The 
United Nations list and African Union classification of the 55 African countries were 
utilised232 for the search. The French and English names of Cote d’Ivoire and Botswana and 
Batswana (name of the citizens) were used.  “Congo”, “Guinea” and “Sudan” were used to 
represent the countries with the similar names - Democratic Republic of Congo and Congo, 
Guinea, Guinea-Bissau and Equatorial Guinea, and Sudan and South Sudan. Swaziland was 
renamed Eswatini in 2018; therefore, both names were included in the updated search. 
 
Data management and extraction 
The search was first performed in April 2016 and updated in May 2019. AO compiled 
retrieved articles in Endnote referencing software and removed duplicates. AO developed a 
checklist of inclusion and exclusion criteria to assess the eligibility of articles and trained 
Natalie Edgar (NE) and Ese Ebruke (EE) on the use of the checklist to screen article titles 
and abstracts. AO and EE assessed abstracts, titles and titles of citations in articles in English 
while NE assessed articles in French. The references of relevant articles were placed in a 
folder in Endnote. Full-text articles fulfilling eligibility criteria were retrieved and assessed 
by the investigators individually with documentation of reasons for excluding an article. 
Malick Ndiaye (MN)  and NE assessed full articles in French. An independent review by a 
third investigator, Effua Usuf (EU) resolved disagreements between assessors about 
eligibility. Data extraction forms created using Microsoft Excel were piloted. EE, NE and MN 
were trained and extracted data onto validated forms. Assessment for duplicate data was 
done by cross-referencing reports from the same country for the period of data collection, 
location, and sample size. When information was missing, the investigators contacted the 
authors for clarification. AO collated completed data extraction forms.   
The extracted data depended on the study type and included first author’s name, study site 
(country), setting (level of hospital), year of study or year published, eligibility criteria, 
clinical syndrome studied,  age of participants, number of subjects studied, type of sample 
obtained, number of participants positive for S. aureus and for all bacteraemia, person-time 
of follow-up, method of detection (molecular or conventional microbiology) and incidence 
or prevalence of S. aureus meningitis or septicaemia. Other variables included antibiotic use 
before sampling, antimicrobial resistance data, additional tests (for example, HIV or malaria 
testing), number of deaths in cases and the elements of study quality assessment. Data were 
extracted independently by three investigators (AO, NE, and EE). Incidence was extracted 
directly or computed based on the information on the number of cases and person-years of 
follow-up.  The aetiological fraction was calculated as the proportion of S. aureus-positive 
cases among all patients with clinically suspected disease who were investigated and had 
true bacteraemia. CFR was the proportion of cases of S. aureus disease that died of the 
disease before discharge from the hospital and antimicrobial resistance was calculated as 
the proportion of resistant isolates among the tested ones.  
 
Assessment of the risk of bias of literature 
Assessment of the study quality was done independently by AO and EE. Due to the 
constraints of resource-limited settings as seen in most African countries, microbiological 
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methods (transport method or media used) for the isolation of S. aureus and non-reporting 
of contaminants for the studies which alluded to performing blood cultures were not used 
as criteria for quality assessment. Factors considered during quality assessment were: 
i. The use of pre-defined inclusion criteria 
ii. Systematically or consecutively recruited and sampled paediatric hospital 
admissions  
iii. Evaluation of all admissions, all febrile admissions or all patients meeting the pre-
defined eligibility criteria with microbiology culture of body fluid. 
In accordance with the Cochrane Collaboration’s assessment for risk of bias (ROB),233 the 
quality of each article was graded as low, unclear or high risk of bias established on two 
domains; i) the possibility of missing cases and ii) the use of pre-defined eligibility criteria. 
Low ROB was considered if pre-defined inclusion criteria were stated, and at least 80% of 
all eligible participants were investigated and reported. Articles were categorised into three 
groups: 
A: Both investigators agreed on the two domains of ROB 
B: Both investigators agreed on one of the domains of ROB 
C: Both investigators disagreed on the two domains of ROB, or there was no 
information on which to base a judgement. 
Only articles where both investigators agreed on at least one of the domains of ROB were 
used to estimate the incidence, aetiologic fraction or case fatality ratio of S. aureus disease. 




The prevalence of resistance was defined as the proportion of resistant clinical isolates 
among all S. aureus isolates tested for susceptibility. Estimates were reported for each 
antibiotic stated in section 2.3.1 by region, when feasible. 
 
A DerSimonian-Laid random effects meta-analysis234 was used to obtain summary estimates 
of incidence, aetiologic fraction, case fatality ratio and proportion of resistant isolates. 
Statistical analyses were done in Stata 14.0 (College Station, Texas 77845 USA) and RStudio 
Team (Boston, MA). 
 
 
2.3.2 Methods for estimating the burden of disease 
Information required for this analysis was available from three United Nations agencies. The 
United Nations Population Division235 and the Joint United Nations Programme on HIV and 
AIDS (UNAIDS)236 provided information on the population sizes of under-5 children and the 
prevalence of HIV among children aged 0 - 4 years in African countries in 2015,  respectively. 
The United Nations Children's Fund (UNICEF)237 provided information on country-specific 
mortality rates, number of live births, and the proportion of children with pneumonia in the 
preceding two weeks and had access to health care.  
 
Categorisation of countries 
In countries where model parameters (incidence, aetiologic fraction or CFR estimates) were 
missing, these were imputed by hierarchical expansion using data from similar countries. 
Similar countries were identified by creating categories by 1) mortality strata238 according 
to the under-5 mortality rates  into a) low (< 30 per 1,000 live births),  b) medium (30 - < 75 
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per 1,000 live births), c) high (75 - < 150 per 1,000 live births), d) very high (> 150 per 1,000 
live births) and 2) sub-regions as defined by the African Union239 – central, east, north, 
southern and west. A neighbouring country is one that shares a border with the nation of 
interest.  
 
The methods used to estimate the number of cases by clinical syndrome  
Pneumonia cases 
The number of S. aureus bacteraemic pneumonia cases among children aged 0 – 59 months 
was estimated by multiplying the country-specific estimates of hospitalised cases of all-
cause clinical pneumonia as modelled by McAllister and colleagues240 by the aetiologic 
fraction for bacteraemic pneumonia. Aetiologic fraction estimates from population-based 
studies from each country were used, when available. Where more than one estimates were 
available from one country, the pooled estimate was used. Where no country-specific 
estimates of aetiologic fraction were available, these were imputed using the algorithm in 
Figure 2.1. 
The number of cases of non-bacteraemic pneumonia (as defined in section 1.4) was 
calculated similarly using the estimates of the aetiologic fraction of non-bacteraemic 
pneumonia due to S. aureus instead of that due to bacteraemic pneumonia.  
 
Meningitis cases 
Data on country-specific incidence of S. aureus meningitis were not available. The number 
of S. aureus meningitis cases was calculated by multiplying the country-specific incidence of 
all-cause bacterial meningitis (from the systematic review) by the population size and the 
country-specific aetiologic fraction of meningitis attributable to S. aureus from population-
based studies.  
 
𝑁𝑜. 𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑐𝑎𝑠𝑒𝑠 = 𝑀𝑒𝑛𝑖𝑛𝑔𝑖𝑡𝑖𝑠 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 × 𝑃𝑜𝑝2015 × 𝑃𝐶𝑎𝑠𝑒𝑠,𝐷𝑖𝑠𝑒𝑎𝑠𝑒  equation 1) 
 
where PCases,Disease is the proportion of meningitis cases attributable to S. aureus, meningitis 
incidence is the incidence of all-cause bacterial meningitis per 100,000 population while 
Pop2015 is the population size of children less than five years of age in each country.  
In the absence of country-specific information, estimates of incidence and aetiologic fraction 
were imputed based on the algorithm in Figure 2.1. 
 
Septicaemia cases 
The incidence, aetiologic fraction and CFR of septicaemia were derived from the systematic 
review. Incidence of S. aureus septicaemia (per 100,000 population) was applied to the 
estimates of country-specific population size235 to determine the number of S. aureus cases. 
 
                  𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑐𝑎𝑠𝑒𝑠 = 𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑠𝑒𝑝𝑡𝑖𝑐𝑎𝑒𝑚𝑖𝑎 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 × 𝑃𝑜𝑝2015            equation 2)       
                         
The number of cases of neonatal septicaemia was derived by applying the neonatal S. aureus 
incidence (per 1,000 live births) to the estimate of live births for each country.  
 
𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑐𝑎𝑠𝑒𝑠 = 𝑁𝑒𝑜𝑛𝑎𝑡𝑎𝑙 𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑠𝑒𝑝𝑡𝑖𝑐𝑎𝑒𝑚𝑖𝑎 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 ×  𝐿𝐵2015 equation 3) 
 
where S. aureus septicaemia Incidence is the incidence of S. aureus septicaemia in neonates 

























Country-specific data were used when available, and values were imputed for countries 
without information using estimates (or pooled estimates) from the countries in the same 
 
Figure 2.1: The algorithm for imputing country-specific estimates of incidences, aetiologic 
fraction, case fatality ratio for meningitis and septicaemia and aetiologic fraction for 
pneumonia  
a Countries were categorised by 1) mortality strata  according to the under-5 mortality rates  into a) low (< 30 
per 1,000 live births),  b) medium (30- <75 per 1,000 live births), c) high (75 - <150 per 1,000 live births), d) 
very high (> 150 per 1,000 live births) and 2) African Union sub-regions used– central, east, north, southern 
and west.  
b A neighbouring country is one that shares a border with the country of interest.  
under-5 mortality stratum or from that of a neighbouring country with data (see the 
algorithm in Figure 2.1). Incidence rates adjusted for the proportion seeking healthcare51,241 
were used whenever available. This was done to account for the under-estimated incidences 
reported by other studies because some children would not have been taken for a health 
facility visit. 
 
Non-pneumonia non-meningitis non-septicaemia disease (NPNMNS) cases 
Disease burden due to non-pneumonia non-meningitis non-septicaemia clinical syndromes 
such as endocarditis, osteomyelitis, pericarditis, peritonitis, pyomyositis, scalded skin 
syndrome, septic arthritis, toxic shock syndrome, and urinary tract infections could not be 
obtained because there were no incidence data on these diseases and no prospective study 




Number of deaths by clinical syndrome  
Pneumonia deaths 
Due to the scarcity of data on S. aureus pneumonia CFR, the number of S. aureus pneumonia 
deaths was calculated by multiplying the WHO estimates for all-cause pneumonia deaths in 
children aged 0 – 59 months3 by the aetiologic fraction of bacteraemic pneumonia. This 
approach assumes that the proportion of pneumonia cases due to S. aureus was similar to 
the proportion of deaths due to S. aureus and that the CFR for S. aureus pneumonia is the 
same as pneumonia caused by other pathogens. The CFR for S. aureus pneumonia was taken 





None of the studies reported on the CFR for S. aureus meningitis cases; therefore, the 
number of S. aureus meningitis deaths was calculated by multiplying the estimates of the 
number of S. aureus meningitis cases by the all-cause bacterial meningitis CFR. For cases 
without access to healthcare, a CFR of 90% was used. The proportion of children under the 
age of five years with pneumonia in the preceding two weeks and had access to health care 
obtained from UNICEF237 was used as a proxy for the proportion of meningitis cases who 
had access to health care and received treatment. For countries without data, the coverage 
for the third dose of Diphtheria-Pertussis-Tetanus vaccine for the country also obtained 
from UNICEF,237 was used. 
 
Septicaemia deaths 
The number of deaths due to S. aureus septicaemia was calculated by multiplying the 
number of cases by the country-specific CFR from the systematic review (observed or 
imputed).   
 
𝑁𝑜. 𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑠𝑒𝑝𝑡𝑖𝑐𝑒𝑎𝑚𝑖𝑐 𝑑𝑒𝑎𝑡ℎ𝑠
= 𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑠𝑒𝑝𝑡𝑖𝑐𝑎𝑒𝑚𝑖𝑐 𝐶𝐹𝑅 × 𝑁𝑜. 𝑆. 𝑎𝑢𝑟𝑒𝑢𝑠 𝑠𝑒𝑝𝑡𝑖𝑐𝑎𝑒𝑚𝑖𝑐 𝑐𝑎𝑠𝑒𝑠 
  Equation 4) 
 
Inferring the rate (incidence or deaths) in children < 5 years from the rate in 
children < 2 year  
Although, the majority of studies reported incidence in children less than five years of age, 
some reported incidence for those less than two years of age. For these studies, incidence 






   Equation 5) 
where Rate<5 and Rate<2 represent estimates of incidence in children less than 5 years and 
less than two years respectively; P<2 is the proportion of all cases in children less than two 
years (89.9%)242 and %U5Pop<2 is the proportion of under-five population that are less than 
two years of age (50.7%).243 
 
Sensitivity analysis 
Sensitivity analyses were performed to assess the difference between using aetiologic 
fractions from hospital-based compared to population-based studies.  
For bacteraemic pneumonia, aetiologic fractions derived from hospital-based studies were 
applied to the country-specific number of hospitalised cases of all-cause severe pneumonia 
modelled by McAllister and colleagues.240 For meningitis, aetiologic fractions derived from 
hospital-based studies were applied to the country-specific number of cases of all-cause 
bacterial meningitis.  
For septicaemia, the number of S. aureus septicaemia cases was calculated by applying 
country-specific population size estimate (number of live births) to the incidence of all-
cause septicaemia (neonatal septicaemia) and the aetiologic fractions derived from hospital-
based studies. (Equation 1).  
The number of S. aureus deaths for each of the clinical syndrome was determined as 
described above. 




The data used for the derivation of the estimates were characterised by substantial 
uncertainty. However, there were few studies which threaten the precision of the estimates 
of uncertainty ranges; therefore, this step was omitted.  
 
Data cleaning and the algorithm in Figure 2.1 were implemented in a Microsoft Excel 
Spreadsheet (Version 16.5). 
 
2.4 Results of the systematic review 
2.4.1 Summary of included studies 
The search yielded 90,524 titles which were narrowed down to 55,759 after excluding 
duplicates. Most of the further exclusions (54,213) were because the titles were unrelated 
or, to a lesser extent, because the full text was not found (Figure 2.3). Of the full articles 
retrieved, 345 were excluded. Reasons for exclusion included retrospective studies (70), 
isolates not disaggregated by samples or age (39), methodological issues (35), study 
participants less than 50 cases (29), hospital-acquired diseases (16) and 13 studies which 
did not differentiate between community-acquired and hospital-acquired diseases. Articles 
on the incidence of pneumonia, early neonatal septicaemia and the aetiologic fraction of 
urinary tract infection were also excluded. Figure 2.3 shows the full screening outcome. 
Thirty-nine studies from four of the five African regions and eleven countries were included 
in the quantitative synthesis. There was one study from Central Africa which did not 
disaggregate data by age and so was excluded.244 A third of the studies (12/39; 30.8%) were 
from Nigeria and four studies from Kenya (Table 2.2). The majority of the included studies 
were hospital-based (26/39; 66.7%), one was in a randomised controlled trial setting (1/39; 
2.6%), and one a case-control study (1/39; 2.6%). The population-based studies were from 
Burkina Faso and Togo (1),245 The Gambia (1),242 Ghana (1),51 Kenya (3),6,46,246 Mozambique 
(3),45,60,247 Nigeria (1),54 and Tanzania (1).241 The articles had information on at least one of 
the following estimates: incidence, aetiologic fraction, case fatality ratio, and neonatal 
septicaemia incidence and aetiologic fraction. Nine articles reported on two 
estimates,6,46,49,53,241,248-252 four on three45,51,54,60 and one article on six estimates.242 All the 
























Figure 2.2: Flow chart of the study selection process 
1 CA=Community-acquired; HA=Hospital-acquired; UTI=urinary tract infection 











Records identified through 
database search (n = 90,520) 
 
Additional records identified 
through other sources (n =4) 
 
Records after removing 
duplicates  
(n = 55,759) 
 
Records excluded 
(n = 1,162) 
412 Retrospective studies 
185 Specific patient groups 
  99 Hospital-acquired  
  80 Molecular methods 
  81 Case report/series 
  76 Patients ≥ 5 years 
  67 Reviews 
  38 Asymptomatic persons 
  35 MRSA/MSSA specific 
  25 Other countries 
  21 Duplicates 
  13 No microbiology data 
  13 Outbreak studies 
    9 No S. aureus disease 
    6 Editorials/Letters 
    2 Molecular diagnosis 
 
Irrelevant records  
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Full-text articles assessed 
for eligibility  
(n = 384) 
 
Full-text articles 
excluded, with reasons  
(n = 345) 
70 Retrospective studies 
60 Not found 
39 Isolates not disaggregated 
35 Methodology issues 
29 Less than 50 cases 
21 No S. aureus disease 
21 Non-serious diseases 
16 Hospital-acquired  
16 Duplicates  
13 No difference CA and HA1  
10 Pneumonia incidence  
7 Age < 1 year                                                        
3 No microbiology data 
    2 UTIa aetiologic fraction 
    1 Early neonatal sepsis 
    1 Letter 








 Studies included in 
quantitative synthesis 
meta-analysis (n = 39) 
   5 Meningitis                                  
10 Pneumonia                 
12 Septicaemia                 
16 Neonatal septicaemia2  
 
2.4.2 Risk of bias 
Thirty-five studies were considered poor quality based on selection bias (21/35; 60.0%), no 
or vague clinical definitions (9/35; 25.7%) or issues with case ascertainment (5/35; 14.3%) 
and were excluded from the analysis. Of the included studies, 100% stated pre-defined 







Figure 2.3: Risk of bias graph of included studies 
 
S.  aureus disease articles 
Although there was a large body of literature on S. aureus disease in Africa, only 1.3% 
(11/869) of the studies were prospective and population-based among children under the 
age of five years. Of the full articles assessed for eligibility, 20.3% (70/345) were 
retrospective (Figure 2.3). 
Pneumonia 
Two population-based (one from Kenya246 and the other from Mozambique247) and four 
hospital-based studies (two each from Nigeria54,56 and Gambia53,251) provided information 
on the aetiologic fraction of bacteraemic and non-bacteraemic pneumonia, respectively 
(Table 2.2). Four hospital-based studies reported on the hospital-based aetiologic fraction 
of bacteraemic pneumonia (Supplementary Table 2.1).253-256 All these studies except one 
were from mortality stratum 3. 
Use of pre-defined eligibility criteria                     
 
Possibility of missing cases                      
           
 
 0% 20% 60% 100% 40% 80% 





Four prospective studies – two population-based60,252 and two hospital-based161,257 - 
reported on the aetiologic fraction of S. aureus meningitis and the incidence and CFR of all-
cause meningitis (Table 2.2 and Supplementary Table 2.1). Three studies were from 
mortality stratum 3 and one from mortality stratum 2. 
 
Septicaemia  
Five population-based studies reported on the incidence of all-cause septicaemia and S. 
aureus septicaemia – two from Kenya,6,46 and one each from The Gambia,242 Ghana,51 and 
Mozambique (Table 2.1).45 Two of these articles also provided information on the incidence 
and aetiology fraction of neonatal septicaemia.6,242 Two other studies reported on the 
incidence of all-cause septicaemia alone.8,241 In hospital-based settings, five studies from 
three countries23,258-261 and ten studies from three countries48,49,250,262-268 provided data on 
the aetiologic fraction of S. aureus septicaemia among children less than five years of age and 
neonates, respectively (Supplemental Table 2.1). Information on CFR of septicaemia cases 
among under-5 children45,242 and neonates242 49,248-250 were obtained from two and five 
studies, respectively. 









Figure 2.4: Random-effects pooled incidence of community-acquired S. aureus bacteraemia in 




















































Effect size (95%CI) 
Pneumonia      % 
Bacteraemic 
aetiologic fraction 
Pooled1  3 2  1.6 (0.9 – 2.4) 
 Kenya East 3 1  1.7 (0.9 – 2.8) 
 Mozambique South 3 1  1.5 (0.7 – 2.8) 
      
Non-bacteraemia 
aetiologic fraction 
Pooled  3 4  25.0 (4.0 – 46.0) 
 Gambia West 3 2  5.0 (1.0 – 10.0) 
 Nigeria West 3 2  33.0 (26.0 – 40.0) 
      
Meningitis      per 100,000 person-years 
All-cause incidence2 Pooled  3 3 85.1 (69.2 – 102.6) 
 Mozambique South 3 1  171.9 (110.4 – 246.3) 
 Mali West 3 1 76.9 (69.0 – 85.4) 
 Togo/Burkina 
Faso 
West 3 1 79.8 (73.0 – 87.0) 
      
    Aetiologic fraction Mozambique South 3 1  16.0 (5.0 – 36.0) 
      
    All-cause CFR3 Mozambique South 3 1  24.0 (11.0 – 42.0) 
      
Septicaemia     per 100,000 person-years 
Incidence2 Pooled  3 5  126.7 (61.0 – 214.4) 
 Gambia West 3 1  78.0 (67.5 – 89.3) 
 Ghana West 3 1  630.1 (430.0 – 868.9) 
    Kenya East 3 2  44.8 (12.4 – 161.7) 
 Mozambique South 3 1  118.3 (92.0 – 148.0) 
      
    CFR Pooled  3 3  9.0 (6.0 – 12.0) 
 Gambia West 3 2  14.0 (10.0 – 20.0) 
 Mozambique South 3 1  6.0 (3.0 – 11.0) 
      
Neonatal septicaemia     per 1,000 live births 
   Incidence4 Pooled  3 2  1.3 (0.2 – 9.6) 
 Gambia West 3 1  3.5 (2.9 – 4.7) 
 Kenya East 3 1  0.4 (0.2 – 0.8) 
      
CFR Pooled  3 5  21.0 (14.0 – 26.0) 
 Gambia West 3 1  18.0 (10.0 – 28.0) 
 Nigeria West 3 4  23.0 (14.0 – 32.0) 
 Tanzania East 2 1  33.3 (4.0 – 78.0) 
1 Summary estimate of the meta-analysis of the countries in the same stratum 
2 Incidence in cases per 100,000 person-years  
3 CFR=Case fatality ratio 
4 Incidence in cases per 1,000 live births 
 
 









































2012 2014 22/95 
(23.2%)3 





1986 - 1988 



































































































NR4 Blood 2012 2014 22/205 
(10.7%)5 
1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live 
births), c) high (75 - < 150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2Year of Haemophilus influenzae type b vaccine (Hib) and pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MS 
ZpbmRpY 2F0b3Jp ZD01NSZvdm VybGF5a WQ9NA==) 
3Aetiolofic fraction for non-bacteraemic pneumonia 
4NR=Not Reported  
5Aetiologic fraction for bacteraemic pneumonia 
















































NR Blood 2002 2013 9/157 
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< 5 years Cough, increased 
respiratory rate, 
indrawing 
NR Blood 2009 2013 9/613  
(1.5%)5 











< 5 years WHO definition 
of CXR-confirmed 
pneumonia 
NR Blood NR 2010 1/76 
(1.3%)7 
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2001 2011 14/836  
(1.7%)5 





2011 – 2012 













Blood 2007 2011 1/118  
(0.9%)5 
1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live births), c) high (75 - 
< 150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2Year of Haemophilus influenzae type b vaccine (Hib) and pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b3Jp 
ZD01NSZvdmVybGF 5aWQ9NA==) 
4NR=Not Reported; CSF=Cerebrospinal fluid 
5Aetiologic fraction for bacteraemic pneumonia 








































































NR CSF 2012 2014 2/27 
(7.4%)7 
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< 5 years Clinically 
suspected 
meningitis 
NR CSF NR NR 
1 MS=Mortality Stratum;  Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live 
births), c) high (75 - < 150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2 Year of Haemophilus influenzae type b vaccine (Hib) and Pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MS 
ZpbmRpY2F0b3 JpZD01NSZvdm VybGF5aWQ9NA==) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation; IPSC= International Paediatric Sepsis Consensus 
6 Case fatality ratio 
7Aetiologic fraction 
8Incidence 




1 MS=Mortality Stratum;  Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 
live births), c) high (75 - < 150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2Year of Haemophilus influenzae type b vaccine (Hib) and pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MS 
ZpbmRpY2F0b3Jp ZD01NSZvdm VybGF5a WQ9NA==) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation 
6 Case fatality ratio 
7Aetiologic fraction 
8 Incidence 
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Blood 2012 2014 28/68 
(41.2%)7 
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Blood 2012 2014 26/55 
(47.7%)7 
              
1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live births), c) high (75 - < 
150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2 Year of Haemophilus influenzae type b vaccine (Hib) and Pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b 3JpZD01NSZvdm 
VybGF5aWQ ) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation 
6 Case fatality ratio 
7Aetiologic fraction 
8 Incidence 


































































































NR Blood 2008 2015 26/48 
(54.2%)7 
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Blood 2002 2013 19/45 
(42.2%)7 
              





















Blood 2012 2014 18/32 
(56.3%)7 
1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live births), c) high 
(75 - < 150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2 Year of Haemophilus influenzae type b vaccine (Hib) and Pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b3Jp 
ZD01NSZvdm VybGF5aWQ ) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation 
6 Case fatality ratio 
7Aetiologic fraction 
8 Incidence 
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Neonates Presence of risk 
factors ± signs 
of sepsis 
NR Blood 2012 2014 8/31  
(25.8%)9 
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1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live births), c) high (75 - < 150 
per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2 Year of Haemophilus influenzae type b vaccine (Hib) and Pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b3Jp ZD01NSZvdm 
VybGF5a WQ9NA==) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation; IPSC= International Paediatric Sepsis Consensus 
6 Case fatality ratio 
7Aetiologic fraction 
8Incidence 
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Blood 2002 2013 69/110  
(62.7%)9 
             












Neonates Clinical sepsis 
by WHO4 
classification 
NR4 Blood 2009 2012 32/149  
(21.5%)9 
              
















NR Blood 2009 2012 27/74 
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Blood 2002 2013 16/26 
(44.4%)9 
1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live births), c) high (75 - < 
150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2 Year of Haemophilus influenzae type b vaccine (Hib) and Pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b3Jp 
ZD01NSZvdm VybGF5aWQ9NA==) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation; IPSC= International Paediatric Sepsis Consensus 
6 Case fatality ratio 
7Aetiologic fraction 
8Incidence 
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Blood 2012 2014 34/169  
(20.0%)9 
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1 MS=Mortality Stratum; Countries were stratified according to the under-5 mortality rates into a) low (< 30 per 1,000 live births), b) medium (30 - < 75 per 1,000 live births), c) high (75 - < 
150 per 1,000 live births), d) very high (> 150 per 1,000 live births) 
2 Year of Haemophilus influenzae type b vaccine (Hib) and Pneumococcal conjugate vaccine (PCV) introduction (source: http://view-hub.org/viz/?YXBwaWQ9MSZpbmRpY2F0b3 JpZD01NSZvdm 
VybGF5aWQ9NA==) 
4 NR=Not Reported; BW=birth weight; temp=temperature; WHO=World Health Organisation; IPSC= International Paediatric Sepsis Consensus 
6 Case fatality ratio 
7Aetiologic fraction 
8Incidence 






There was considerable heterogeneity in all the meta-analyses both by mortality stratum 
and country (I2 range 0% - 99%) (Figure 2.5 and Appendix 3).  
 
2.4.3  Antimicrobial resistance (AMR) 
Eighteen studies reported on AMR of S. aureus isolates, but data from two studies that did 
not disaggregate results by either age45 or clinical syndrome250 were not utilised. All the 
studies used the disc diffusion laboratory method to determine antibiotic resistance. Eight 
studies each were from East and West Africa, and eight studies were conducted among 
neonates. All isolates were from blood samples of patients with community-acquired 
infections. Most of the tested isolates (n=364; 69.5%) were from West Africa.  
 
Pre-treatment antibiotic use   
Of the included studies, only 18 (41.9%) reported on antibiotic use before sampling. Four 
studies excluded patients who had received antibiotics before presentation,53,259,261,268  while 
eight studies reported that between 5.6% and 67.0% of the study participants had used 
antibiotics before sampling.6,23,51,56,60,161,251,254 The commonly used antibiotics before 




 Oxacillin (n=225)241, 23,242,249 susceptibility was reported by four studies. Of these isolates, 
4.9% were resistant to oxacillin.,241 The prevalence of MRSA (based on oxacillin testing) was 
0% in East Africa241,249 and 5.1% in West Africa.23,242 One study reported the prevalence of 
    Table 2.3: Summary of antimicrobial resistance patterns in East and West Africa 
Antibiotic East Africa West Africa 
 
Number of resistant isolates/numbers  
tested (%) 





56/69 (81)268 - 30/32 (95),262 39/53 (74)49 87.0 (80.0 – 94.0) 
Ampicillin 
 
1/69 (88),268 23/27 (85)48 88.0 (81.0 – 94.0) 3/8 (38),263  28/32 (88),262 12/20 (60)23 68.0 (53.0 – 84.0) 
Amoxicillin-
clavulanic acid 
NR2 - 6/21 (29),23 8/53 (15)49 18.0 (9.0 – 26.0) 
Cefotaxime 
 
NR  0/26 (0),260 10/32 (31)262 - 
Cefoxitin 
 
NR - 6/193 (3)242 - 
Ceftriaxone 
 
4/27 (15)48 - 1/8 (13),23 9/53 (17)49 20.0 (11.0 – 30.0) 
Cefuroxime 
 




1/5 (20), 5/12 (42),267 51/69 (74),268  
6/9 (67)253 
64.0 (44.0 – 83.0) 0/26 (0),260 0/8 (0),263 29/31 (94),51  
8/186 (4)242 




5/32(16),264  - 0/26(0),260 3/32(9),262 10/31 (32),51  
1/5 (20),23 7/53 (13)49 
26.0 (9.0 – 44.0) 
Clindamycin 
 




9/32 (28), 22/27(82)48 0/12 (0),267  
24/69 (35)268 
48.0 (17.0 – 79.0) 0/26 (0),260 1/8 (13),263 28/32 (88),262 5/30 
(17),51 23/25 (92)270 




2/5 (40),241 19/32 (59)264 57.0 (41.0 – 73.0) 1/6 (17),23, 0/26 (0),260, 2/8 (25),263   
11/24 (46),51 40/180 (22)242 




1/5 (20),241 21/32 (66),264 2/9 (22)253 54.0 (40.0 – 68.0) 0/26 (0),260 0/8 (0),263 10/31 (32),51 8/21 (38),23 
21/53 (40),49 8/173 (5)242 




3/69 (4),268 15/27 (56),48 3/9 (33.3),253 0/6 (0)249, 
0/9 (0),271 0/12 (0)267 
30.0 (7.0 – 68.0) 3/8 (38),23 0/26 (0),260 0/8 (0),263 19/32 (59),262 
9/31 (29),51 29/53 (55),49 3/177 (2)242 
37.0 (1.0 – 63.0) 
Oxacillin 
 
0/5 (0),241 0/6 (0),249  - 11/22 (50),23 0/194 (0)242  
Penicillin 
 
4/5 (80),241 11/69 (16),268 29/32 (91),264  
12/12 (100),267 
87.0 (80.0 – 93.0) 6/8 (75),26316/31 (52),51  58.0 (42.0 – 73.0) 




MRSA using cefoxitin as a surrogate (3.1%).242 The use of cefoxitin as a surrogate for MRSA 
is preferred because oxacillin disc testing is not reliable.272 There was a higher resistance 
rate of S. aureus to ampicillin in East Africa compared to West Africa (88.0% versus 68.1%) 
as well as to penicillin (87.0% versus 58.0%) (Table 2.4). The resistance rate of S. aureus to 
amoxicillin was similar in the two regions (81.0% – 87.0%). S. aureus was still relatively 
susceptible to cloxacillin (48.0% - 56.0%), chloramphenicol (44.0% - 64.0%), erythromycin 
(28.0% – 54.0%), and gentamicin (30.0% – 37.0%) in East and West Africa (Table 2.3). There 
were no AMR data from Central or North Africa. 
 
2.5 Disease burden results 
2.5.1 The population size of African children 
There were an estimated 186,884,000 children aged less than five years on the African 
continent in 2015, 31.7% of them in the West, 13.3% in Southern, 12.2% in the North, 13.0% 
in the Central and 29.8% in the East sub-region (Table 2.4). The country with the least 
population was Seychelles (n=8000; 0.004%) and that with the largest was Nigeria 
(n=31,109,000; 16.7%) (See Appendix 4). The proportion of countries in mortality stratum 
1 or 2 by region was 22.2%, 42.9%, 85.7%, 40.0% and 13.3% for Central, East, North, 
Southern, and West, respectively. 
 
2.5.2 Staphylococcal cases 
In 2015, an estimated 392,066 cases of staphylococcal infection occurred among children 
aged less than five years in Africa (Table 2.4). Six countries (two from the West - Nigeria 
(17.3%) and Ghana (5.4%); one from Central Africa - Democratic Republic of Congo (7.6%), 
two from the East – Ethiopia (7.7%) and Tanzania (4.9%) and one from the North - Egypt 
(7.1%)) accounted for 50.0% of cases staphylococcal diseases in Africa. Country-specific 
incidence varied widely from 124 cases per 100,000 children per annum in Kenya to 693 
cases per 100,000 children in Ghana (Figure 2.6, Appendix 5). West Africa had the highest 
incidence and the largest number of cases, Nigeria being the main contributor. 
In the sensitivity analysis, where data from hospital-based studies were used to derive the 
aetiologic fraction of each of the three clinical syndromes, the estimated number of cases 
was 1,032,218, with an incidence of 552 cases per 100,000 children (Table 2.5). Using 
aetiologic fraction data from the hospital-based studies, the total estimated number of cases 




Figure 2.5: Incidence of staphylococcal infections in children aged less than five years in Africa (per 
100,000 children) 
               
Table 2.4: Estimated numbers of staphylococcal cases and deaths by sub-region (using population-based studies)1 
 Africa Central East North Southern West 
Total  
Total deaths among children < 5 years in 2015 = 2,907,444273  
Children aged < 5 
years  
186,884,000 24,311,000 55,598,000 22,844,000 24,858,000 59,273,000 
       









































































CFR4 7  9  6  3  15  8  
       












No. deaths 8,083 1,402  1,917  252  1,065 3,430  
Meningitis 
























CFR4 57  64  58  50  48  64  
       












No. deaths 15,977 2,120 4,357 1,567 2,861 5,071 
                     1 Aetiologic fractions used to derive the number of cases were pooled estimates from population-based studies 
                         2 Incidence rates of pneumonia, meningitis and septicaemia are per 100,000 children, neonatal septicaemia per 1,000 live births in 2015 
                         3  Mortality rate=proportion of the under-five children (total live births) who died of S. aureus disease per 100,000 in 2015 
                         4 CFR=Case fatality ratio (%) 
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Table 2.4: Estimated numbers of staphylococcal cases and deaths by region (using population-based studies)1 (continued) 
 Africa Central East North Southern West 
Septicaemia       
























CFR4 9  9 9  9  9  9 
       











No. deaths 22,407 2,772 5,824 2,605 2,626 8,580 
       
Non-bacteraemic pneumonia 
























CFR4 7  8  6 3 6  9 
       












No. deaths 126,908  19,774  31,400 3,517 13,467 58,652 
Neonatal Septicaemia 
Total neonatal deaths in 2015=1,112,623  273 
Live births 41,521,718 5,377,820 12,145,000 5,066,898 5,401,000 13,531,000 






















17,235   
 
CFR4 26  21  28  33  25  23  
       












No. deaths 13,091  1,432 3,970  2,105  1,705   3,880  
                          1 Aetiologic fractions used to derive the number of cases were pooled estimates from population-based studies 
                               2 Incidence rates of pneumonia, meningitis and septicaemia are per 100,000 children, neonatal septicaemia per 1,000 live births in 2015 
                               3 Mortality rate=proportion of the under-five children population (total live births) who died of S. aureus disease per 100,000 in 2015 
                               4 CFR=Case fatality ratio (%) 
             
Table 2.5: Estimated numbers of staphylococcal cases and deaths by region (sensitivity analysis - using hospital-based 
studies)1 
 Africa Central East North Southern West 
Total       
Total deaths among children < 5 years in 2015 = 2,907,444 273 
Children aged < 5 years 235 186,884,000 24,311,000 55,598,000 22,844,000 24,858,000 59,273,000 





































































CFR4 8  9  6  3  8  9  
       

















































CFR4 59  65 57 53  51  65  
       












No. deaths 6,415 995 1,499  419 1,156 2,346 
                      1 Aetiologic fractions used to derive the number of cases were pooled estimates from both hospital-based studies 
                          2 Incidence rates of pneumonia, meningitis and septicaemia are per 100,000 children, neonatal septicaemia per 1,000 live births in 2015 
                          3 Mortality rate=proportion of the under-five children population (total live births) who died of S. aureus disease per 100,000 in 2015 




        
                      
Table 2.5: Estimated numbers of staphylococcal cases and deaths by region (sensitivity analysis - using hospital-based 
studies)1 (continued) 
 Africa Central East North Southern West 
Septicaemia       
























CFR4 9  9  9  9  8 9  
       

























Total neonatal deaths=1,112,623 273 
Live births 41,521,718 5,377,820 12,145,000 5,066,898 5,401,000 13,531,000 
       
























CFR4 24  21  26  33  23  22  
       
























                      1 Aetiologic fractions used to derive the number of cases were pooled estimates from hospital-based studies 
                          2 Incidence rates of pneumonia, meningitis and septicaemia are per 100,000 children, neonatal septicaemia per 1,000 live births in 2015 
                          3 Mortality rate=proportion of the under-five children population (total live births) who died of S. aureus disease per 100,000 in 2015 
                          4 CFR=Case fatality ratio (%) 
 
The burden due to staphylococcal meningitis was higher using population-based than 
hospital-based studies. On the contrary, the burden due to staphylococcal bacteraemic 
pneumonia and septicaemia were higher using hospital-based studies. 
 
2.5.3 Deaths due to S. aureus diseases 
There were an estimated 46,467 deaths from staphylococcal diseases in children aged less 
than five years (Table 2.4) on the African continent. This represents 1.6% of all-cause deaths 
in this age group in 2015.273 The highest burden of staphylococcal deaths occurred in West 
Africa (36.8%). Six countries (two from the West - Nigeria (18.3%) and Ghana (5.8%), one 
from Central Africa - Democratic Republic of Congo (7.6%), and two from the East – Ethiopia 
(7.8%), and Tanzania (4.3%), and one from the North - Egypt (5.0%)) accounted for 49.0% 
of staphylococcal deaths in Africa. The country-specific mortality rates are shown in Figure 
2.7 (Appendix 6). The mortality rates were highest in West Africa. Ghana had the highest 
mortality rate due to staphylococcal diseases. Septicaemia accounted for 48.2% of 
staphylococcal deaths while pneumonia and meningitis accounted for 34.4% and 17.4% 
respectively.  
Appendices 5 - 11 and 5a – 11a contain the country-specific number of cases and deaths due 
to staphylococcal diseases by clinical syndrome among these children from population-
based and hospital-based studies, respectively. 
 





Bacteraemic pneumonia was defined as cases of severe pneumonia (WHO definition of 
clinical pneumonia – cough, increased respiratory rate for age and lower chest wall in-
drawing) who were S. aureus-blood culture positive. There was an estimated 113,368 cases 
among the children aged less than five years in Africa (Table 2.4; Appendix 7). This number 
accounted for 1.6% of all-cause severe pneumonia cases (7 million) in children aged less 
than five years in Africa.274 The highest number of cases was in West Africa while the lowest 
in North Africa. Nigeria and Seychelles had the highest and lowest number of cases, 
respectively. The incidence of severe pneumonia with S. aureus bacteraemia was 61 cases 
per 100,000 children with the highest rates seen in West Africa (70 cases per 100,000 
children) and lowest in North Africa (39 cases per 100,000 children) (Table 2.4).  
Using data from hospital-based studies to derive the aetiologic fraction, the number of 
staphylococcal severe pneumonia cases increased to 392,069 with about half (50.1%) 
occurring in West Africa (Table 2.5). The estimated incidence of S. aureus pneumonia was 
210 per 100,000 children.  
 
Non-bacteraemic pneumonia 
The number of non-bacteraemic pneumonias defined as cases who are S. aureus-culture 
positive from lung aspirate, but with negative blood culture, was estimated at 1,771,730 
cases in 2015 (Table 2.4; Appendix 8). The highest number of such cases (36.0%) occurred 
in West Africa and the lowest (4.6%) in North Africa. The incidence of non-bacteraemic 
pneumonia was 948 annual cases per 100,000 children much greater than for the 
bacteraemic pneumonia definition (61 cases per 100,000 children). Incidence varied widely 
between the regions ranging from 612 per 100,000 children in North Africa to 1,094 per 
100,000 children in West Africa (Table 2.4).  
The majority of pneumonia deaths attributable to both bacteraemic and non-bacteraemic 




Figure 2.6: Staphylococcal mortality rates among children aged less than five years (per 100,000 
children in 2015. (Mortality rates are the proportion of children aged less than five years who died of 






An estimated 27,973 S. aureus meningitis cases occurred among children aged less than five 
years in Africa, with about one-third (28.6%) occurring in West Africa and 11.8% in Central 
Africa (Appendix 9). The incidence was 15 per 100,000 children (Table 2.4). An estimated 
15,977 S. aureus meningitis cases died, giving a mortality rate of 9 per 100,000 children and 
a CFR of 57% (Table 2.4). Using the aetiologic fraction derived from hospital-based studies, 
there was a lower number of estimated cases of staphylococcal meningitis – 10,699 - with 
an overall incidence of 6 cases per 100,000 children across the sub-regions (Table 2.5). An 
estimated 6,415 S. aureus meningitis cases died, giving a mortality rate of 3 per 100,000 
children (Table 2.5). 
 
Septicaemia 
Children aged less than five years 
The incidence of S. aureus septicaemia among children aged less than five years was 134 
annual cases per 100,000 children with an estimated 250,725 cases (Appendix 10). Most 
cases occurred in West Africa (36.6%). S. aureus septicaemia incidence ranged from 116 per 
100,000 children in East Africa to 261 per 100,000 children in West Africa (Table 2.4).  
Total numbers of deaths due to S. aureus septicaemia followed the same pattern as the 
number of cases. An estimated 22,407 deaths due to S. aureus disease occurred in this age 
group giving a mortality rate of 12 per 100,000 children (Table 2.4).  
Using data from hospital-based studies to derive the aetiologic fraction, the number of 
staphylococcal septicaemia cases increased to 629,334 with almost half of the cases (48.7%) 
occurring in West Africa (Table 2.4). The incidence of S. aureus septicaemia was 337 per 
100,000 children ranging from the lowest (79 per 100,000 children) in North Africa to the 
highest in West Africa (517 per 100,000 children) (Table 2.5).  
 
Neonates 
Using data from population-based studies to derive the aetiologic fraction, 51,215 neonatal 
S. aureus septicaemia cases were estimated (Appendix 11) accounting for 20.4% of all the 
staphylococcal septicaemia cases in children less than five years of age. The highest number 
of cases was seen in West Africa and the lowest in North Africa. The incidence of neonatal 
septicaemia was 1.2 cases per 1,000 live births with a mortality rate of 0.32 per 1,000 live 
births. The estimated number of neonatal deaths due to staphylococcal septicaemia in Africa 
was 13,091, accounting for 58.4% of all deaths due to staphylococcal septicaemia. The 
mortality rate in neonatal septicaemia was higher than in other clinical syndromes. 
Using data from hospital-based studies to derive the aetiologic fraction, the estimated 
number of cases was greater at 107,056 with 25,561 deaths due to neonatal staphylococcal 
septicaemia. The incidence of S. aureus neonatal septicaemia was 2.6 per 1,000 live births 
(Table 2.5).  
 
2.6 Discussion 
An estimated 392,066 staphylococcal cases and 46,467 deaths occurred among children 
aged less than five years in Africa in 2015. These deaths represented 1.6% of the total 
childhood deaths that occurred in 2015.273 Among neonates, there were 51,215 cases and 
13,091 deaths due to staphylococcal septicaemia. These neonatal deaths represented 1.2% 
of all-cause deaths among this age group in 2015.273 In East and West Africa, S. aureus had 
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high resistance rates to ampicillin and amoxicillin, but greater susceptibility to cloxacillin 
and gentamicin. 
 
Burden by sub-region and country 
This review and analysis showed that there is sub-regional variation in the burden of S. 
aureus disease among children aged less than five years in Africa. For each of the clinical 
syndromes assessed, the number of cases and deaths, as well as the incidence and mortality 
rates, were lowest in North Africa (except for incidence and deaths due to septicaemia). This 
pattern is reflected in the lower overall under-five mortality rates (U5MR) and higher gross 
domestic product (GDP) per capita in these countries. With the exception of Mauritania with 
an U5MR of 85 per 1,000 live births, all the North African countries had an U5MR less than 
75 per 1,000 live births.238 The West African sub-region consistently had the highest burden 
of S. aureus cases and deaths. The reason for this is unclear but may be due to variation in 
pathogen virulence, host susceptibility, case definition, blood culture sampling practices, 
laboratory techniques and capacity. Additionally, the West African sub-region had the 
largest population, driven by Nigeria which accounted for 16.7% of the population of 
children aged less than five years in Africa.235 In 2017, Nigeria ranked 17 on the African 
continent in terms of GDP, had the largest population, a high U5MR, and the most substantial 
staphylococcal disease burden on the continent. However, Ghana had the highest incidence 
of S. aureus disease, a high U5MR and ranked 18 on the African continent in terms of GDP. In 
general, the countries in the West African sub-region (13/15) had the highest overall 
mortality rates (≥ 75 per 1,000 live births). 
For countries with a large population size like Nigeria, Ethiopia, Democratic Republic of 
Congo and Egypt interpretation of the estimates can be a challenge because of substantial 
variations in the childhood mortality, access to health care, parent’s health-seeking 
behaviour, and incidence of disease within each country.275 Disaggregation of data by the 
states or provinces would have been ideal but was not possible due to the lack of necessary 
information such as childhood mortality or access to health care by these strata. 
  
Pneumonia 
Using the bacteraemic pneumonia definition, there was an estimated 113,368 cases of S. 
aureus pneumonia, accounting for 1.6% of all-cause severe pneumonia cases (7.0 million)240 
in children aged less than five years. This estimate is based on the aetiologic fraction from 
two population-based studies.246,247 These studies are more likely to be representative of the 
true burden of S. aureus pneumonia in the community than hospital-based studies. This is 
not surprising because most severe cases are selectively referred to the hospital and S. 
aureus is associated with severe pneumonia.274 Conversely, hospital-based studies are 
affected by factors such as parent’s health-seeking behaviour, access to healthcare and the 
subjective decision by the physician to admit or not to admit the patient. 
The assumption that the aetiologic fraction of pneumonia due to S. aureus is the same as the 
proportion of pneumonia deaths due to S. aureus was made because of the dearth of fatality 
data on S. aureus pneumonia; however, this assumption was also used by O’Brien and 
colleagues in their estimation of pneumococcal disease burden.229 The assumption that the 
aetiologic fraction of pneumonia due to S. aureus is similar to the proportion of pneumonia 
deaths due to S. aureus might have under-estimated or over-estimated S. aureus pneumonia 
mortality. This assumption presumes that all bacterial pneumonia deaths would have had 
significant pathology, which would have been evident on chest X-ray (CXR) as alveolar 
consolidation (CXR positive) at the time of death. The other assumption was that the CFR of 
S. aureus CXR positive pneumonia was comparable to that of CXR positive pneumonia due 
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to other pathogens. In countries with good access to health care, the CFR of S. aureus CXR 
positive pneumonia is likely to be lower than CXR positive pneumonia due to other 
pathogens while in poor access to health care settings, the reverse is the case. In the latter 
health care settings, there is a tendency for patients to present late when the disease would 
have spread to affect other contiguous tissues resulting in empyema or purulent 
pericarditis. Consequently, this might have under-estimated the number of deaths due to S. 
aureus pneumonia for some countries and over-estimated for others, which highlights the 
importance of completeness in the reporting of studies and the fact that in Africa, S. aureus 
has not been considered a disease of public health importance.  
The higher incidence of non-bacteraemic than bacteraemic pneumonia may be due to the 
better recovery of S. aureus from lung aspirates compared to blood cultures.276 However, the 
rate of performing lung aspirations was low in the reported studies as the procedure was 
done only in cases who had presented to the hospital with evidence of consolidation on CXR. 
S. aureus is known to be responsible for more severe cases of pneumonia.274,277 This could 
result in an over-estimation of the burden of disease, especially if patients with 
consolidation on CXR were selectively referred to hospitals with facilities for lung aspirates.  
Identification of the aetiological cause of pneumonia can be technically challenging, 
especially in children. The body fluid samples used for pathogen identification in pneumonia 
cases include blood, sputum, bronchoalveolar lavage, nasopharyngeal aspirates or swabs 
and lung aspirates. Blood culture, the most commonly used method, is positive in only about 
5% - 10% of cases, the yield of which may increase to 20% in severe cases.158 
Bronchoalveolar lavage gives a higher rate of pathogen identification (38%). However, it 
requires patient sedation and monitoring, and also runs the risk of contamination with 
upper airways pathogens during bronchoscopy.278 Sputum and nasopharyngeal aspirates or 
swabs have higher culture positivity rate (50% and 70% respectively) but are also often 
contaminated with the upper airway flora especially in children, and may therefore not 
always reflect the aetiology of pneumonia.279 For this review and analysis, the definition of 
non-bacteraemic pneumonia included only those who had lung aspirate performed because 
of the low risk of contamination. 
The yield of pathogens in lung aspirates in children is about 41%.276 Lung aspirate is rarely 
done routinely, although investigators have demonstrated the safety of the procedure in 
children.53,251,280 There is no gold standard test for the detection of pathogens in pneumonia. 
This review disaggregated pneumonia cases by the body fluid sample used for pathogen 
detection, that is bacteraemic, and non-bacteraemic pneumonia cases were analysed 
separately to avoid double-counting cases. Only four studies in two countries (Gambia and 
Nigeria) reported S. aureus data on lung aspirates in children aged less than five 
years.53,54,56,251 
The number of cases of S. aureus bacteraemic pneumonia could have been under-estimated 
because the sensitivity of blood culture, which was used for pathogen identification is low.158 
The number of cases may also have been underestimated because severe cases often die 
before any investigation is done. Only two countries provided data on the aetiologic fraction 




Meningitis was the most severe clinical form of S. aureus disease (in terms of case fatality 
ratio) and had the lowest number of cases.  Although S. aureus rarely crosses the blood-brain 
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barrier,281 it can do so particularly when bacterial loads are high, and fatality is usually 
high.281  
There were only three prospective studies on the continent – from Mozambique, Mali, 
Burkina Faso and Togo - reporting the incidence of meningitis in children aged less than five 
years in a non-outbreak setting and using only conventional microbiology to isolate 
pathogens.60 Prospective population-based data on CFR due to S. aureus meningitis in 
children in Africa were not available; therefore, estimates of CFR from the pre-antibiotic era 
or all-cause bacterial meningitis were the only available options. The use of more 
conservative estimates of CFR of all-cause bacterial meningitis in this analysis was 
preferred229 because treatment may have affected survival.  
 
Septicaemia 
Septicaemia accounted for the majority of the cases of severe staphylococcal diseases. About 
a fifth of S. aureus septicaemia cases (20.4%) occurred during the neonatal period. Immature 
immune function,282 rapid acquisition of S. aureus carriage shortly after delivery101 and 
exposure to unhygienic practices increase the risk of S. aureus disease in newborns.  
Mortality from neonatal septicaemia was higher than for other clinical syndromes due to S. 
aureus, which may be as a result of immature immune response and rapid progression of 
the disease or late presentation to the health facility. Strategies are required to reduce 
neonatal SAB and mortality rates on the continent.  
There was considerable heterogeneity among the studies combined in the meta-analyses of 
incidence and aetiologic fraction estimates (I2=0% - 99%). This may be attributable to the 
varying study designs used, varying levels of poverty, ignorance, overcrowding, poor 
hygienic practices, poor access to healthcare, pre-treatment antibiotic use, public health 
programmes, and the burden of HIV infection in the countries. The burden of childhood HIV 
infection was not considered in this analysis because the prevalence was considered low.236 
Although this assumption might have underestimated the disease burden, but only to a 
negligible degree. 
 
Antibiotic use and antimicrobial resistance 
Most of the studies did not report on pre-treatment antibiotic use; however, some excluded 
patients who had received antibiotics in the preceding 2 – 7 days before presentation. None 
of the studies took a history of pre-treatment antibiotic use into account when interpreting 
data on culture results or antimicrobial susceptibility. 
The use of antibiotics by patients can hinder the aetiologic diagnosis of all infectious disease 
syndromes.158 The extent of the decrease in sensitivity is not known, but it is affected by the 
type of antibiotics, the dose, the duration of use, and possibly the pathogen involved. Data 
on study participants with a history of pre-treatment antibiotics should be reported 
separately to promote the comparability of data and possibly increase the yield of cultures. 
In East and West Africa, resistance to ampicillin, amoxicillin and penicillin was high but 
lower for cloxacillin, chloramphenicol, and erythromycin. This is consistent with the 
findings of two recent systematic reviews on antimicrobial resistance among children in 
sub-Saharan Africa.178,194 The high resistance rates of S. aureus to ampicillin, amoxicillin and 
penicillin may be a result of the strong selective pressure of these drugs in the sub-region.  
The prevalence of resistance to cefotaxime and ceftriaxone, third-generation cephalosporins 
is low in the two sub-regions likely because their use is more restricted since they are 
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administered parenterally and would require skilled persons for administration. Their use 
as second-line drugs for the treatment of S. aureus disease in childhood remains relevant. 
 
Challenges in estimating the burden of disease 
Data from population-based studies were only available from a small number of countries. 
Of note, no relevant population-based data were identified from North and Central African 
countries, although together they account for about a quarter of the population of under-
fives on the continent. Moreover, there were no population-based studies on the NPNMNS 
clinical syndromes for consideration in this review. 
Incomplete reporting of study findings on disease burden was also a challenge. It is plausible 
that studies on the aetiology of pneumonia and meningitis may not have considered S. 
aureus as a significant cause of fatality and therefore not reported this outcome. 
Furthermore, the full texts of 60 articles could not be found, despite substantial efforts 
highlighting the importance of open access publication. 
The burden (incidence, cases, and deaths) of a disease can be estimated using population-
based longitudinal or vaccine probe studies. In population-based studies where case 
ascertainment requires pathogen identification by cultures, the true burden of the disease 
is usually under-estimated. Reasons for this underestimation include low rates of hospital 
presentation and investigation, antibiotic use before investigation and the sensitivity of the 
method used for pathogen identification.  
The vaccine probe approach, which uses the incidence of vaccine-preventable disease and 
the aetiologic fraction, remains the best method to estimate cases of disease attributable to 
a particular pathogen.283 Vaccine probe studies are usually randomised trials of vaccines 
with known efficacy; while vaccine-preventable disease incidence is the difference in the 
disease incidence between the unvaccinated and vaccinated groups, the aetiologic fraction 
is the ratio of vaccine efficacy for a clinical syndrome to that for aetiologically-confirmed 
cases.283 However, currently, there is no effective vaccine against S. aureus disease. In the 
absence of vaccine probe studies, population-based studies reporting systematic blood 
culture collection usually describe a considerable disease burden.6,241 All included studies 
reported investigating all or at least 80% of eligible patients. 
There is a need for consensus with respect to case ascertainment and classification. The case 
definition of septicaemia and meningitis is widely accepted while there is a lack of consensus 
on the definition and classification of pneumonia, even by experts.284 For this review, the 
case definition for severe pneumonia in all included studies was as the presence of cough, 
chest wall in-drawing with or without increased respiratory rate (WHO classification or 
similar). However, for studies in which lung aspirates were performed, the presence of 
consolidation on CXR as well as the signs mentioned earlier made up the case definition of 
severe pneumonia. When combining various data, case definition and methods need to be 
as similar as possible in order to reduce heterogeneity. 
Given the fact that there were few relevant population-based studies in Africa; sensitivity 
analyses were done to compare the estimates of cases and deaths when using the aetiologic 
fraction from hospital-based studies to those from population-based studies. The use of 
aetiologic fraction data from hospital-based studies gave a higher estimated burden of 
invasive staphylococcal diseases due to bacteraemic pneumonia and septicaemia. This 
approach could have over-estimated the number of cases and therefore, the number of 
deaths due to the disease because of referral bias as severe or complicated cases are more 
likely to have presented to the hospitals. In contrast, the burden due to staphylococcal 
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meningitis was higher using population-based studies than hospital-based studies. This can 
be explained by the fact that the population-based study on meningitis included neonates 
while the hospital-based study did not. I chose not to combine the use of both population-
based and hospital-based studies to determine aetiologic fraction because the estimates 
differ. This further highlights the need for increased investments in population-based 
research or routine collection of high-quality data through surveillance systems in Africa. 
 
Strengths and limitations 
To the best of my knowledge, this is the first attempt to estimate the burden of community-
acquired S. aureus disease among children aged less than five years in Africa. This study has 
provided conservative estimates of the burden of diseases caused by S. aureus through a 
rigorous systematic review. These estimates will serve as a baseline, a crucial advocacy tool 
for policymakers, and increase awareness among other stakeholders, including clinicians 
and investigators.  
Second, this review has highlighted a knowledge gap in information on S. aureus disease 
burden in Africa. Even though S. aureus is responsible for a wide range of clinical syndromes, 
there is a dearth of population-level aetiology data on most of the diseases caused by this 
pathogen.  
However, this study has some limitations. A significant limitation is the relatively few 
country representative data from Africa. The lack of representative studies was pronounced 
in North and Central African countries. Given this dearth of data, imputation of data for 
countries without information was done which might have over-estimated the numbers for 
some countries and under-estimated for others. In addition to the lack of data on incidence, 
there was a scarcity of prospectively collected data on AMR in community-acquired 
infections in Africa. However, the findings of this study are similar to those of two high-
quality reviews on AMR in African children.178,194 There was also a lack of data on the 
incidence of key clinical syndromes such as endocarditis, septic arthritis and osteomyelitis 
caused by S. aureus. Given the limited data on these syndromes, the true burden of S. aureus 
disease cannot be estimated. Third, even though immunocompromised patients such as 
those with malnutrition, haemoglobinopathy and HIV-infection are at increased risk of 
acquiring S. aureus disease due to repeated exposure to healthcare facility and recurring 
antibiotic use, the estimates were not disaggregated according to these sub-groups. It was 
assumed that these subgroups of patients were included in the estimation because 
individual studies did not screen for these patients. Lastly, uncertainty ranges were not 
determined because of the scarcity of eligible studies. The resampling methods used to 




This study provides the first estimates of the burden of diseases caused by S. aureus in 
children aged less than five years in Africa. The burden is substantial, with an estimated 
392,000 cases and 47,000 deaths. The burden is particularly high among neonates with 
about one-fifth of the septicaemia cases occurring among this age group. S. aureus isolates 
showed relatively high rates of susceptibility to the first-line drug, cloxacillin.  
The findings of this review and analysis will inform policy decisions and prioritization in the 
treatment and prevention of S. aureus disease in Africa. There is a need for population-based 
research, especially in North and Central Africa. These data will also serve as a useful 
baseline to evaluate the impact of interventions. It is hoped that these findings will 
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encourage stakeholders to pursue the development of an effective vaccine and undertake 
clinical trials of such vaccines among African children.  
Chapter 3: The burden of community-acquired Staphylococcus 
aureus bacteraemia in children aged less than five 
years in rural Gambia 
 
Preamble  
This chapter describes the burden (the incidence and case fatality ratio) of S. aureus 
bacteraemia (SAB) among children aged less than five years using data from a surveillance 
study carried out in the Basse Health and Demographic Surveillance System in The Gambia. 
Data collection covered the period before and six years after the introduction of 
pneumococcal conjugate vaccine (PCV) during the course of a study which evaluated the 
impact of PCV introduction on the incidence of SAB. 
 
3.1 Overview 
There is a lack of recent population-based data on the burden of S. aureus bacteraemia (SAB) 
among children in The Gambia. Most of the data available on S. aureus SAB in The Gambia 
come from studies investigating the overall aetiology of invasive bacterial infections 
(IBI).7,47,53,285 Some of these studies were population-based7 while others were hospital-
based.47,53,285,286 The results from these studies cannot be compared because of the different 
study settings and populations. Hospital-based studies have shown that the proportion of 
bacteraemia due to S. aureus seems to be increasing following the introduction of 
pneumococcal conjugate vaccine (PCV).287,288 However, an increase in incidence post-PCV 
introduction has not been confirmed using population-based studies. Such studies are 
essential to assess disease burden because they are less prone to bias as everyone in a 
defined geographical area is under surveillance.  
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Before the introduction of the Hib vaccine in 1997, S. aureus was not considered a significant 
cause of IBI in The Gambia. Two hospital-based studies which assessed children aged less 
than five years with features of pneumonia reported that between 0.6% and 0.8% of all 
patients recruited had SAB, and S. aureus accounted for between 1.3% and 3.6% of all 
significant isolates recovered from these children between 1987 and 1992.53,251 These two 
studies were restricted to children with clinical features suggestive of pneumonia. In a 
population-based study in rural Gambia conducted at a similar time (1989 - 1991), S. aureus 
was detected in 0.4% of all recruited patients with suspected IBI and accounted for 2.7% 
(5/187) of all isolates (Table 3.1).7  Another hospital-based study conducted in 1990 – 1992 
in the same area of The Gambia showed that S. aureus was the leading cause of IBI in children 
less than 91 days of age, representing 3.6% of all cases recruited and accounted for 35.4% 
(17/48) of all isolates.47 Apart from the age difference of the children in these last two 
studies, the different findings may be because the former study recruited children from 
outpatient clinics in a rural community while the latter recruited patients from a secondary 
and a tertiary health care facilities in a semi-urban area. Children seen at the semi-urban 
hospitals might have presented to other primary healthcare facilities before presenting to 
these hospitals and therefore, be exposed to healthcare-associated pathogens such as S. 
aureus. In this era, S. aureus was not demonstrated to be a significant cause of IBI. 
Following the introduction of the Hib vaccine and before the introduction of PCV, the 
proportion of bacteraemia due to S. aureus appeared to increase. A study assessing the 
aetiological agents of bacteraemia in all patients admitted to the MRC Gambia hospital 




Table 3.1: Summary of the studies reporting S. aureus bacteraemia in The Gambia (1980 - 2015) 





Year of data 
collection 
Study site Population  Prevalence of S. 
aureus disease1,2 











1987 - 1988 MRC4 
Hospital, 
Fajara, WCR5 















1989 - 1991 Basse, URR5 < 5 years 5/1162 1  
(0.4) 
 






  Malnourished  




  Malnourished 







      with 
pneumonia  
 
1990 - 1992 MRC4 
Hospital, 
Fajara, WCR5 





















1 Proportion of S. aureus-positive cases among all investigated cases  
2 Proportion of S. aureus-positive cases among true bacteraemia cases  
3 Hib=Haemophilus influenzae type b; PCV=pneumococcal conjugate vaccine 
4 MRC=Medical Research Council Unit The Gambia; RVH=Royal Victoria Hospital 









Table 3.1: Summary of the studies reporting S. aureus bacteraemia in The Gambia (1980 - 






Year of data 
collection 
Study site Population  Prevalence 
of S. aureus 
disease1,2 










1992 - 1994 RVH4, Banjul, 
WCR5 
1 - 9 years 6/276 1 
(2.2) 
 


















< 91 days 17/476 1  
(3.6) 
 
17/38 2  
(44.7) 









2003 - 2005 MRC4 
Hospital, 
Fajara, WCR5 





10/65 2  
(15.4) 
 








2005 - 2015 MRC4 
Hospital, 
Fajara, WCR5 
1 - 59 months 125/477 2 
(26.2) 
1 Proportion of S. aureus-positive cases among all investigated cases  
2 Proportion of S. aureus-positive cases among true bacteraemia cases  
3 Hib=Haemophilus influenzae type b; PCV=pneumococcal conjugate vaccine 
4 MRC=Medical Research Council Unit The Gambia; RVH=Royal Victoria Hospital 
5 WCR=West Coast Region; URR=Upper River Region 
 
 (after S. pneumoniae) representing 1.8% of all investigated children aged 2 months – 5 
years; and accounting for 15.4% (10/65) of bacterial isolates recovered from these patients. 
Following the introduction of PCV, a retrospective study of microbiological data from 
children aged less than five years with features suggestive of bacteraemia admitted into the 
same hospital reported S. aureus as the leading cause (26.2%; 125/477) of IBI.287 Though 
these were hospital-based studies in which the investigation of patients was not 
standardised, the temporary increase in the prevalence of SAB raised the possibility that the 
incidence of SAB may also be increasing. 
It is thought that PCV may affect the nasopharyngeal microbiome,289,290 may impact on the 
prevalence of carriage and potentially the incidence of diseases caused by organisms other 
than S. pneumoniae. As discussed in chapter one, the introduction of PCV has led to a 
considerable reduction in carriage and disease due to vaccine-type S. pneumoniae thereby 
altering the balance of the organisms in the nasopharynx with, in many cases, an increase in 
carriage of non-vaccine types.11,12  Therefore, there has been a growing concern about the 
association between the risk of S. aureus disease and changes in pneumococcal carriage 
following the introduction of PCV. Some investigators have reported an inverse association 
between S. aureus and S. pneumoniae carriage.101,291 However, others have reported that the 
association is confounded by age.25 Given that the vaccine did not substantially change the 
overall pneumococcal carriage, the replacement of S. pneumoniae by other respiratory 
pathogens following the introduction of PCV may be a fallacy. 
Nonetheless, a study in The Netherlands reported an increase in the carriage of S. aureus 
after the administration of PCV,292 even in the setting of a randomised controlled trial.293 In 
the US, a study which compared the proportion of pathogens causing bacteraemia in 
children 3 - 36 months of age in the pre-PCV era to that in the post-PCV era reported an 
increase in S. aureus.288 In The Gambia, a retrospective study of laboratory data suggested 
an increase in the prevalence of SAB after the introduction of PCV.287  
It has been 23 years and 11 years since the introduction of Hib vaccine and PCV respectively 
in The Gambia, yet their effects on S. aureus have not been systematically evaluated. Given 
the paucity of recent population-based data on the epidemiology of SAB in The Gambia and 
sub-Saharan Africa, the incidence, clinical characteristics, case-fatality, and risk factors for 
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SAB in young children in rural Gambia have been studied. I also explored the association of 
SAB with the introduction of PCV.  
Hypothesis 
The incidence of S. aureus bacteraemia among children aged less than five years in Gambia 
did not increase after the introduction of PCV. 
 
3.2 Objectives 
The objectives of this study were to: 
a. Estimate the incidence of and risk factors for SAB among children aged below 
five years in rural Gambia.  
b. Identify risk factors for fatality from SAB. 




Study site, study design and population 
The study was conducted in the Basse Health Centre (BHC) (now known as Basse District 
Hospital) and the Basse Health and Demographic Surveillance System (BHDSS) in the south 
bank of the Upper River Region, and the Bansang Hospital and the Fuladu West Health and 
Demographic Surveillance System (FWHDSS) in the Central River Region of The Gambia 
(Figure 3.1). The BHDSS was established in 2007, comprising 225 villages with a population 
of ~179,000 in 2015 (19% of whom were children aged less than five years). The population 
is enumerated every four months by updating records of all births, deaths, migration, 
pregnancies and marriages.243 A resident in the BHDSS was defined as someone who had 
lived in the area for at least four uninterrupted months, and such a person was assigned a 
unique14-digit identifier. 
The BHDSS is served by five satellite clinics (Demba Kunda, Fatoto, Gambisara, Garawol and 
Koina) and the BHC, a 58-bed primary/secondary healthcare facility with 25 paediatric beds. 
The health centre has an average of 3,600 and 2,000 admissions and deliveries per year, 
respectively. Severe cases that cannot be managed in BHC are referred to Bansang Hospital, 
about 60 km away.  
 
 
Surveillance for pneumonia, meningitis and septicaemia was conducted among residents of 
the BHDSS aged two months and under five years from May 12, 2008, to December 31, 2015. 




From January 1, 2011, until December 31, 2015, surveillance criteria were expanded in the 
BHDSS to include all children less than five years of age who were admitted with an acute 
medical problem from whom blood was collected for culture (admission surveillance). 
Similarly, the surveillance criteria were expanded to include all children aged 0 – 59 months 
admitted with an acute medical problem in the adjacent geographic area of the Fuladu West 
Health and Demographic Surveillance System (FWHDSS, Figure 3.1) from September 12, 
2011, until December 31, 2014 (admission surveillance). The FWHDSS, with a population of 
92,464 in 2014 (18% of which are children aged less than five years) was enumerated 
annually. The FWHDSS is served by Bansang hospital and two satellite clinics - Brikama Ba 
and Jakhaly. Bansang Hospital is a 160-bed secondary health facility with 84 paediatric beds; 
it has an average of 7,000 and 2,000 admissions and deliveries annually, respectively.  
  
Ward admission surveillance in 
Fuladu West HDSS  
0 - 59 months 
(Jan 2012 – Dec 2014) 
 
 
Ward admission surveillance in   
Basse HDSS 
0 - 59 months 
(Mar 2011 – Dec 2015) 
        
Referral surveillance in  
Basse HDSS  
2 - 59 months 
(Jan 2008 – Dec 2015) 
 
2008 2009 2010 2011 2012 2013 2014 2015 
Figure 3.2: Diagram showing the type and different surveillance periods of observation in the Basse and 
Fuladu West HDSS 
 
Conjugate vaccines against H. influenzae type b and pneumococcus were introduced into the 
Gambian National Programme on Immunization in 1997 and 2009, respectively. In 2011, 
the 13-valent vaccine (PCV13) replaced the seven-valent pneumococcal conjugate vaccine 
(PCV7). Vaccine coverage for the third dose of diphtheria-pertussis-tetanus vaccine in these 
regions was about 81.7% in 2012.294 In The Gambia, the transmission of Plasmodium 
falciparum occurs mostly during the short rainy season between July and November.295 In 
2018, 40.6% of children under the age of five years slept under insecticide-treated nets.296 




After obtaining written approval to conduct the study from the director of the Regional 
Health Team, we undertook community sensitisation in stages. A series of meetings to share 
the details of the study were held with the village heads, members of the Village 
Development Committees, religious leaders, and all members of all the villages in the south 
bank of the Upper River Region. Also, the villagers had an opportunity to ask questions at 
the end of each meeting. 
 
Training 
At the beginning of, and whenever a new staff member joined the study, clinicians, nurses, 
laboratory, and radiology staff were trained on study-specific procedures. Retraining 






Surveillance was conducted between May 12, 2008 and December 31, 2015, except for four 
weeks in 2010 (October 5 – November 3, 2010) when there was flooding of the Medical 
Research Council (MRC) Basse field site. All children aged 2 - 59 months who had an HDSS 
unique identifier and presented to the BHC or any of the other five satellite clinics in the 
BHDSS were screened for pneumonia, meningitis and septicaemia by a study nurse using 
standardised criteria (referral surveillance) (Table 3.2).243 These included children who 
were treated as either as outpatients or admitted. 
 












Patients 2 – 59 months of age 
The presence of one or more of the following: 
• Bulging fontanelle 
• History of convulsion 
• History of cough or difficulty in breathing accompanied by raised respiratory rate1 
• Impaired consciousness2 
• Irrespective of age any child with suspected meningitis 
• Local musculoskeletal swelling or tenderness 
• Lower chest wall in-drawing, or nasal flaring or grunting 
• Oxygen saturation less than 92% 
• Prostration3 
• Stiff neck 
• Weight for age z-score ≤-3 for age 
1 Raised respiratory rate for age referred to above 60 breaths per minute for infants less than 2 months of age, above 
50 breaths per minute for those between 2 and 12 months of age and above 40 breaths per minute for children more 
than 12 months of age but less than 5 years. 
2 Impaired consciousness was accessed using the Blantyre Coma Scale. From Taylor, T. Caring for children with 
cerebral malaria: insights gleaned from 20 years on a research ward in Malawi. Transactions of the Royal Society of 
Tropical Medicine and Hygiene 2009:103 (Suppl 1): S6-S10 DoI: 10.1016/j.trstmh.2008.10.049 
3 Prostration is defined as inability to drink or sit in a child who had been able to do so before the illness started 
 
Study nurses referred infants or children who were positive on screening to a clinician, who 
used standardised criteria for assessment and investigation (Table 3.3).243 Data collected 
included age, sex, anthropometric measurements, presenting symptoms and signs, and 
suspected diagnosis.  
UNICEF chronometers were used to count respiratory rates which were observed for one 
minute in an awake quiet child, while a digital pulse-oximeter was used to measure the pulse 
rate and oxygen saturation. Blood was collected for culture and depending on clinical 
presentation, cerebrospinal fluid, lung aspirates or pleural fluid samples were taken for 
conventional microbiology.12 A rapid diagnostic test (RDT) for malaria (ICT Diagnostics, 
Cape Town, South Africa) was routinely done between August and December, and at other 
times at the discretion of the clinician. All SAB cases identified were linked to the DSS 
databases using the unique 14-digit identifier. 
 
Anthropometry 
Weight, assessed to the nearest 100 g, was measured using a digital weighing scale (TANITA, 
Arlington Height, IL, USA), and length or height and mid-upper arm circumference were 
recorded to the nearest millimetres with a ShorrBoard (Weigh and Measure, Olney, MD, 
USA) and measuring tapes, respectively. 
 
Blood culture collection procedure 
All the equipment required for the procedure were set in a tray, and the required sample 
bottles labelled. The mother carried the patient on her lap, and the phlebotomist identified 
the vein to use, tied a tourniquet above the selected vein, and cleaned the skin over the area 
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with an alcohol swab in a concentric circular motion and allowed this to dry. Meanwhile, the 
phlebotomist put on a pair of sterile gloves. After that, the vein was cannulated using a sterile 
 














butterfly needle and one to three millilitres of blood drawn into a syringe. The needle was 
removed from the syringe and replaced with a sterile needle which was then used to 
inoculate the BD BACTEC™ Peds Plus™/F culture vial.   
 
Patients 2 – 59 months of age 
Pneumonia 
Cough or difficulty breathing AND one or more of the following: 
•   Raised respiratory rate for age1 
•   Lower chest wall in-drawing, nasal flaring or grunting 
•   Oxygen saturation < 92% 
•   Focal chest sign (dull percussion notes, coarse crackles, bronchial breathing) 
 
Meningitis 
One or more of the following: 
•  Convulsion 
•  Impaired consciousness2 
•  Neck stiffness with or without photophobia 
•  Prostration 
•  Bulging fontanelle 
 
Septicaemia 
One or more of the following: 
•   Any patient with axillary temperature <36°C or ≥38°C 
•   Any patient with severe clinical malnutrition 
•   Clinician diagnosis of focal sepsis (including but not limited to cellulitis, endocarditis, liver 
abscess, osteomyelitis, peritonitis, septic arthritis, soft tissue abscess), or of generalised 
septicaemia 
1 Raised respiratory rate defined as above 60 breaths per minute for infants less than 2 months of age, above 50   
breaths per minute for those between 2 and 12 months of age and above 40 breaths per minute for children more 
than 12 months of age but less than 5 years. 
2 Impaired consciousness is accessed using the Blantyre Coma Scale. Taylor, T. Caring for children with cerebral 
malaria: insights gleaned from 20 years on a research ward in Malawi. Transactions of the Royal Society of Tropical 
Medicine and Hygiene 2009:103 (Suppl 1): S6-S10 DoI: 10.1016/j.trstmh.2008.10.049 
 
 
3.3.2 Laboratory methods 
One to three millilitres of blood collected from patients with suspected pneumonia, 
meningitis, or septicaemia was inoculated into a paediatric BACTEC™ bottle and incubated 
in an automated BACTEC™ 9050 blood culture system for a maximum of five days. Standard 
methods were used to investigate other microbiological samples.53 Positive cultures were 
subcultured on blood agar plates and isolates were confirmed as S. aureus by catalase and 
coagulase tests. Cultures that grew Bacillus spp, Corynebacteria spp, Streptococcus viridans 
and coagulase-negative Staphylococcus were classified as contaminated. Disc diffusion 
methods were used to determine antibiotic susceptibility according to Clinical and 
Laboratory Standards Institute (CLSI) guidelines.272 Cefoxitin was used as a surrogate for 
methicillin-resistance with a cut-off diameter of 21mm.272 All laboratory processes were 
internally controlled. The laboratory submitted to external quality assurance by the WHO 
Reference Laboratory, Denmark, the Royal Australasian College of Pathologists, Sydney, 
Australia and United Kingdom National External Quality Assessment Service, Sheffield, UK. 
 
3.3.3 Management of patients 
Any child with an oxygen saturation of less than 92% had oxygen therapy. According to the 
Gambian national treatment guidelines175 for treating suspected septicaemia, we 
commenced empiric antibiotics after sampling and before the results of blood cultures were 
available. For suspected mild and severe pneumonia, oral amoxicillin and intravenous 
penicillin and gentamicin were administered, respectively; for meningitis, intravenous 
chloramphenicol, and penicillin and for suspected septicaemia, intravenous ampicillin and 





SAB cases were clinically suspected cases of pneumonia, meningitis, septicaemia, abscess,  
osteomyelitis, pyomyositis, or septic arthritis identified using standardised criteria243 and 
from whom S. aureus was isolated only from the blood. 
When the surveillance diagnosis included more than one clinical syndrome, the most 
clinically severe one was chosen as the diagnosis for the participant 
(meningitis>>septicaemia>> pneumonia>>focal sepsis). 
 
3.3.4 Ethical considerations 
Ethical approval for the study was granted by the Gambia Government/Medical Research 
Council Joint Ethics Committee, and the London School of Hygiene and Tropical Medicine 
Ethics Committee. Written informed consent was obtained from the parents or guardians 
of all patients. 
 
3.3.5 Statistical methods 
Surveillance data from two sources were used for statistical analyses:  
a) standardised nursing referrals (referral surveillance) in the BHDSS from May 12, 2008 - 
December 31, 2015 restricted to children aged 2 - 59 months who met clinical criteria for 
investigation and, b) routine admissions (admission surveillance) in the BHDSS (2011 - 
2015) and FWHDSS (2012 - 2014) which included children aged 0 - 59 months admitted 
with an acute medical problem (Figure 3.2). Each patient had a unique identifier irrespective 
of the dataset in which he or she appeared, so was not counted twice. The referral data were 
used to investigate trends in incidence because it covered a more extended period (2008 - 
2015) than the admissions data (2011 – 2015). While the combined admission (2011 – 
2015) and referral data (2011 – 2015) were used to estimate the age-specific incidence and 
case fatality ratio.  
Incidence estimates were obtained by dividing the number of SAB cases by the number of 
person-years at risk, calculated from mid-point population estimates. To account for the 
shorter period of observation in 2008 (May 12 – December 31), person-years at risk were 
calculated as the mid-year population multiplied by 234/365. The incidence in neonates was 
calculated using two methods: firstly, as cases per 1,000 live births and secondly as cases 
per 100,000 person-years. Neonatal period was defined as the period between birth and 28 
days of life. 
Using the data from referral surveillance, trends in incidence over time and variation in 
incidence before and after the introduction of PCV were assessed using Poisson regression 
with robust error variance to allow for over-dispersion of the data. The era before PCV 
introduction (pre-PCV period) was defined as the interval between May 12, 2008 and May 
11, 2010 while that after the introduction (PCV13 period) as the period between January 1, 
2013 and December 31, 2015. To account for an increase in the rate of eligible patients 
requiring blood culture over time, the annual numbers of age-specific SAB cases were 
multiplied by a correction factor, the reciprocal of the ratio of the annual rate of eligibles 
enrolled/mean rate of enrolment of eligibles over the study period. The population 
denominators for the pre-PCV and PCV13 periods were averages of the mid-point 
populations in the BHDSS in the comparator periods. Categorical variables were compared 
using the Chi-square test. Surveillance diagnosis was categorised into mutually exclusive 
groups in the order of severity (meningitis>> septicaemia>>pneumonia). 
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The case fatality ratio (CFR) was defined as the ratio of the number of SAB cases who died 
before discharge to the total number of SAB cases. Potential risk factors for fatality before 
discharge were identified using logistic regression, although surveillance was not designed 
to assess risk factors. The risk factors assessed include age, sex, nutritional status, axillary 
temperature, pulse rate, respiratory rate, cough, difficult breathing, prostration, hypoxia, 
admission in the preceding two weeks before presentation and season. SAB death in relation 
to the total number of deaths in the population was determined by dividing the number of 
SAB deaths by those of the total number of deaths in both HDSS areas between 2011 and 
2015. 
Weight-for-age (WAZ) and weight-for-height (WHZ) z-scores were generated using 2006 
WHO child growth standards. Children with WAZ and WHZ z-scores <-3 were considered 
severely underweight and wasted, respectively. 
Analyses were done using Stata 14.0 (College Station, Texas 77845 USA). A p-value of <0.05 
was used to indicate statistical significance. 
 
3.4 Results 
A total of 33,060 children met the criteria for investigation and 27,851 (84.2%) blood 
culture samples were collected at presentation at the health facility (Figure 3.3). Of the 5,209 
children who did not have samples taken for blood culture, 487 (9.3%) had an unsuccessful 
venepuncture, 416 (8.0%) declined consent for venepuncture, 249 (4.8%) declined to join 
the study, and for 4057 (77.9%) no reason was given. Contaminants grew in 2,539 (9.1%) 
of blood cultures, and these children were excluded from the analysis as contamination may 
have masked a true SAB.  
3.4.1 Characteristics of included patients 
Using the combined admission and referral data, 8.3% (2,092/25,307) of all enrolled 
patients were neonates, 44.0% (11,138/25,307) were less than one year of age and 56.8% 
(14,369/25,307) were males. Of all patients, 20.0% (4,541/22,729) were severely 
underweight, 16.1% (3,661/22,729) severely wasted, and 18.3% (4,183/22,902) had been 
admitted in the two weeks before presentation. Antibiotic use in the week before 
presentation was uncommon (11.0%; 1,694/15,407). The majority of patients had pyrexia 
(≥37.5OC) and tachypnoea (Table 3.4). 
 
3.4.2 Bacteraemia 
Bacteraemia were identified in 1,130 children aged 0 - 59 months (Figure 3.3). Nine hundred 
and thirty-two of these children (521 identified through referral surveillance and 418 
through admission surveillance) had pathogens other than S. aureus isolated. These 
pathogens include S. pneumoniae (35.0%; n=326), Salmonella spp (15.1%; n=141) and 
Escherichia spp (10.7%; n=100). S. aureus was isolated from 198 (17.5%) of children with 
bacteraemia and was the most common cause of neonatal bacteraemia (46.4%; 84/181). Of 
the 198 S. aureus bacteraemia cases, 76 were identified through referral surveillance and 
122 through admission surveillance. In seven children with bacteraemia, S. aureus and a 





Figure 3.3: Study profile (2008 - 2015) 
1 Reasons for not having blood culture done include unsuccessful venepuncture 487, declined consent for 
venepuncture 416, declined consent to join study 249, reasons not given 4057 
2 76 identified through referral surveillance and 122 admission surveillance 
3 Seven patients had polymicrobial (S. aureus and a second bacterial pathogen) bacteraemia, n=521 cases 
identified through  referral surveillance  and n=418 through  admission surveillance 
 
 
3.4.3 Clinical features of all patients identified through both surveillance 
systems  
Patients with SAB were significantly younger than those with bacteraemia due to other 
pathogens and those without bacteraemia (p<0.001) (Table 3.4). Fewer SAB patients 
presented with a cough and difficult breathing than patients with bacteraemia caused by 
other pathogens and those without bacteraemia (Table 3.5). SAB patients were less likely to 
be severely wasted compared to patients with bacteraemia due to other pathogens and more 
likely to be severely wasted compared to patients without bacteraemia. More SAB patients 
presented with an altered level of consciousness compared to patients with bacteraemia due 
to other pathogens, while the reverse was the case for signs of meningism. SAB patients were 
more likely to have a diagnosis of suspected septicaemia or other focal sepsis and less likely 
33,060 
children 















to have a diagnosis of suspected pneumonia compared with patients with bacteraemia 
caused by other pathogens and those without bacteraemia (p<0.001) (Table 3.5). 
Among SAB cases, a diagnosis of suspected pneumonia, meningitis, or septicaemia was made 
in 28.3%, 6.7%, and 56.2% of cases, respectively (Table 3.5). The median (IQR) duration of 
hospital stay for SAB patients was 5 (2, 6) days (Table 3.4). SAB patients had significantly 
longer hospital stay compared to patients with other bacteraemia and those without 
bacteraemia (Table 3.4). One hundred and thirty-one SAB cases were tested for malaria, of 















Table 3.4:  Characteristics of patients with S. aureus bacteraemia, bacteraemia other than 
due to S. aureus, and those with suspected pneumonia, meningitis, or septicaemia without 
bacteraemia, identified through referral and admission surveillance in the Basse and Fuladu 
















































Age     
<1 month 84/198 (42.4) 97/932 (10.4) 1911/24177 (7.9)  
1 – 11 months 61/198 (30.8) 310/932 (33.3) 8675/24177 (35.9)  
12 – 23 months 33/198 (16.7) 265/932 (28.4) 7505/24177 (31.0)  
24 – 59 months 
 
20/198 (10.1) 260/932 (27.9) 6086/24177 (25.2) <0.001 
Sex     
Males 97/198 (49.0) 532/932 (57.1) 13740/24177 (56.8)  
Females 
 
101/198 (51.0) 400/932 (42.9) 10437/24177 (43.2) 0.14 







20/109 (18.3) 216/884 (24.4) 3425/21736 (10.5) <0.001 
Mid-upper arm circumference (cm)    
< 11 81/198 (40.9) 184/932 (19.7) 3080/24182 (12.7)  
≥ 11 
 
117/198 (59.1) 748/932 (80.3) 21102/24182 (87.3) <0.001 
Admitted in the past two weeks    
Yes 
 
31/162 (19.1) 157/843 (18.6) 3995/21897 (18.2) 0.93 
Length of hospital stay (days)    
Median (IQR) 
 
5 (2, 6) 4 (3, 6) 3 (2,4) <0.001 
Season3     
Dry 101/198 (51.0) 597/932 (64.1) 13836/24171 (57.2)  
Wet 
 
97/198 (49.0) 335/932 (35.9) 10335/24171 (42.8) <0.001 
Outcome     
Recovered 170/198 (85.9) 771/932 (82.7) 23322/24182 (96.4)  
Died  
 
28/198 (14.1) 161/932 (17.3) 860/24182 (3.6) <0.001 
SD=standard deviation. Weight-for-height was calculated in STATA using z-scores from the 2006 WHO child growth 
standards in STATA. 
1 p-value was calculated using Chi-square test; comparison is across patient groups 
2 Neonates were excluded 
3 Wet season = July-October; dry season=November-June 
 
 Table 3.5:   Symptoms and signs of patients with S. aureus bacteraemia, bacteraemia other than due to S. 
aureusS. aureus , and those with suspected pneumonia, meningitis, or septicaemia without bacteraemia, 








































Symptoms     
Cough 103/198 (52.0) 675/928 (72.7) 19523/24148 (80.9) <0.001 
Difficult breathing 89/197 (45.2) 535/927 (57.7) 14280/24102 (59.3) 0.003 
Prostration 29/197 (14.7) 147/918 (16.0) 1602/23906 (6.7) <0.001 
Diarrhoea 38/190 (20.0) 271/861 (31.5) 5798/22772 (25.5) <0.001 
Convulsion 8/198 (4.0) 72/927 (7.8) 1174/24127 (4.9) <0.001 
Signs     
Lower chest wall 
in-drawing 
164/198 (82.8) 732/927 (79.0) 17856/24129 (74.0) <0.001 
Meningism1 1/192 (0.5) 34/867 (3.9) 174/22841 (0.8) <0.001 
Altered level of 
consciousness 
 
124/193 (64.2) 407/873 (46.6) 9590/23518 (40.8) <0.001 
Axillary Temperature    
<36.5oC 18/198 (9.1) 79/932 (8.5) 2405/24182 (10.0)  
36.5 – 37.5oC 40/198 (20.2) 147/932 (15.8) 6819/24182 (28.2)  
>37.5oC 
 
140/198 (70.7) 706/932 (75.7) 14958/24182 (61.8) <0.001 
Pulse Rate (/min)2    
Abnormal for age 
 
84/198 (42.4) 621/932 (66.6) 15107/24182 (62.5) <0.001 
Respiratory Rate3 (/min)     
Abnormal for age 128/198 (64.6) 
 
682/932 (73.2) 17157/24177 (71.0) 0.07 
Oxygen saturation (%)    
≤92% 
 
33/198 (16.7) 116/932 (12.4) 2140/24182 (8.9) <0.001 
Suspected diagnosis4    
Pneumonia 55/194 (28.3) 347/896 (38.8) 13244/23068 (57.4)  
Meningitis 13/194 (6.7) 96/896 (10.7) 718/23068 (3.1)  
Septicemia 109/194 (56.2) 434/896 (48.4) 8549/23068 (37.1)  
Other focal sepsis 
 
17/194 (8.8) 19/896 (2.1) 557/23068 (2.4) <0.001 
Malaria positivity5    
Yes 14/131 (10.7) 84/723 (11.6) 3276/21626 (15.2) 0.01 
1 Meningism is defined as the clinical syndrome of headache, neckstiffness and photophobia. Solomon T., Manji  H. 
Neurologic Diseases: In Hunter's Tropical Medicine and Emerging Infectious Disease (9th Edition) Saunders Elsevier2013, 
Pages 84-97 
2 Definition of normal pulse rate: Less than 1 month old: 70 to 190 beats per minute; 1 to 11 months old: 80 to 160 beats 
per minute;  1 to 2 years old: 80 to 130 beats per minute;  3 to 4 years old: 80 to 120 beats per minute; Bernstein D. 
Evaluation of the cardiovascular system: History and physical evaluation. In: Kliegman RM, Stanton BF, St. Geme JW III, et al., 
eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Elsevier Saunders; 2011: chap 416. 
3 Abnormal respiratory rates: >60 breaths per minute for children less than two months of age, >50 breaths per minute for 
children between 2 months and 12 months of age, >40 breaths per minute for children between >12 months and five years 
of age (Handbook of IMCI). 
4 Surveillance diagnosis was categorised into mutually exclusive groups in order of severity 
(meningitis>>septicemia>>pneumonia). 





3.4.4 Incidence and risk factors for S. aureus bacteraemia 
Using the combined referral and admission data (2011 - 2015 in BDHSS and 2012 - 2014 in 
FWHDSS), the incidence of SAB was 78 cases per 100,000 person-years (95% CI 67 - 91 
cases per 100,000 person-years) in children aged 0 - 59 months. The incidence was highest 
in the neonatal period (2,080 cases per 100,000 person-years; 3.5 cases per 1,000 live 
births) and decreased in older age groups (Figure 3.4). The incidence of SAB in the 1 - 11 
month age group was 133 cases per 100,000 person-years (95% CI 99 – 174 cases per 
100,000 person-years) and in the 1 - 4 year age group the incidence was 27 cases per 
100,000 person-years (95% CI 20 – 36 cases per 100,000 person-years). Among the 84 
neonatal SAB cases, 13 (15.5%) and 35 (41.6%) presented in the first and second weeks of 
life, respectively (Figure 3.5). The incidence of SAB was higher in the wet season than in the 
dry season (Table 3.6). 
 















years at risk 
Rate/100,000 
person-years 
Rate ratios  
(95% CI) 
p-value 
Age     
24-59 months  18/128994 14.0 1  
12-23 months 29/44433 65.3 4.7 (2.6-8.4)  
1–11 months 53/39969 132.6 9.5 (5.6-16.2)  
< 1 month 
 
70/3367 2079.6 149.0 (88.8 – 250.1) <0.001 
Sex     
Males 82/107515 76.3 1  
Females 
 
88/109248 80.6 1.06 (0.8-1.4) 0.72 
Season     
Dry  85/144508 58.8 1  
Wet 
 
85/72255 117.6 2.00 (1.5-2.7) <0.001 
             CI=Confidence Interval 
 
 
Figure 3.4: Age-specific incidence of S. aureus bacteraemia (cases identified through combined referral 










































2011 2012 2013 2014 2015 All years
Year























1 2 3 4
Age in weeks 
Bars = confidence intervals 
137 
 
3.4.5 Trends in the incidence of SAB over time 
Based on referral surveillance conducted between 2008 and 2015 in the BHDSS, the mean 
annual incidence of SAB in children aged 2 - 59 months was 22.3 cases per 100,000 person-
years (95% CI 16.7 – 29.2). There was no change in incidence over this period (p-value for 
trend=0.28) although PCV vaccination coverage increased during the period (Figure 3.6). 
Using referral data, among children aged 2 - 59 months there were nine observed and ten 
adjusted SAB cases in the pre-PCV period (May 12, 2008 – May 11, 2010) and 26 observed 
and 23 adjusted SAB cases in the PCV13 period (January 1, 2013 - December 31, 2015). After 
adjusting for increased enrolment of eligible children over time, there was no significant 
increase in SAB incidence from the pre-PCV (18 cases per 100,000 person-years) to the 
PCV13 period (23 cases per 100,000 person-years) (IRR=1.3, 95% CI 0.6 – 2.7; p=0.49). 
 
3.4.6 Case fatality ratios and risk factors associated with fatality 
There were 28 deaths before discharge among 198 SAB cases (CFR=14.1% 95% CI 9.4 – 
20.4). In comparison, the CFR in patients without bacteraemia was 3.6% (95% CI 3.3 – 3.8) 
and 17.2% (95% CI 14.7 – 20.1) in patients with bacteraemia due to other pathogens. The 
SAB CFR did not vary by year (p-value for trend=0.75) or with age (p-value for trend=0.99). 
Deaths associated with SAB were most common on the day of admission (71.4%; 20/28). Of 
the fatality that occurred in neonates, 15.0% (2/13) died in the first week of life while 85.0% 
(11/13) occurred in the last three weeks of the neonatal period. SAB deaths accounted for 
7.6% (13/171; 0.7 per 1,000 live births) and 4.2% (28/662; 1.4 per 1,000 live births) of all 
deaths in neonates and children aged less than five years, respectively between 2011 and 
2015. About 5.5% (3/55), 38.5% (5/13), and 17.4% (19/109) of patients with pneumonia, 
meningitis, and septicaemia, respectively died. A risk factor for fatality was clinical 




Figure 3.6: Annual incidence of S. aureus bacteraemia per 100,000 person-years in children aged 2 - 59 
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             Table 3.7: Case fatality associated with S. aureus bacteraemiaS. aureus  and socio-demographic,    






























Age    
< 1 month 13/84 (15.5) 1  
1 – 11 months 8/61 (13.1) 0.8 (0.3 – 2.1)  
12 - 23 months 4/33 (12.1) 0.8 (0.2 – 2.5)  
24 - 59 months  
 
3/20 (15.0) 1.0 (0.3 – 3.8) 0.961 
Sex    
Males 16/97 (16.5) 1  
Females 
 
12/101 (11.9) 0.7 (0.3 – 1.5) 0.35 
Severely wasted (weight-for-height <-3SD)2   
No 19/149 (12.8) 1  
Yes 4/40 (10.0) 0.8 (0.2 – 2.4) 0.63 
Axillary temperature    
36.5 – 37.5oC 4/18 (22.2) 1  
<36.5oC 4/40 (10.0) 0.4 (0.1 – 1.8)  
>37.5oC 
 
20/140 (14.3) 0.6 (0.2 – 2.0) 0.48 
Pulse Rate (/min)    
Normal for age 13/114 (11.4) 1  
Abnormal for age 
 
15/84 (17.9) 1.7 (0.8 – 3.8) 0.20 
Respiratory Rate (/min)    
Normal for age 8/70 (11.4) 1  
Abnormal for age 
 
20/128 (15.6) 1.4 (0.6-3.5) 0.41 
Need for oxygen supplementation   
No 21/165 (12.7) 1  
Yes 7/33 (21.2) 1.9 (0.7 – 4.8) 0.22 
Season    
Dry 18/101 (17.8) 1  
Wet 
 
10/97 (10.3) 0.5 (0.2 – 1.2) 0.13 
Cough    
No 13/95 (13.7) 1  
Yes 
 
15/103 (14.6) 1.1 (0.5- 2.4) 0.86 
Difficult breathing    
No 14/108 (13.0) 1  
Yes 
 
 14/89 (15.7) 1.3 (0.6 – 2.8) %)0.58 
Prostration   % 
No 17/168 (10.1) 1  
Yes 
 
11/29 (37.9) 5.4 (2.2 – 13.4) 0.0004 
Admitted in the past two weeks   
No 20/131 (15.3) 1  
Yes 2/31 (6.5) 0.4 (0.1- 1.7) 0.16 
   OR=Odds Ratio; CI=Confidence Interval; SD=Standard Deviation.  
    1 p-value for trend 
    2 Weight-for-height were calculated using z-scores from the 2006 WHO child growth standards in STATA. 
 
3.4.7 Treatment and susceptibility of isolates 
Among SAB cases identified through referral surveillance, 17.1% (13/76) received initial 
empiric therapy with cloxacillin, 23.7% (18/76) empiric ampicillin and 31.6% (24/76) 
empiric penicillin while 50.0% (38/76) received empiric gentamicin. Fifty (65.8%) patients 
received more than one antibiotic while 26 (34.2%) had monotherapy. Only 53 (69.7%) 
patients had appropriate antibiotics. Appropriate antibiotics are those that were considered 
effective for treatment of diseases caused by S. aureus. There was no difference in mortality 
according to the empiric treatment received. Among the SAB cases, 3.1% of the 193 isolates 
tested were methicillin-resistant using cefoxitin as a surrogate (Table 3.8). At least 80% of 
the isolates were sensitive to all the antibiotics tested except cotrimoxazole and penicillin. 
 




















Cefoxitin 193 187 (96.9) 0 (0.0) 6 (3.1) 
Chloramphenicol 186 176 (94.7) 2 (1.0) 8 (4.3) 
Cotrimoxazole 180 119 (66.1) 21 (11.7) 40 (22.2) 
Erythromycin 173 141 (81.5) 24 (13.9) 8 (4.6) 
Gentamicin 177 174 (98.3) 0 (0.0) 3 (1.7) 
Oxacillin 194 170 (87.6) 24 (12.4) 0 (0.0) 
Penicillin 101 7 (7.0) 0 (0.0) 94 (93.0) 





The incidence and case fatality ratio of S. aureus bacteraemia (SAB) in rural Gambia were 
estimated using surveillance data over five years and trends in incidence over 8 years were 
also evaluated. The incidence was high, particularly in neonates (3.5 cases per 1,000 live 
births) but did not increase with time or following the introduction of PCV (Figure 3.6). The 
case fatality ratio (14.1%) was substantial (Table 3.6) and did not vary with age. 
 
Incidence of SAB 
The observed incidence of SAB in children aged 0 - 59 months (78 cases per 100,000 person-
years) was higher than that reported in some studies conducted in high-income countries 
(6.5 – 42.0 cases per 100,000 person-years),26,70 and in some African6 and Asian44,298 studies 
but lower than in others.45 An incidence of SAB of 10.9 cases per 100,000 person-years was 
reported among children less than 18 years of age in Iceland.70 This was a retrospective 
study in which both clinical and microbiological data were obtained from medical records 
in the two tertiary hospitals serving the area. Additionally, other secondary healthcare 
facilities in the area sent their blood cultures to one of the tertiary hospitals. In Australia and 
New Zealand, a study that prospectively reviewed cases of SAB in 33 hospitals reported an 
incidence of 8.3 cases per 100,000 person-years and 14.4 cases per 100,000 person-years, 
respectively in children less than 15 years of age.79 However, the reported incidence in both 
studies might have been under-estimated because some cases may have presented to 
hospitals other than those used in the studies. The difference in our estimate and those of 
these studies may be related to the age of the population studied. 
In Thailand, a study of bacteraemia which reviewed national hospital-based data reported a 
SAB incidence of 83.5 cases per 100,000 person-years in children less than 12 months old.44 
A Bangladeshi population-based study which focused on children aged 1 - 59 months with 
respiratory symptoms reported an incidence of 9.9 cases per 100,000 person-years.298  
In South Africa, a study that reviewed the records of SAB patients aged less than 13 years in 
the only public hospital serving the study area reported an incidence of 26 cases per 100,000 
person-years.71 The difference in incidence reported in the South African and Asian studies 
may be due to the high prevalence of HIV in the community. S. aureus diseases have higher 
incidence rates in HIV-infected compared to HIV-uninfected children.71,82 Other reasons for 
the difference include the age of the population and the clinical syndrome studied. A Kenyan 
study reported a SAB incidence of 27 cases per 100,000 person-years in children less than 
five years of age6 while an incidence of 118 cases per 100,000 person-years was observed 
in children aged less than five years in Mozambique.45 Even though the Kenyan and 
Mozambican studies were population-based, the difference in reported incidence may be 
attributable to the prevalence of HIV in the two countries. The prevalence of HIV in pregnant 
women attending the antenatal clinic in Kenya was 9.8%299 while that in Mozambique was 
23.4%.300 Other differences in incidence between these studies including the current study 
are likely to be related to the selection criteria employed by the various studies or related to 
the high levels of antibiotic use without a prescription, especially in Asia.301  
There was no trend over time in the incidence of SAB between 2008 and 2015. Researchers 
in the United States and The Gambia have reported an increase in the proportion of all 
bacteraemia caused by S. aureus following the introduction of PCV.287,288 Both of these 
studies were retrospective reviews of medical records. However, our data do not support an 
association between SAB incidence and the introduction of PCV. Nevertheless, this study 
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S. aureus was the most common cause of bacteraemia in neonates, and the incidence of SAB 
was highest in neonates, eight times greater than that reported in Kenya.6 This finding is 
similar to other studies in Africa,45,48,250,302 where S. aureus was responsible for between 
39.0% and 56.2% of isolates recovered from neonates.  
S. aureus carriage, which is a prerequisite for disease, is also highest during the neonatal 
period, higher than the carriage of S. pneumoniae and H. influenzae.100 In addition to high 
carriage rates of S. aureus in the neonatal period, other reasons for the high risk of SAB may 
include an immature innate immune system. 
The incidence of neonatal SAB (3.5 cases per 1,000 live births) was higher than the other 
pathogens responsible for neonatal bacteraemia. In Africa, the pooled incidence of neonatal 
bacteraemia caused by group B streptococcus (GBS) was 1.12 cases per 1,000 live births,303 
while the incidence of E. coli bacteraemia ranged between 0.8 cases per 1,000 live births6  
and 1.7 cases per 1,000 live births.250  
In this study, only 16% and 42% of the neonatal SAB cases presented within the first and 
second weeks of life respectively unlike neonatal GBS disease where about 80% of patients 
present within this period. Reasons for the difference in timing of presentation may relate 
to the age at, and source of S. aureus acquisition. Unlike neonatal GBS disease where the 
source of transmission is from the mother’s birth canal during delivery, the source of 
acquisition may be different in neonatal SAB. Acquisition of S. aureus during the neonatal 
period peaks by the end of the first week of life.25,100,101 In Tanzania, a study on the aetiology 
of neonatal infections reported that SABS. aureus  was more common in babies after the first 
week of life (which is similar to the finding in this study) and that S. aureus was the most 
frequent cause of pustules and omphalitis throughout the neonatal period.48  This finding 
demonstrates that the source of S. aureus infection may be from handling by healthcare 
workers or family members or contact with hospital surfaces and fomites. A Ugandan study 
which aimed to correlate the pathogens recovered from neonates with sepsis with those 
recovered from their mothers’ vagina demonstrated no concordance between the pair.266 
This shows that transmission to neonates may be from a different source. Further studies 
are needed to clarify how neonates acquire their infection. 
 
Risk factors for S. aureus bacteraemia 
S. aureus bacteraemia was found to be more common during the wet season. This seasonal 
variation may relate to S. aureus carriage (a prerequisite for disease), the prevalence of 
which is highest during the wet season304 or seasonal differences in the incidence of viral 
infections which are known to disrupt the mucosal epithelium, thereby encouraging S. 
aureus invasion.305 In a study of US adults,306 the peak incidence of S. aureus infection 
occurred during the winter months and coincided with the peak incidence of viral infections. 
In Africa, the incidence of viral infections usually peaks during the wet season,246 coinciding 






Blood culture was the diagnostic method used in this study because it is the gold standard 
and affords the opportunity for antibiotic sensitivity testing and comparability to other 
studies. However, blood culture has a low sensitivity which might have led to an 
underestimation of the incidence. The yield could have been increased from about 65% to 
between 80% – 95% by taking two or more blood cultures per patient. Most authorities 
recommend collection of multiple sets of blood culture samples. However, such an approach 
is not the norm in epidemiological studies. 
The administration of antibiotics before sampling inhibits the growth of the pathogen 
leading to an under-estimation of disease incidence. In this study, apart from the fact that 
the use of antibiotics before sampling was uncommon, the utilisation of BACTEC culture 
media with antimicrobial-binding agents such as resins and charcoal should have reversed 
the inhibitory effects of the antibiotics.307 This is particularly true for staphylococci.307  
 
Prior antibiotic use, treatment, and antimicrobial resistance 
Use of antibiotics in the week before presentation or sampling for cultures is known to delay 
the median time to grow or outrightly mask the yield of pathogens. In this study, the use of 
antibiotics in the week before presentation was uncommon and would have had a negligible 
influence on the incidence of SAB.  
Only 70% of SAB cases received appropriate antibiotics in this study. However, there was 
no difference in mortality by treatment groups. About 66% of the patients received more 
than one antibiotic concurrently.  As per the National guidelines, two antibiotics are 
recommended for the treatment of suspected septicaemia and severe pneumonia.  
About 12% of the S. aureus isolates were resistant to oxacillin. This is similar to the reports 
from some studies from Tanzania and Gambia249,285 and different from other studies from 
Nigeria.48,250 In this study, only a few isolates (2%) were resistant to gentamicin. This is 
comparable to reports from some studies45,249,285 and contrary to reports from other studies 
where about 50% of their isolates were resistant.48  Diverse patterns of antibiotic use may 
explain this disparity in antimicrobial susceptibility patterns in different settings and varied 
forms of referral from primary to secondary health facilities.195 The prevalence of 
methicillin-resistance is low in this setting and similar to some African studies50,241 but lower 
than in a South African study.71 This difference may be due to the high prevalence of HIV in 
the South African population because HIV infected patients are exposed to repeated hospital 
visits,71 and recurrent antibiotics use.308  
 
Contamination 
The contamination rate in this study is high (9.1%). This finding is similar to the reports 
from Iceland and South Africa70,72 and less than the reports from Kenya, Mozambique and 
Guinea Bissau.6,45,46,260 The differences may be due to the method of sample collection 
(peripheral venepuncture or use of an intravenous catheter for collection), mode of asepsis 
before sample collection, type of antiseptic, type of gloves, competency of staff and the 
number of pathogens considered to be contaminants. However, most of these studies did 
not discuss the process of blood culture sample collection in detail. According to CLSI and 
the British Department of Health, contamination rate should be less than 3%;166,309 however, 
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the National Health Service (NHS) Trusts in the UK state that the rate can be as high as 
10%.309  
Outcomes 
Length of hospital stay 
The duration of hospital stay in our study population was shorter compared to reports from 
South Africa71 and other high-income countries.200 The differences in the prevalence of HIV 
and co-morbidities in the populations studied may explain this difference in length of 
hospital stay. Additionally, according to the Gambian national treatment guidelines, 
duration of therapy for uncomplicated S. aureus disease is five to seven days,175 shorter than 
in high-income countries. South Africa has a higher HIV prevalence than The Gambia. HIV 
patients are more likely to have drug-resistant strains of bacteria71 and therefore have an 
extended hospital stay. In this study, we did not perform HIV tests routinely on the study 
participants as HIV prevalence in The Gambia is low.297  
  
Case fatality ratio 
Studies from high-income countries reported CFR ranging from 1.5% to 2.6%.27,70,79 In LMIC, 
investigators have reported a CFR of between 6.0% and 71.7%.49,71,247 The CFR observed in 
the current study (14.1%) is, therefore, within the range of what is expected for a LMIC 
study. The considerable variation in CFR between studies may be explained by the 
differences between the study populations regarding age, quality of and access to 
healthcare, the focus of infection, antibiotic resistance rates, the severity of SAB cases and 
presence of co-morbidities. In our study, 71.4% of deaths occurred on the day of admission, 
which may reflect the severity of disease at presentation. Even though age is strongly 
associated with SAB-related deaths,27 in this study, CFR did not vary with age. 
 
Mortality  
SAB death in relation to the total number of deaths in the population is a measure of its 
contribution to neonatal and under-five mortality. In this study, SAB deaths accounted for 
7.6% and 4.2% of neonates and children less than five years who died in the population 
between 2011 and 2015, respectively. These figures are underestimated as some patients 
might have died before presentation to the hospital. Therefore, SAB makes a considerable 
contribution to neonatal and child mortality in this setting. 
 
Risk factors for fatality 
Even though age is strongly associated with SAB-related death in HIC,27,310 in our study, CFR 
did not vary with age. This variation of fatality with age maybe because the majority of the 
SAB cases seen in high-income countries are hospital-acquired, especially in neonates and 
infants due to the use of central venous catheters, parenteral nutrition and high survival 
rates of premature babies.70 Hospital-acquired infections have the worse prognosis. In this 
present study, all cases were community-acquired. Other risk factors associated with fatality 
include the organisation of the health systems, the presence of co-morbidities such as 
congenital malformations, musculoskeletal diseases, and digestive diseases, among others.  
 
Strengths and limitations 
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The strengths of this study were that the surveillance was population-based and 
uninterrupted.  Data collection spanned from the pre-PCV era to the post-PCV era, and over 
84% of eligible patients had blood culture performed. However, the study also had some 
limitations. First, the incidence may have been underestimated as some SAB cases never 
present to the hospital, and the sensitivity of blood culture is less than 100%. Second, an 
increasing rate of enrolment and investigation overtime required adjustment of annual case 
counts. Third, prior consumption of antibiotics, although uncommon in this study area, may 
reduce the detection of SAB by blood culture. Lastly, this study was not explicitly designed 
to evaluate risk factors for SAB such as S. aureus nasal carriage, hospitalisation in the past 
six months and HIV status.  
 
Conclusion 
The incidence of SAB is high in rural Gambia, especially in neonates and infants. Priority 
should be given to diagnosis, treatment, and prevention of SAB in this and similar settings. 
Clearly, strategies are urgently needed to reduce the burden of SAB and should target 
children in the first month of life. Further research into strategies to reduce the disease 
burden in this age group will be required to decrease neonatal and childhood mortality in 
The Gambia and similar settings.
Chapter 4: Acquisition of Staphylococcus aureus in neonates in 
rural Gambia: a longitudinal study 
Preamble 
Chapter three showed that neonates have the highest burden of S. aureus bacteremia. S. 
aureus carriage is a significant risk factor for S. aureus disease. Therefore, in this chapter, I 
have explored the risk factors for neonatal S. aureus carriage at birth, and those for 
acquisition at one week of age. Carriage data from a newborn’s mother, caregiver, household 
children and midwife were used to identify potential sources of acquisition. 
 
4.1 Overview 
Carriage of S. aureus is a significant risk factor for S. aureus disease. As discussed in chapter 
1, this is evidenced by the fact that patients who develop S. aureus disease usually carry the 
same strain of bacteria as the one causing disease.24,89,90 Reducing the acquisition of S. aureus 
carriage in newborns is, therefore, an important step in reducing the disease burden among 
neonates.  
As discussed in chapters 2 and 3, neonates have a higher risk of S. aureus disease compared 
to older children, possibly due to the high prevalence of S. aureus carriage and poorly 
developed innate immunity. Studies in low- and middle-income countries (LMIC) have 
shown that neonatal carriage peaks in the first week of life at between 50% to 60% (See 
section 1.1.2).101,103 However, the source of, and the risk factors for acquisition of S. aureus 
in neonates in LMIC are poorly documented. In high-income countries (HIC), longitudinal 
studies applying both conventional microbiology and molecular methods have identified the 
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mother as the primary source of neonatal and infantile carriage acquisition either through 
vertical or horizontal transmission.94,100,105  
Only two African studies – one in Gabon and the other in The Gambia - have evaluated the 
source of S. aureus carriage acquisition in infants.104,107 These two studies produced 
significantly different estimates of the proportion of neonatal carriage that was attributable 
to maternal carriage: the Gabonese study estimated the figure to be 5.6% while the Gambian 
study estimated it to be 21.0%. The disparity between these estimates might be due to the 
differences between the studies in terms of the timing of screening, the anatomical screening 
sites used, the use of antibiotics and the method of S. aureus identification (the Gabonese 
study used molecular methods and the Gambia study used conventional microbiology). 
Although, molecular methods are more sensitive than cultures at detecting S. aureus,311 the 
participants in the Gabonese study used antibiotics in the immediate post-partum period. 
Despite the differences, these African studies suggest that newborns frequently acquire S. 
aureus carriage from sources other than the mother. Other potential sources could include 
healthcare workers (HCW), hospital surfaces and equipment, other caregivers, siblings, or 
household members.  
While risk factors for S. aureus carriage in infants have been studied,100,107 there are few data 
regarding carriage at birth or carriage acquisition in the early neonatal period. Risk factors 
for S. aureus carriage among infants include maternal carriage,100,107 breastfeeding,100 
increasing number of older siblings, and ethnicity.107 It is unclear if these risk factors apply 
equally to carriage at birth and carriage acquisition shortly thereafter.  
Furthermore, a significant pathway for the emergence and spread of resistant strains of 
bacteria is the development of resistance first in carriage isolate due to exposure to 
antibiotics during carriage and then transfer of these genes horizontally to pathogenic 
strains.312 In The Gambia, few studies have reported on the pattern of antibiotic 
susceptibility of S. aureus isolates among healthcare workers or in the community.98,313 
Given the genetic similarities between carriage and clinical strains in patients with 
disease,24,314 knowledge of antibiotic susceptibility profiles in the community can inform the 
choice of empirical therapy in community-acquired S. aureus disease. Accordingly, this study 
was conducted to close these gaps in knowledge.  
Hypothesis 
Risk of S. aureus carriage acquisition in a newborn in the first week of life after exposure to 
maternal sources is higher than the risk after exposure to non-maternal sources 
 
4.2 Objectives 
The study objectives were to: 
a. Determine the incidence of carriage acquisition on the seventh day of life and 
assess the associated risk factors  
b. Determine the prevalence of S. aureus carriage at birth and assess the associated 
risk factors  
c. Describe the antibiotic susceptibility pattern of S. aureus carriage isolates obtained 
from study participants 
  
Outcomes: Microbiological isolation of S. aureus from the nose or umbilicus of the newborn 
at birth and on the seventh day of life. 
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Exposures: Potential sources of exposure of the newborn were investigated by assessment 
of the carriage of S. aureus in the nasal, vaginal or breastmilk samples obtained from the 
mother, or in nasal samples obtained from the midwife or TBA and household contacts, and 
isolation of S. aureus from delivery-related hospital surfaces. In addition, a questionnaire 
was used to collect information on sociodemographic data and maternal factors such as age 
at delivery, occupation, educational status, parity, hospitalisation in the preceding six 
months, antibiotic use in the preceding six months, current skin disease, nose-picking and 
degree of contact with animals. The questionnaire was also used to collect data on perinatal 
and postnatal factors such as premature rupture of membranes, dysuria, foul-smelling 
vaginal discharge, mode and place of delivery, maternal history of fever in the week 
preceding delivery, umbilical cord care, breastfeeding, hand washing, and the sharing of 
fomites with the newborn.  
 
4.3  Methods 
4.3.1 Fieldwork 
Study site, design, and population  
The study was conducted in the Basse Health Centre (BHC) and villages located in the Upper 
River Region of The Gambia between February and June 2017. The study site is described in 
section 3.1.1 and includes villages that are part of the Basse Health and Demographic 
Surveillance System. The labour ward in the BHC has three delivery couches separated by 
plastic drapes, three beds for women in active labour, a resuscitaire, a sink, an autoclave and 
a nurses’ station. The postnatal ward, directly opposite the labour ward, has six beds with a 
cot next to each bed. Visitors are allowed in the postnatal ward but not in the labour ward. 
Annually, about 2,000 deliveries take place at the BHC, which is the main referral hospital in 
the region. Box 4.1 highlights the prevailing infection control practices in the labour ward 
during the study period. The study recruited mothers and their healthy infants delivered 
either at home or at the labour ward of the BHC and the midwife or traditional birth 
attendant (TBA) conducting the delivery. In addition, two children under five years of age 
resident in the same household as the newborn and a caregiver other than the mother 
(usually the maternal grandmother) were recruited. 
 
Recruitment of participants  
In The Gambia, 98% of pregnant women attend an antenatal clinic (ANC) at least once before 
delivery.315 We approached consecutive pregnant women in their third trimester of 
pregnancy (as assessed by trained staff), and those who met the eligibility criteria (Table 










Infection prevention and control practices in the labour ward during the 
study period. 
Hand hygiene 
• Handwashing with liquid soap and water 
• Hand hygiene with alcohol-based hand rubs  
• Dress code – short-sleeve tops or dresses exposing elbows 
• Nurse-to-patient ratio 1:4 during the day and 1:9 at night 
Environmental cleaning and decontamination 
• Daily cleaning of the floor with water, soap, and disinfectant 
• Daily disposal of hospital waste 
• Decontamination of delivery couch and resuscitaire after every delivery 
• Plastic drapes only cleaned and disinfected if visibly stained with blood 





them and they had provided written informed consent. We excluded high-risk pregnancies 
(as defined in Table 4.1) because the underlying risks for newborn acquisition of S. aureus 
in high-risk pregnancies are likely to be different compared to healthy pregnancies. 
Additionally, mothers with high-risk pregnancy were likely to have eventful deliveries and 
therefore require antibiotics postpartum. 
Pre-delivery visit  
A member of the study field staff visited the pregnant woman’s household to further explain 
the details of the study to household members and reinforce the previously written consent. 
This process was completed within two weeks of obtaining written informed consent. 










At birth and follow-up visits 
Willingness to continue participation in the study was verbally confirmed from the mother 
when she presented in labour. Pre-delivery, while the mother was in labour, we obtained 
vaginal and nasal samples from the mother, nasal, and hand swabs from the attending 
 Inclusion criteria Exclusion criteria 
Mother All pregnant women (between 30- and 36-
weeks’ gestation) aged 15-49 years attending 
the antenatal clinic at Basse Health Centre  
 
High-risk pregnancy1 
 No plans to travel out of the study area in the 
week after delivery 
Maternal use of antibiotics within 
one month of enrolment  
 
   
Newborn Alive and apparently healthy infants born to 
women who had provided consent to participate 
in the study 
 
Acute or chronic illness or obvious 
congenital abnormality  
 
  Birth weight less than 2.0kg   
 
1High risk pregnancy is defined as one that threatens the health or life of the mother or her foetus for example, teenage 
pregnancy, antepartum haemorrhage, postpartum haemorrhage, eclampsia, diabetes, hypertension, premature labour or 
delivery, oligohydramnios, polyhydramnios. 
 
midwife- or TBA-in-charge of the delivery and swabbed the delivery couch and resuscitaire 
(or improvised delivery couch and resuscitaire if the delivery took place at home). 
Within the first two hours, post-delivery, we obtained nasal and umbilical samples from the 
newborn. The questionnaire was used to obtain information on potential risk factors during 
pregnancy, labour, and delivery from the mother postpartum (see the section on exposure). 
At discharge from the hospital, participants were visited in their homes where further 
information on potential risk factors was documented, and nasal swabs were collected from 
caregivers and two children under the age of five years living in the household (randomly 
selected for the BDHSS list). The caregiver was defined as the person, as identified by the 
mother, who provided the most care for the newborn other than the mother (usually the 
maternal grandmother).  













One week after delivery, a field assistant or nurse visited the newborn’s home and obtained 
Time/Study Procedure Pre-delivery 
Birth, 
Day 0 (Visit 1) 
1 week post-
delivery, Day 7 
(Visit 2) 
Inform HHH1 √  √ 
Written consent √   
Administer questionnaire  √ √ 
Maternal    
      Vaginal swab  √  
      Nasal swab  √ √ 
      Breast milk   √ 
Newborn    
      Nasal swab  √ √ 
      Umbilical swab  √ √ 
One other caregiver    
      Nasal swab  √ √ 
Midwife/TBA1    
      Nasal swab  √  
      Hand swab  √  
Delivery equipment    
      Resuscitaire  √  
      Delivery bed  √  
Other HH1 children (age 
<5years) 
   
      Nasal swab  √ √ 
1 HHH= Household head, HH=Household; TBA=Traditional Birth Attendant  




nasal samples from the mother, baby, caregiver and the two other children already selected 
for sampling. An umbilical swab was obtained from the newborn, and breast milk was 
collected from the mother (Table 4.2). The field assistant or nurse recorded the date and 
time of sample collection. A questionnaire was administered to obtain information on 
umbilical cord care, breastfeeding, as well as the sharing of bed and fomites between other 
family members and the newborn. For mothers who opted to deliver at home, the TBA 
notified the study team that the woman was in labour. The study team visited the home of 
the woman, obtained samples, and administered questionnaire as described above. 
The study team did not provide medicines. Instead, mothers were encouraged to report at 
the clinic or call the study team if they or their newborn were unwell or had concerns about 
their health or that of their newborn. Participants were free to withdraw from the study at 
any time and were not obliged to provide a reason. 
 
4.3.2 Sample size calculation 
The sample size calculation was based on the expectation that 63% of newborns would 
acquire S. aureus in the first week of life,107 and that the prevalence of exposure (e.g. carriage 
in adults and children in the community) would be 25%.98 Based on these parameters, it was 
estimated that a minimum of 216 mother-newborn-contact pairs would be required to 
detect a risk ratio of at least 1.3 between exposed (for example, exposure to carrier non-
maternal sources) and unexposed groups with 80% power at the 5% significance level.   
 
4.3.3 Samples and laboratory assessments  
Sample collection and handling 
Nasal Swab  
Nasal swabs were collected by brushing the walls of both nostrils with nylon flocked swabs 
FLOQSwabs™ (Copan, Brescia, Italy).  
 
Vaginal Swabs 
We obtained low vaginal swabs by inserting a cotton swab (Sterlin Ltd, Newport, UK®) 2-3 
cm into the vagina, sweeping the mucosa of the vagina and rotating the swab. 
 
Breast milk samples  
Mothers were asked to express breast milk manually after disinfecting the nipple and areola 
with 0.02% chlorhexidine. After discarding the initial 0.5 mL, 1 - 2 mL of breast milk was 
expressed directly into a sterile Bijoux bottle (Thermo Fischer Scientific, Loughborough, 
UK®).  
 
Umbilical swab  
Umbilical swabs were collected by brushing a cotton swab (Sterlin Ltd, Newport, UK®) 
moistened with normal saline and applying the wet swab around the umbilical stump in a 
clockwise fashion.  
 
Hand swab  
Shortly before delivery, a moistened cotton swab (Sterlin Ltd, Newport, UK®) was rubbed 
on both hands and between the digits, nail beds, and ring area of the midwife or TBA, paying 




Environmental swab  
A moistened cotton swab (Sterlin Ltd, Newport, UK®) was used to brush a marked 10 cm by 
10 cm area on the delivery couch and resuscitaire. The swab was wiped horizontally and 
then vertically over the area. Sampling was done immediately before delivery and not after 
cleaning of the surfaces. 
 
All swabs were immediately inoculated into skim-milk-tryptone-glucose-glycerol (STGG)-
containing vials placed in a cold box maintained at between 20C – 80C and transported to the 
MRC laboratory, at the Basse Field Station within 8 hours of collection. At the laboratory, 
samples were stored at -700C until they were analysed. Each sample had a unique 
identification number which was also placed on the laboratory request form.  
 
4.3.4 Laboratory methods 
Standard microbiology  
Stored frozen samples were thawed to room temperature and vortexed for 20 seconds to 
give a homogenised suspension. An aliquot of the suspension was added to an enrichment 
broth (tryptone soy) to increase the yield of S. aureus316 and incubated overnight. A 10 µl 
aliquot of the suspension was plated on mannitol salt agar (MSA) and incubated aerobically 
at 370C overnight. The golden yellowish raised colonies on the MSA plate were subcultured 
on blood agar (BA) plates and incubated at 37OC for 24 hours to obtain pure colonies. 
Presumptive isolates were confirmed as S. aureus by performing catalase and coagulase 
tests using the Staphaurex latex agglutination test (Remel, Lenexa, KS).  
 
Antibiotic Susceptibility screen  
The Kirby-Bauer disc diffusion method was used to determine antibiotic susceptibility in 
accordance with CLSI guidelines.272 Isolated colonies of S. aureus were suspended in normal 
saline and turbidity adjusted to a 0.5 McFarland standard. The vortexed suspension was 
used to inoculate a dried Mueller-Hinton Agar plate. Antibiotic discs (Oxoid, UK) were placed 
on plates and incubated aerobically at 35°C - 37°C for 24 hours. The discs contained cefoxitin 
(30 μg), clindamycin (2 μg), cloxacillin (5 μg), cotrimoxazole (25/125 μg), erythromycin (15 
μg), and penicillin (10 µg). After incubation, the zones of inhibition were measured using a 
transparent ruler under white light. Diameters of inhibition (in millimetres) were recorded 
and interpreted as sensitive, resistant or intermediate using the CLSI standards.166 Cefoxitin 
was used as a surrogate for methicillin-resistance with a cut-off diameter of 21 mm.272  The 
laboratory subscribed to external quality assurance schemes with the World Health 
Organization Reference Laboratory, Denmark, and United Kingdom National External 
Quality Assessment Service, Sheffield, UK and Oneworld Accuracy, Canada. 
 
4.3.5 Data collection  
Training of staff 
The study team comprised five field assistants, two nurses, a scientific officer, a laboratory 
technician, and a data manager. Staff were trained on the study rationale and objectives. An 
introductory session was followed by practice sessions on sample collection and labelling, 
administering questionnaires and sample transport. The investigator developed working 
documents on study-specific procedures for use by study team members. A separate 
training session was conducted for the laboratory staff on sample processing. The team met 
every week to discuss progress, and further periodic training sessions were conducted when 
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required. Additionally, laboratory staff were trained on the laboratory processes using the 
study-specific procedure.  
 
Quality assurance for data collection 
Trained field assistants and nurses used a questionnaire for data collection. Field assistants 
reviewed their forms before submission to a supervisor who in turn reviewed the forms 
every week. In addition, the principal investigator reviewed a randomly selected subset of 
forms (10%) collected each week before submission for data entry. Field assistants 
corrected missing data or errors during the next visit or by a phone call. Similarly, the 
laboratory staff did a self-assessment of their forms before submission for data entry. 
Concerns related to data quality were discussed at the weekly team meetings. 
The principal investigator was present at all enrolment and follow-up visits for the first two 
months of data collection to ensure proper collection and storage of samples.  
 
Data entry, verification, and cleaning 
Data were double entered into a Microsoft Access database by trained data entry clerks. The 
field supervisor resolved inconsistencies using the forms, phone calls to the participants or 
by visiting the participant at home. The investigator did consistency checks in Stata and 
inconsistencies were resolved by re-visiting the completed questionnaire. 
 
 
4.3.6 Ethical consideration  
Ethical approval for the study was given by the London School of Hygiene & Tropical 
Medicine (LSHTM) ethics committee (Ref: 11677) (Appendix 13) and the Gambia 
Government/Medical Research Council Joint ethics committee (SCC 1510) (Appendix 14). 
Each participant gave written informed consent and participation was voluntary. Appendix 
15 appendix shows a sample consent form. 
 
4.3.7 Statistical methods 
The prevalence of S. aureus carriage in neonates, mothers, caregivers, and siblings was 
estimated at day 0 (delivery) and day 7 and that of midwives on day 0 only. Newborns were 
considered carriers if the nasal or umbilical or both swabs were positive while mothers were 
considered carriers if nasal or vaginal swabs or breastmilk were positive for S. aureus. 
Midwives or TBAs were considered positive if either nasal or hand or both swabs were 
positive for S. aureus. The presence or absence of S. aureus was determined by conventional 
microbiology. Carriage acquisition in newborns was defined as carriage on day 7 but not at 
birth, and persistent carriage was defined as being S. aureus positive at both time points. S. 
aureus-carrying babies at birth were considered to have acquired carriage before delivery; 
therefore, were only included in the analysis of carriage at birth but not in the acquisition 
analysis.  
Risk factors for newborn carriage at birth and acquisition were evaluated using logistic 
regression (see section 4.3.1). Factors (carriage status of all contacts) whose association 
reached p<0.05 in the univariate analysis were adjusted for maternal age, maternal 
educational status, and ethnicity in the multivariate analysis. The punaf command in STATA 
was used to compute the population attributable fractions (PAF) of the acquisition 
associated with specific exposures. The formula for the calculation of PAF is: 
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where Riskp is the risk in the population and Riske is the risk in the exposed group. 
 
4.4 Results 
Four hundred and forty-five eligible pregnant women were approached to join the study, 
and 231 (51.9%) were enrolled. Of the 214 women who did not join the study, 32 (15.0%) 
declined, and 182 (85.0%) travelled out of the study area during a period of political 
instability (Figure 4.1). After excluding two newborns because of missing carriage data at 
one-week post-delivery and two early neonatal deaths, the analysis dataset consisted of 227 
(51.0%) newborn-contact pairs. All visits scheduled for the day of delivery (day 0) occurred 
as planned while visit 2 (one-week after delivery) occurred on day 7 for 147 (64.8%) 
participants, on day 6 for 35 (15.4%) and day 8 for 45 (19.8%) participants. 
 
4.4.1 Characteristics of participants 
Mothers 
The median (IQR) age of mothers was 27 years (24, 30). Most of them were housewives 
and about a quarter had primary school education or above. All the women were married,  
 
Figure 4.1: Study profile 
and one-fifth had more than five living children. About half (53.3%) alluded to nose-picking, 
and 64.6% had daily contacts with animals (Supplemental Table 4.1 – Appendix 16). 
Forty-one deliveries (18.1%) took place at home; all pregnant women delivered vaginally at 
term, and none of them had a history of prolonged rupture of membranes. Forty-two per 
cent of the mothers reported a history of fever one week before delivery (Supplemental 
Table 4.2 – Appendix 16) for which 12 had antibiotics (Amoxicillin), 61 had an antipyretic 
(paracetamol), and others were not treated.  
 
Newborns 
Of the 227 newborns, 122 (53.7%) were boys, and the mean (SD) birth weight was 3.1kg 
(0.4). For the majority of the newborns, the umbilical cord was cut using a new blade 
(96.9%) and tied with a piece of thread (62.0%). At home, mothers applied substances such 
as shea butter, ash, baby powder and cow dung to the umbilical stump of 166 (73.1%) of the 




























Midwives or Traditional birth attendants 
Twenty-eight traditional birth attendants and 25 midwives were recruited; four midwives 
and one TBA were males. Supplemental Table 4.3 (Appendix 16) shows the characteristics 
of the deliveries by midwives and TBAs. The midwives were significantly younger than the 
TBAs (median age: 36 years versus 55 years). There was no difference between TBAs and 
midwives in the reporting rates of having a cold and cough, nose-picking and antibiotic use 
in the past six months between TBAs and midwives. In 12.2% and 2.7% of the deliveries 
facilitated by TBAs and midwives, respectively, they had reported not washing their hands 
before taking the delivery (Supplemental Table 4.3 – Appendix 16). The reasons given for 
not washing their hands included: no water, no soap, time pressure, had washed their hands 
before taking the last delivery and wearing gloves. The majority of TBAs or midwives 
delivered one (22/53; 41.5%) or two (14/53; 26.4%) babies. 
 
Household children 
Four hundred and fifty-four household children were recruited. The median (IQR) age of 
household children was 38 months (29, 50), and about half were males (53.2%). Bed-
sharing with the newborn and antibiotic use were uncommon (Supplemental Table 4.4 – 
Appendix 16).  


































The caregivers sampled were either fathers (4.1%) or grandmothers (71.2%). The median 
(IQR) age of the caregivers was 54.5 (44, 65) years. About half of them lived in the same 
Characteristics n/N (%) 
Sex  
       Male 122/227 (53.7) 
       Female 105/227 (46.3) 
  
Birth weight (kg)   
       Mean (SD) 
 
3.1 (0.4) 
GA by Ballard score1  
       Median (IQR) 
 
38 (36, 39) 
Mode of resuscitation  
       None 122/227 (53.7) 
       Airway suctioning   89/227 (39.2) 
       Others2 
 
  16/227 (7.1) 
Instrument used to cut the umbilical cord 
       New razor blade 220/227 (96.9) 
       Non-sterile material 
 
     7/227 (3.1) 
Material used to tie the cord  
       Cord clamp    86/226 (38.0) 
       Piece of thread 
 
140/226 (62.0) 
Substance applied to the cord  
       Methylated spirit   18/227 (7.9) 
       Cow dung   19/227 (8.4) 
       Baby powder   16/227 (7.0) 
       Shea butter 110/227 (48.5) 
       Others3   39/227 (17.2) 
       Nothing 
 
  25/227 (11.0) 
Bed shared with baby (mother)  
        Yes 
 
196/227 (86.3) 
Number of people who shared bed with baby 
        1   88/227 (38.8) 
       >1 139/227 (61.2) 
  
Length of hospital stay after birth  
       < 6 hours 101/212 (47.6) 
       ≥ 6 hours 111/212 (52.4) 
          1 GA=Gestational Age by Ballard score; SD=Standard deviation; IQR=Interquartile range 
        2 Ambu bagging, endotracheal intubation 





house as the newborn; only 3.8% of them shared a bed with the newborn (Supplemental 
Table 4.5 – Appendix 16). 
 
Medications 
Apart from a few caregivers (3.3%) and household children (2.3%), none of the participants 
used medications during the study period. However, 5.3% of mothers, 29% of midwives and 
14.7% of TBA reported the use of antibiotics in the preceding six months.  
 
Number of swabs  
A total of 3,987 swabs were collected, representing 97.6% of the expected number of 
samples (Table 4.4). Nasal and umbilical swabs were obtained for 189 (83.3%) and 31 
(13.7%) newborns within the first 2 and 2 - 6 hours of life, respectively. 











4.4.2 Carriage of S. aureus among study participants 
 
Newborns 
Type of swab Day 0 (Visit 1) 
n/N (%) 




Newborn Nasal 227/227 (100.0) 227/227 (100.0) 454/454 (100.0) 
Newborn Umbilical 226/227 (99.6) 227/227 (100.0) 453/454 (99.8) 
Mothers Nasal 227/227 (100.0) 227/227 (100.0) 454/454 (100.0) 
Mother Vaginal 227/227 (100.0) NA1 227/227 (100.0) 
Breast milk NA  227/227 (100.0) 227/227 (100.0) 
 Midwives/TBAs1 Nasal 198/227 (87.2) NA 198/227 (87.2) 
Midwives/TBAs Hand 222/227 (97.8) NA 222/227 (97.8) 
Delivery bed 227/227 (100.0) NA 227/227 (100.0) 
Resuscitaire 226/227 (99.6) NA 226/227 (99.6) 
Household children 440/454 (96.9) 423/454 (93.2) 863/908 (95.0) 
Caregiver 226/227 (99.6) 210/227 (92.5) 436/454 (96.0) 
Total 2446/2497 (98.0) 1541/1589 (97.0) 3987/4086 (97.6)  
1 TBAs=Traditional birth attendants; NA=Not applicable 
 
Twenty-two newborns (9.7%) were S. aureus carriers at birth; more than half of which 
(59.1%) were already carriers within two hours of age. The prevalence of umbilical carriage 
at birth was higher than nasal carriage (8.4% versus 2.2%; p=0.002). One week post-
delivery, 179 (78.9%) babies were carriers. The prevalence of nasal carriage was similar to 
that of umbilical carriage at one-week post-delivery (63.9% versus 66.5%; p=0.45). One 
week post-delivery, the prevalence of nasal and umbilical carriage (78.9%) was higher than 
at birth (9.7%) (Table 4.5). Persistent nasal and umbilical carriage occurred in one (20.0%) 
and 11 (57.9%) of the carrier newborns, respectively.  
 




















Fifty-eight women (25.6%) were carriers at delivery (19 in the vagina, 35 in the nares and 
4 in both sites) and 91 (40.1%) at one-week post-delivery (47 in the nares, 32 in the breast 





delivery (day 7) 
n/N (%) 
p-value1 
Newborn Nasal   5/227 (2.2) 145/227 (63.9) < 0.001 
Newborn Umbilical 19/227 (8.4) 151/227 (66.5) < 0.001 
Mothers Nasal 39/227 (17.2)   59/227 (26.0) 0.03 
Mother Vaginal 23/227 (10.1) NA b - 
Breast milk NA   44/227 (19.4) - 
Midwives/TBAs b Nasal 15/198 (7.6) NA - 
Midwives/TBAs Hand   1/222 (0.5) NA - 
Delivery bed   4/182 (2.2) NA - 
Resuscitaire   4/181 (2.2) NA - 
Household children 37/442 (8.4)   47/423 (11.1) 0.23 
Caregiver 16/219 (7.3)   21/210 (10.0) 0.25 
Total 163/2350 (6.9) 467/1541 (30.3)  
1 p-value was calculated using McNemar’s test; the comparison is across visits 




milk and 12 in both) corresponding to an increase of 34% of nasal carriage (p=0.008). More 
mothers were nasal carriers one-week post-delivery than at birth (26.0% versus 17.2%; 
p=0.03). Nasal carriage at delivery was significantly higher than vaginal carriage (17.2% 
versus 10.1%; p=0.001); and nasal carriage at one-week post-delivery was higher than in 
breast milk (26.0% versus 19.4%; p<0.001) (Table 4.5). Fourteen of the S. aureus positive 
mothers (35.9%) had persistent nasal carriage.  
 
Household children 
Table 4.5 shows that there was no difference in the prevalence of S. aureus carriage among 
the household children at delivery (8.4%) compared to one-week post-delivery (11.1%) 
(p=0.23). Persistent carriage occurred in nine of the S. aureus positive household children 
(24.3%) at one-week post-delivery. There was no difference in S. aureus carriage between 
males or females either at day 0 (p=0.28) or at day 7 (p=0.34). 
 
Caregivers 
Among the caregivers, the prevalence of S. aureus carriage was similar at day 0 (7.3%) and 
day 7 (10.0%) (p=0.25) (Table 4.5). Only four of the S. aureus positive (25.0%) caregivers 
were persistent carriers.  
 
 
Midwives or Traditional Birth Attendants 
Of the 227 deliveries, sixteen (7.1%) were conducted by a midwife or TBA who was a carrier. 
Among the deliveries where the midwife or TBA tested S. aureus positive, 15 were carriers 
in the nares while only one on the hand. 
Delivery surfaces 
Eight (1.8%) of the delivery surfaces were contaminated. The rate of contamination was 
similar in the deliveries that occurred at home and those that occurred at the BHC (2.4% 
versus 1.6%). 
 
4.4.3 Risk factors for S. aureus carriage at birth 
The prevalence of S. aureus carriage at birth was 9.7% (22/227). S. aureus carriage at birth 
was associated with the midwife’s or TBA’s report of not washing hands before delivery 
(Table 4.9). However, it was not associated with maternal S. aureus carriage; neither was it 























































Mother       
    Nasal at birth      
          No 18/188 (9.6) 1    
          Yes   4/39 (10.3) 1.08 (0.34 – 3.39) 0.90   
      
    Vaginal       
          No 20/204 (9.8) 1    
          Yes   2/23 (8.7) 0.88 (0.19 – 4.01) 0.86   
      
    Any site at birth (Nasal or Vaginal)     
          No 17/169 (10.1) 1    
          Yes   5/58 (8.6) 0.84 (0.30 – 2.40) 0.75   
      
Midwife/TBA2      
     Nasal or Hands      
          No 20/211 (9.5) 1    
          Yes   2/16 (12.5) 1.36 (0.29 – 6.44) 0.71   
      
Household children      
     Nasal at birth      
           No 21/193 (10.9) 1    
          Yes   1/34 (2.9) 0.25 (0.03 – 1.91) 0.10   
      
Caregiver      
    Nasal at birth      
           No 19/203 (9.4) 1    
           Yes   3/16 (18.6) 2.23 (0.58 – 8.55) 0.27   
      
Delivery surfaces      
          No 20/219 (9.1) 1    
          Yes   2/8 (25.0) 0.30 (0.06 – 1.59) 0.20   
1 Adjusted for maternal age, maternal educational status, and ethnicity 
2 TBA=Traditional birth attendant 
 









































Age (years)      
17-24   5/64 (7.8) 1    
25-30 12/109 (11.0) 1.46 (0.49 – 4.35)    
>31   5/54 (9.3) 1.20 (0.33 – 4.40) 0.78   
      
Ethnic group       
Sarahule 7/105 (6.7) 1    
Fula 7/57 (12.3) 1.96 (0.65 – 5.90)    
Other2 8/65 (12.3) 1.97 (0.68 – 5.70) 0.35   
      
Educational level      
None 10/80 (12.5) 1    
Arabic school   6/94 (6.4) 0.48 (0.17 – 1.38)    
Primary and above   6/53 (11.3) 0.89 (0.30 – 2.62) 0.34   
      
Occupation      
Unemployed 19/200 (9.5) 1    
Employed3   3/27 (11.1) 1.19 (0.33 – 4.33) 0.79   
      
Number of siblings     
0-3   6/101 (5.9) 1  1  
4-5 14/87 (16.1) 3.04 (1.11 – 8.29)  3.39 (0.86 – 11.48)  
>5    2/39 (5.1) 0.86 (0.17 – 4.43) 0.04 0.95 (0.13 – 6.55)  0.08 
      
Antibiotic use within the previous 
six months 
    
Yes   1/12 (8.3)     
No 21/205 (10.2)     
Unsure   0/10 (0.0) - - - - 
      
Nose picking      
No   7/106 (6.6) 1    
Yes 15/121 (12.4) 2.00 (0.78 – 5.11) 0.14   
      
Current skin disease, e.g. dermatitis 
or skin ulcers  
    
No 20/217 (9.2) 1    
Yes   2/10 (20.0) 2.46 (0.48 – 13.4) 0.31   
      
Daily contact with animals     
No   4/80 (5.0) 1    
Yes 18/147 (12.2) 2.65 (0.87 – 8.12) 0.06   
1 Adjusted for maternal age, maternal educational status, and ethnicity 
2 Other ethnic groups include Mandinka, Wolof, Jola 













































Sex      
Male 15/122 (12.3) 1    
Female   7/105 (6.7) 1.96 (0.77 – 5.01) 0.15   
      
Mode of 
resuscitation 
     
None 12/122 (9.8) - - - - 
Airway suctioning 10/89 (11.2)     
Other2   0/16 (0.0)     
      
Instrument used to cut the umbilical 
cord 
    
New razor blade 22/220 (10.0) - - - - 
Non-sterile material   0/7 (0.0)     
      
Material used to tie the cord     
Cord clamp    5/86 (5.8) 1    
Piece of thread 17/140 (12.1) 2.24 (0.80 – 6.30) 0.11   
      
Substance applied to the cord     
Methylated spirit   3/18 (16.7) 1    
Other3 17/184 (9.2) 0.51 (0.13 – 1.94)    
Nothing   2/25 (8.0) 0.44 (0.06 – 2.92) 0.62   
1 Adjusted for maternal age, maternal educational status, and ethnicity 
2 Ambu bagging, endotracheal intubation 
3 Ash, local herbs, soil 
 
 
Table 4.9: Characteristics of midwives or traditional birth attendants potentially associated with S. 
















4.4.4 Risk factors for S. aureus carriage acquisition at one week of age 
In the unadjusted analysis, maternal nasal carriage at one week, breast milk colonisation at 
one week (Table 4.10), household child nasal carriage at one week (Table 4.10), maternal 
history of dysuria or UTI in the week preceding delivery (Table 4.11), duration of hospital 
stay (Table 4.12) and midwife or TBA report of use of antibiotics in the preceding six months 
(Table 4.13) were associated with S. aureus carriage acquisition at one week of age. In the 
adjusted analysis, S. aureus carriage acquisition at one week of age was positively associated 
with maternal nasal carriage at one week, breast milk colonisation at one week, household 
child nasal carriage at one week, midwife or TBA report of the use of antibiotics in the 
preceding six months and negatively associated with maternal history of dysuria or urinary 










Odds Ratios 1 
(95% CI) 
p-value 
Hand wash before taking delivery     
          No   3/10 (30.0) 1  1  
          Yes 19/217 (8.8) 0.22 (0.05 – 0.94) 0.04 0.19 (0.04 – 0.87) 0.04 
      
Nose picking      
          No   9/82 (11.0) 1    
          Yes 13/145 (9.0) 0.80 (0.32 – 1.96) 0.62   
      
Cough or cold since the last visit     
          No 17/165 (10.3) 1    
          Yes   5/62 (8.1) 0.76 (0.27 – 2.17) 0.61   
      
Travelled out of the village in the past 
two weeks 
    
          No 18/173 (10.4) 1    
          Yes   4/54 (7.4) 0.69 (0.22 – 2.14) 0.52   
      
Antibiotic use since the last visit     
          No 22/226 - - - - 
          Yes   0/1     





Table 4.10: Site-specific carriage or contamination as potential risk factors for S. aureus carriage 































Table 4.10: Site-specific carriage or contamination as potential risk factors for S. aureus carriage 
acquisition between birth and one-week post-delivery in neonates (continued) 















Mother carriage      
    Nasal at birth      
          No 135/188 (71.8) 1  1  
          Yes 
 
  28/39 (71.8) 1.00 (0.47 – 2.15) 1.00 1.06 (0.49 – 2.32) 0.88 
    Vaginal at delivery      
          No 145/204 (71.1) 1  1  
          Yes 
 
  18/23 (78.3) 1.47 (0.52 – 4.13) 0.46 1.47 (0.51 – 4.23) 0.46 
    Nasal at one week      
          No 112/168 (66.7) 1  1  
          Yes 
 
  51/59 (86.4) 3.19 (1.42 – 7.18) 0.002 3.18 (1.40 – 7.22) 0.003 
    Breast milk at one week     
          No 124/183 (67.8) 1  1  
          Yes 
 
  39/44 (88.6) 3.71 (1.39 – 9.90) 0.003 3.81 (1.38 – 10.49) 0.004 
    Any site at birth (Nasal or Vaginal)     
          No 119/169 (70.4) 1  1  
          Yes 
 
  44/58 (75.9) 1.32 (0.67 – 2.62) 0.42 1.37 (0.68 – 2.74) 0.35 
    Any site at one week (Nasal or Breast milk)     
          No 83/136 (61.0) 1  1  
          Yes 
 
80/91 (87.9) 4.64 (2.26 – 9.52) <0.001 4.76 (2.29 – 9.89) <0.001 
Midwife/TBA2 carriage     
    Nasal at delivery      
          No 147/207 (71.0) 1  1  
         Yes 
 
  13/15 (86.7) 2.65 (0.58 – 12.11) 0.16 2.75 (0.59 – 12.74) 0.15 
     Nasal or Hands at delivery     
          No 149/211 (70.6) 1  1  
          Yes 
 
  14/16 (87.5) 2.92 (0.64 – 13.20) 0.12 2.96 (0.68 – 13.62) 0.12 
Household children carriage     
    Nasal at birth      
           No 137/193 (71.0) 1  1  
          Yes 
 
  26/34 (76.5) 1.33 (0.67– 3.11) 0.51 1.36 (0.57 – 3.21) 0.48 
    Nasal at one week      
          No 127/184 (69.0) 1  1  
          Yes   36/43 (83.7) 2.31 (0.97 – 5.50) 0.04 2.37 (0.97 – 5.74) 0.04 
      
1 Adjusted for maternal age, maternal educational status, and ethnicity 














































Caregiver carriage     
 Nasal at birth      
           No 147/203 (72.4) 1  1  
           Yes 
 
    8/16 (50.0) 0.38 (0.14 – 1.06) 0.07 0.44 (0.15 – 1.27) 0.14 
    Nasal at one week     
          No 140/194 (72.2) 1  1  
          Yes 
 
  16/21 (76.2) 1.23 (0.43 –3.54) 0.69 1.15 (0.39 – 3.36) 0.80 
Contaminated delivery surfaces     
          No 159/219 (72.6) 1    
          Yes 
 
    4/8 (50.0) 0.38 (0.09 – 1.56) 0.19 - - 













































History of dysuria or UTI2 one week before delivery    
          No 158/215 (73.5) 1  1  
          Yes     5/12 (41.7) 0.26 (0.08 – 0.84) 0.03 0.27 (0.08 – 0.91) 0.03 
      
History of vaginal discharge one week 
before delivery 
    
          No 155/215 (72.1) 1  1  
          Yes     8/12 (66.7) 0.77 (0.22 – 2.67) 0.69 0.79 (0.23 – 2.79) 0.75 
      
History of vaginal bleeding one week 
before delivery 
    
          No 155/213 (72.8) 1  1  
          Yes     8/14 (57.1) 0.50 (0.17 – 1.50) 0.23 0.48 (0.16 – 1.48) 0.21 
      
Peripartum fever within one week of 
delivery 
    
         No 94/132 (71.2) 1  1  
          Yes 69/95 (72.6) 1.07 (0.60 – 1.93) 0.81 1.06 (0.52 – 1.92) 0.86 
      
Foul-smelling 
liquor 
     
          No 138/192 (71.9) 1  1  
          Yes    25/35 (71.4) 0.98 (0.44 – 2.17) 0.96 0.94 (0.41 – 2.16) 0.88 
      
Place of delivery      
          Home    28/41 (68.3) 1  1  
          Health Centre 135/186 (72.6) 1.23 (0.59 – 2.56) 0.58 1.28 (0.59 – 2.65) 0.57 
     
Health care talks on cord care     
          No 95/137 (69.3) 1  1  
          Yes 68/90 (75.6) 1.37 (0.75 – 2.50) 0.31 1.30 (0.70 – 2.42) 0.41 
      
Admitted during this pregnancy     
          No 152/213 (71.4) 1  1  
          Yes   11/14 (78.6) 1.47 (0.40- 5.46) 0.55 1.62 (0.42 – 6.19) 0.47 
1 Adjusted for maternal age, maternal educational status, and ethnicity 
2 UTI=Urinary tract infection; TBA=traditional birth attendant 
 
Table 4.11: Obstetric factors potentially associated with S. aureus carriage acquisition between birth and 










































Nurse/TBA2 washed hands before 
taking delivery 
    
          No      6/11 (54.6) 1  1  
          Yes 144/198 (72.7) 2.22 (0.65 – 7.58)  2.52 (0.70 – 8.99)  
          Don’t know    13/18 (72.2) 2.17 (0.45– 10.40) 0.46 2.92 (0.56 – 15.37) 0.36 
      
Nurse/TBA wore gloves before taking 
delivery 
    
          No    12/21 (57.1) 1  1  
          Yes 149/203 (73.4) 2.07 (0.83 – 5.19)  2.24 (0.87 – 5.)  
          Don’t know      2/3 (66.7) 1.52 (0.12 – 19.2) 0.31 2.12 (0.16 - 29.07) 0.26 
1 Adjusted for maternal age, maternal educational status, and ethnicity 












































Odds Ratio 1 
(95% CI) 
p-value 
Sex      
          Male 88/122 (72.1) 1  1  
          Female 75/105 (71.4) 1.04 (0.58 – 1.85) 0.91 1.08 (0.60 - 1.95) 0.88 
      
Mode of resuscitation      
          None 84/122 (68.9) 1  1  
          Airway suctioning 64/89 (71.9)  1.16 (0.64 – 2.11)  1.26 (0.67 – 2.38)  
          Other2 15/16 (93.8) 6.79 (0.87 – 53.3) 0.06 7.18 (0.90 – 57.22) 0.06 
      
Instrument used to cut the umbilical 
cord 
    
          New razor blade 157/220 (71.4) 1  1  
          Non-sterile material      6/7 (85.7) 2.41 (0.28 – 20.4) 0.38 3.09 (0.35 – 27.48) 0.26 
      
Material used to tie the cord     
         Cord clamp   61/86 (70.9) 1  1-  
        Piece of thread 101/140 (72.1) 1.06 (0.59 – 1.92) 0.84 1.14 (0.61 – 2.14) 0.68 
      
Substance applied to the cord     
         Methylated spirit      9/18 (50.0) 1  1 - 
         Other3 136/184 (73.9) 1.43 (1.06 – 7.56)  2.63 (0.95 – 7.23)  
         Nothing    18/25 (72.0) 1.42 (0.72 – 9.17) 0.12 2.53 (0.69 – 9.24) 0.18 
      
Bed shared with the newborn (mother)     
          No 140/196 (71.4) 1  1  
          Yes    23/31 (74.2) 0.87 (0.37 – 2.06) 0.75 0.92 (0.38 – 2.26) 0.86 
      
Number of people who shared a bed 
with a newborn 
    
         1    54/88 (61.4) 1  1  
         >1 109/139 (78.4) 2.29 (1.27 – 4.13) 0.006 2.50 (1.36 – 4.57) 0.003 
      
Duration of hospital stay after birth     
         < 6 hours 78/101 (77.2) 1  1  
         ≥ 6 hours 72/111 (64.9) 0.54 (0.30 – 1.00) 0.05 0.57 (0.30 – 1.09) 0.09 
1 Adjusted for maternal age, maternal educational status, and ethnicity 
2 Ambu bagging, endotracheal intubation 
3 Ash, local herbs, soil 
Table 4.13: Midwife or traditional birth attendant factors potentially associated with S. aureus 


















4.4.5 Population attributable fraction 
At birth, 2.2% and 6.8% of S. aureus carriage was attributable to exposure to carriage in 
midwife or TBA and caregivers, respectively (Table 4.14). At one week post-delivery, 15.5%, 
5.2%, and 1.9% of S. aureus carriage acquisition was attributable to maternal carriage and 




















Odds Ratio 1 
(95% CI) 
p-value 
Hand wash before taking delivery     
          No      6/10 (60.0) 1  1  
          Yes 157/217 (72.4) 1.74 (0.47 – 6.42) 0.40 1.93 (0.50 – 7.37) 0.35 
      
Nose picking      
          No    63/82 (76.8) 1  1  
         Yes 100/145 (69.0) 0.67 (0.36 – 1.25) 0.21 0.66 (0.35 – 1.25) 0.20 
      
Cough or cold since the last visit     
          No 117/165 (70.9) 1  1  
          Yes    46/62 (74.2) 1.18 (0.06 – 2.29) 0.63 1.12 (0.56 – 2.23) 0.75 
      
Travelled out of the village in the past 
two weeks 
    
          No 13/64 (20.3) 1  1  
          Yes 41/163 (25.2) 1.30 (0.65 – 2.67) 0.44 1.27 (0.62 – 2.62) 0.51 
      
Antibiotic use in the past six months     
          No 114/167 (68.3) 1  1  
          Yes   49/60 (81.7) 2.07 (1.00 – 4.31) 0.05 2.04 (1.00 – 4.42) 0.05 





   














4.4.6 Susceptibility of isolates 
Of the isolates tested, 2.2% and 9.2% were resistant to cloxacillin and erythromycin, 
respectively, and 3.3% were methicillin-resistant using cefoxitin as a surrogate measure 
(Table 4.15). Resistance to penicillin was high (90.1%) but to all other antibiotics tested, it 
was less than 10%. The pattern of antimicrobial resistance was similar across the study 
participant groups and time points (Table 4.15). 
Contacts Carriage at birth  
PAF % (95%CI)  
Acquisition at one week  
PAF % (95%CI)  
Maternal carriage   
At birth  -3.8 (-28.9 – 16.4) 1   1.9 (-2.8 - 6.5) 2 
At one week  NA3 15.0 (8.3 – 21.2) 
Birth or one week NA 15.5 (6.0 – 23.5) 
   
Midwife/TBA carriage 2.2 (-10.7 – 13.6) 1.9 (0.3 – 7.8) 
   
Household children carriage4  
At birth  -12.3 (-22.8 - -2.6) 1.1 (-2.2 – 4.3)  
At one week  NA 3.8 (0.3 – 7.3) 
Birth or one week NA 5.2 (1.0 – 10.0) 
   
Caregiver carriage5   
At birth  6.8 (-8.4 – 19.9) -2.3 (-5.0 – 0.3)  
At one week  NA 0.5 (-2.1 – 3.1) 
Birth or one week NA -1.2 (-4.7 – 2.2) 
   
Non-maternal carriage6   
At birth  5.6 (-23.7 – 28.0) -1.1 (-6.3 – 4.0) 
At one week  NA 2.4 (1.1 – 9.4) 
Birth or one week NA 4.2 (-0.3 – 8.5) 
1 Maternal nasal and vaginal carriage at birth  
2  Maternal nasal and vaginal carriage at birth and nasal and breastmilk carriage at one week 
3 NA=Outcome (carriage at birth) occurred before exposure (contacts at one week); 
PAF=Population Attributable Fraction 
4 Nasal carriage by household children at birth and one week 
5  Nasal carriage by caregiver at birth and one week 
6 Carriage by all contacts except the mother 
 
 



















































































































































































































This study assessed the rate of and risk factors for S. aureus carriage at birth and carriage 
acquisition in the first week of life. The carriage rate at birth was low (9.7%) and was 
negatively associated with handwashing by the midwife or TBA. The risk of carriage 
acquisition within the first week of life was high (79.5%) and was associated with maternal 
nasal and breast milk carriage at one week, household child nasal carriage at one week, and 
healthcare worker antibiotic use in the preceding six months and negatively associated with 
maternal history of dysuria or urinary tract infection one week before delivery.  
 
Prevalence of S. aureus carriage 
Newborn 
S. aureus has a broad predilection of body sites for carriage, occurring most frequently in the 
nares followed by the umbilicus in newborns.94,104,105 Other sites include the nasopharynx, 
ears, rectum and gastrum.106,107 In this study, more newborns carried S. aureus in the 
umbilicus than in the nares, which is contrary to the findings of Maayan-Metzger and 
colleagues317 who reported higher carriage in the nares. The reason for this difference is 
unclear but may be related to umbilical cord care at birth and in the first few days of life. In 
this study, although the midwives or TBA used a sterile blade to cut the cord in most of the 
newborns, post-ligation cord care involved the use of substances such as shea butter, cow 
dung, baby powder and ash, which may have been contaminated with S. aureus.318 
Though the prevalence of carriage was low at birth, the acquisition risk by day 7 was high. 
The immaturity of the immune system could influence the high risk of acquisition in 
newborns. Secretory IgA antibodies are required for protection on the mucosal surfaces 
against S. aureus and may reduce the risk of its acquisition. These antibodies are not 
produced in significant quantities by the newborn to prevent acquisition; neither are they 
transferred to the newborn through the placenta.319 Furthermore, maternal IgG antibodies 
transferred to the newborn during pregnancy do not protect the newborn against S. aureus 
carriage.133 Breastfeeding leads to a substantial increase in IgA levels and may be part of the 
reason for declining carriage with time in infants. Other factors that might influence the high 
incidence of S. aureus carriage acquisition include close contact with a carrier mother, 
colonised breast milk, contaminated hands of the midwife during delivery and the large 
household sizes that are common in The Gambia. 
 
Mother 
The prevalence of vaginal S. aureus carriage in this cohort was similar to the estimates from 
other studies in The Gambia,107 China,320 Israel,105 France106 and Taiwan94 (5.0% - 13.5%). 
In keeping with the findings from the Gabonese104 and Gambian107 studies, maternal nasal 
carriage was higher one-week post-delivery than at birth. The reason for this is unclear, but 
it is possible that the mothers acquire S. aureus from their babies during this period. 
Schaumburg and colleagues104 established infant-to-mother transmission in 2.1% of 
mother-infant pairs in their study. Another reason may be that the mother acquires S. aureus 
from the health facility, including its staff. The health facility is a known reservoir for S. 
aureus and associated with increased risk of transmission. 
The occurrence of S. aureus in breast milk is consistent with an earlier study in The 
Gambia.107 Although human breast milk was thought to be sterile, recent studies have 
demonstrated that it frequently contains bacteria (96%), S. aureus inclusive (32% - 
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42%).107,321 The origin of bacteria in breast milk is unclear. One possibility is that bacteria 
could reach the breast milk by retrograde flow from the newborn’s mouth to the mother’s 
lactiferous ducts during breastfeeding322 or from the mother’s clothing. Another possibility 
is the migration of bacteria from the maternal intestine through an endogenous cellular 
route to the mammary gland and then into the breast milk (entero-mammary pathway) 
during late pregnancy and lactation.323 The latter option may explain why pre-colostrum 
secreted before the commencement of breastfeeding contains bacteria.  
 
Household children 
The prevalence of S. aureus carriage among household children in this study was similar to 
that reported in Israel96 but lower than reports from another study in The Gambia98 and a 
study in Ghana.324 These disparities may be due to the differences in the profile of study 
participants. The Gambian study included newborns, while the Ghanaian study was among 
children admitted to a hospital where there is an increased risk of S. aureus acquisition. 
Secondly, the studies were conducted in different seasons: this study was conducted during 
the dry season, while the Gambian and Ghanaian studies took place over at least one whole 
year. There are seasonal variations in S. aureus carriage with higher prevalence during the 
wet season.304 
 
Midwives and traditional birth attendants 
The prevalence of S. aureus carriage among midwives in this study was similar to reports 
from the Democratic Republic of Congo (16%)325 and Ethiopia (12%).326 The prevalence of 
S. aureus carriage was higher among midwives than among TBAs, even though more 
midwives used antibiotics in the six months preceding screening. This may be due to higher 
levels of exposure to patients who are potential S. aureus carriers and an environment that 
is more likely to be contaminated with S. aureus. Training of midwives and TBAs on infection 
prevention and control measures, improving hand hygiene compliance, regularly cleaning, 
and disinfecting of the health facility and strengthening the other infection control measures 
may help to reduce carriage in midwives and TBAs. 
 
Caregivers 
The prevalence of S. aureus carriage in caregivers should reflect the prevalence in adults in 
the community. The prevalence of S. aureus carriage among caregivers in this study was 
similar to the findings from the adult population in Ghana,327 and lower than the reports 
from Gabon.328 The reason for the difference, maybe because of the number of body sites 
screened or the characteristics of the population studied. 
Increasing the number of body sites screened results in a cumulative increase in the 
prevalence of carriage in each of the study participant groups.95 Additionally, the variations 
in S. aureus carriage in the participant groups in this study and other studies may be due to 
geographical and seasonal variations, characteristics of the study participants, and 
laboratory techniques used to isolate S. aureus.  
 
Risk factors associated with S. aureus carriage at birth 
Two African studies have examined the source of S. aureus carriage in infancy;94,106 but, none 
have assessed risk factors associated with carriage at birth. In this study, I examined 27 risk 
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factors, but none except hand washing (midwife or TBA) was associated with S. aureus 
carriage at birth in the newborn.  
The TBAs reported not washing hands significantly more than midwives (12.2% versus 
2.7%). The reasons midwives gave for not washing their hands before attending a delivery 
were time pressure and wearing gloves while TBAs said not having water or soap, time 
pressure, wearing gloves and having washed before the last delivery. A lack of hand hygiene 
agents both at home and in health facilities and lack of knowledge and compliance with 
infection prevention and control measures are common in Africa.217,318 In Uganda, provision 
of hand hygiene agents (including alcohol-based hand rub) especially at the point-of-care, 
and training and re-training of HCWs in paediatric wards on infection control measures 
including hand hygiene reduced transmission of bacteria to the children.329 In the UK with a 
high level of hygiene and compliance with infection prevention and control guidelines, Price 
and colleagues111 demonstrated that in the high-dependency and intensive care units, HCWs 
infrequently transmitted S. aureus to patients. Hand hygiene, though simple, remains the 
most effective intervention for the prevention of the spread of infection both at the home 
and hospital setting.218  
Interestingly, handwashing by the midwife or TBA was associated with reduced carriage at 
birth, even though S. aureus positivity was not associated with increased carriage at birth. A 
possible explanation for this discrepancy is that the bacterial load obtained from the 
midwife or TBA hands was insufficient for culture. Another possibility is that the midwife or 
TBA were transient carriers330 or carried the bacteria in other body sites not screened (for 
example, the throat) acting as vectors of transmission to the newborn.  
Contrary to reports from other studies,94,106 maternal carriage of S. aureus at the time of 
delivery was not associated with S. aureus carriage at birth in this study. The French106 and 
Taiwanese94 studies reported higher carriage rates in babies born vaginally compared to 
those delivered by caesarean section. However, vaginal carriage and maternal carriage (both 
nasal and vaginal) at birth in the two studies were similar to the estimates in the current 
study. The reason for this difference is unclear. 
 
Neonatal S. aureus carriage acquisition one-week post-delivery and associated risk 
factors 
The incidence of S. aureus carriage acquisition in this study (79.5% in the first week of life) 
was higher than that seen in a previous study in The Gambia107 and much higher than the 
reports from Israel105 where only 12.5% of neonates acquired S. aureus in the first 72 – 100 
hours of life. This disparity may be related to the differences in the levels of hygiene 
compliance and the timing of screening the newborn. The current study and the Gambian 
study took place in primary health centres while the Israeli study was undertaken in a 
tertiary hospital. The primary care facility in rural Gambia is likely to have lower barriers to 
transmission compared to the tertiary hospital in Israel. Secondly, newborns were screened 
at 72 - 100 hours of life in the Israeli study, and therefore had less time to acquire carriage 
than newborns in The Gambia who were screened at one week of age. Additionally, cord 
care practices were different in the three studies. 
In this study, maternal nasal and breast milk S. aureus carriage at one week were associated 
with neonatal carriage acquisition suggesting postpartum transmission to the newborn 
from the mother or vice versa. This finding is in keeping with the report from Israel105 where 
maternal S. aureus carriage (vagina and nasal carriage) was the only risk factor associated 
with carriage acquisition in newborns. Leshem and colleagues105 also observed similar rates 
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of acquisition among babies born vaginally and those born by caesarean section suggesting 
postpartum transmission. Using molecular methods, they also showed that 80% of the 
mother-newborn pairs who were carriers during the study carried genetically identical 
strains and 90% of the maternal strains were from the nares which further supports the 
importance of postpartum transmission to the newborn. 
In this study, maternal vaginal carriage was not associated with S. aureus carriage 
acquisition in the newborn either at birth or one week of age. It is possible that intrapartum 
transmission to the newborn could have been missed because of low inoculum in the 
newborn. It is also possible that most transmissions from the mother occurred postpartum. 
This hypothesis is supported by the fact that less than 10% of them were carriers within the 
first 24 hours of life, and carriage acquisition increased to 79.5% by the end of one week. A 
similar age profile of carriage was observed in the Israeli study105 which reported an 
association between maternal nasal carriage and carriage acquisition in the newborn but 
not vaginal carriage. The prevalence of maternal vaginal carriage was similar in this study 
to that found in the Israeli study. By contrast, a previous Gambian study107 found a positive 
association between maternal vaginal carriage and carriage in the newborn. The reason for 
this difference in findings is unclear but may be related to the larger sample size and the 
seemingly higher prevalence of vaginal carriage reported in the previous Gambian study 
(17%).   
In this study, 15.5% of S. aureus acquisition at one week of age was attributable to maternal 
carriage at the time of birth or one week later. This finding is similar to a previous report 
from The Gambia107 but higher than that from Gabon.104 This difference could be because 
the Gabonese study infrequently sampled the nares and throat over the first year of life or 
due to antibiotic use by mother and newborn in the immediate postpartum period. During 
the first year of life, the infant would have acquired other bacteria competing for the niche, 
and the prevalence of S. aureus in the infant would have fallen considerably. Besides, the 
infant would have been in contact with other members of the household who could have 
been the source of transmission at that time. Despite these differences, the contribution of 
the mother to carriage acquisitions in the newborn is small, suggesting the unattributed 
acquisitions are from other contacts not sampled in this study or misclassification of 
carriage in the newborn or mother. Nevertheless, decolonisation of the mother using 
intrapartum antibiotics has been shown to reduce S. aureus carriage both in the mother and 
newborn up to 28 days post-delivery.107  
The history of maternal urinary tract infection was negatively associated with carriage 
acquisition. This is surprising because maternal infections, including urinary tract 
infections, are usually risk factors for neonatal bacterial carriage and infections.331 This 
negative association may be due to antibiotic use by the mother to treat the infection. 
Healthcare workers are known vectors for the transmission of infection in healthcare 
facilities.111 Only a negligible proportion of S. aureus acquisition by the newborn could be 
attributed to the midwife or TBA (2.2%). The proportion may be small because the 
healthcare workers improved their handwashing frequency and technique because they 
knew they were being observed (Hawthorne’s effect). It is also possible that the proportion 
was small due to the short duration of the contact with the newborn as most women were 
discharged from the hospital within 24 hours. Furthermore, the midwife or TBA reported 
the use of antibiotics in the preceding six months in about one-third of deliveries 
(Supplemental Table 4.3). This lends support to the fact that reinforcement of handwashing 
with or without decolonisation will contribute to improved infection control strategies. 
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Children are known to transmit carriage and disease in the household332; however, only a 
small proportion of S. aureus acquisition by the newborn could be attributed to the 
household children (5.2%). This finding may be specific to the Gambian setting, where 
limited contact takes place between the newborn and the household children in the first few 
weeks of life.  
Despite the poor compliance with infection control measures in the hospital and home 
settings in this study, we were unable to demonstrate an attributable source of carriage 
acquisition from the health facility. Low bacterial loads (not detectable by culture) from the 
mother, midwives, household children or caregivers may be the cause of the unattributable 
carriage acquisitions. Molecular methods (PCR) are more sensitive at detecting S. aureus 
both in neonates and adults.311,333 These methods might have increased the yield of S. aureus 
in the study participants. It is also possible that the bacteria in the contacts were not 
culturable because either they were located intracellularly in macrophages or monocytes or 
existed in biofilms,152,334 and rapid replication of the bacteria in the newborn with new 
acquisition. Although the inoculum from the contact to the newborn might have been low, 
rapid replication of the bacteria in the new immunologic environment may be responsible 





The prevalence of antimicrobial resistance to all tested antibiotics was low. The prevalence 
of MRSA among S. aureus isolates was low (3.3%) and similar to previous estimates from 
The Gambia.98,313 Taken together the results from these studies suggest that the prevalence 
of MRSA among carriage isolates in The Gambia has been stable over the last decade.  
Though the prevalence of MRSA has been steady, there is still the need for continuous MRSA 
surveillance and establishment of policies to prevent an increase in the prevalence or the 
spread of MRSA in the community and hospital given its grave consequences. Continuous 
MRSA surveillance will aid the identification of temporal trends, implementation of effective 
IPC and evaluation of the intervention.  
The prevalence of resistance to cloxacillin, which is the first-line drug for the treatment of S. 
aureus infections in rural Gambia (2.2%) was higher than previous reports from the 
Gambia98 but not sufficiently high to warrant a revision of the national guidelines for the 
treatment of S. aureus infections in the country. Resistance to erythromycin was also low. It 
is, therefore, worth retaining as a second-line medication against S. aureus, especially in 
those with an allergy to penicillin and penicillin-like drugs. In keeping with reports from 
Ethiopia335 and Ghana,324,327 resistance to clindamycin was negligible. Different rates of 
unrestricted antibiotic use in humans and livestock may explain the variations in 
antimicrobial susceptibility in different studies.  
 
Strengths and limitations 
The inclusion of different participants groups in the study was a significant strength because 
it allowed the exploration of the different sources of newborn acquisition of S. aureus and 
for comparison of carriage and AMR among the groups. It also allowed the comparison of 
AMR among community and hospital carriage strains. Second, detection of S. aureus carriage 
was enhanced by screening two body sites for the mother, baby, and healthcare worker. 
Third, the use of enrichment broth before plating enhanced the sensitivity of detection by 
culture. Fourth, the study design allowed the evaluation of the temporal association between 
contacts and acquisition by the newborn. Screening of all contacts took place before the 
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assessment of the outcome (carriage acquisition in the newborn). Lastly, real-time collection 
of information on perinatal history circumvented recall bias.  
However, this study has some limitations. First, only 51.9% of women asked to join the study 
were enrolled due to migration during a period of political instability. Second, a significant 
proportion of the carriage acquisitions among the newborns were not attributable to a 
particular source, which may be because other sources of transmission were not sampled. 
Possible sources that were not sampled include midwives’ throat, mother’s skin, throat and 
hands, baby cot, baby’s swaddling clothes, hospital bed, taps, doorknobs, air samples and 
other members of the household. However, even in a study where intensive sampling was 
done and molecular methods used, the investigators could link a source to only 26% of 
acquisitions events.111 This may be because not all possible sources can be screened.  
 
Conclusion 
The prevalence of S. aureus carriage in newborns in rural Gambia was low at birth, but with 
a high acquisition rate in the first week of life. Only a modest proportion of the carriage 
acquisition was attributable to a particular source. This implies that there are other sources 
of acquisition that were not sampled or that the laboratory methods were not sensitive 
enough to detect the relatively small inoculum carried by screened individuals. 
Nevertheless, given that carriage often precedes disease, the high rate of S. aureus carriage 
acquisition in the first one week of life calls for strengthening of existing strategies to 
prevent transmission of S. aureus as well as the development of new tools to reduce the risk 
of S. aureus transmission to newborns.  
Chapter 5: Implications for policy, practice, and future research 
Preamble 
This thesis describes the burden of S. aureus disease in children aged less than five years in 
Africa, provides updates on the burden of S. aureus bacteraemia (SAB) in The Gambia and 
explores the risk factors for S. aureus carriage at birth as well as those for carriage 
acquisition in newborns. This chapter summarises the key findings of the thesis, discusses 
the implications of the results for practice and policy and highlights areas for future 
research.  
 
5.1 Key findings and contribution to the body of knowledge 
5.1.1 The burden of severe S. aureus disease in Africa 
The analyses described in Chapter 2 provided an estimate of 392,066 cases and 46,467 
deaths due to severe S. aureus diseases among children aged less than five years in 2015 in 
Africa (Box 5.1). The burden is probably higher than these estimates because of the lack of 
data on the clinical syndromes caused by S. aureus. The burden of S. aureus disease showed 
substantial variability by region and country. However, the disease burden was consistently 
highest among neonates; therefore, tools are needed to reduce the burden of staphylococcal 
diseases in this population and hence contribute to a reduction in neonatal mortality in line 
with the targets of SDG 3.2. 
 
5.1.2 The burden of S. aureus bacteraemia in The Gambia 
Data on the epidemiological features of S. aureus disease from population-based studies are 
rare in Africa. As described in Chapter 3, the incidence of S. aureus bacteraemia in young 
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children in The Gambia was estimated to be 78 per 100,000 person-years (Box 5.1). This 
study found that the rate in neonates (3.5 per 1,000 live births) was higher than the global 
and African estimates of the incidence of neonatal GBS.303 The case fatality ratio (CFR) 
among young children in this study was substantial (14.1%). The neonatal CFR was similar 
to the African estimates of the neonatal GBS case fatality ratio. Therefore, interventions are 
required to prevent S. aureus disease in children, especially neonates in rural Gambia and 
similar settings.  
This study, therefore, provides valuable data on the burden of SAB in African children. 
Additionally, data collection spanned the period before and after PCV introduction and 
allowed assessment of its impact on SAB. I found no evidence that the introduction of PCV 
influenced the incidence of SAB. 
 
5.1.3 Carriage acquisition of S. aureus in newborns in The Gambia 
The risk of S. aureus carriage acquisition in the first week of life was high (79.5%). Potential 
sources of S. aureus carriage acquisition in newborns were identified, but the proportion of 
carriage acquisition associated with these sources was low at 22%, perhaps due to the 
diagnostic methods used (culture). Neonatal carriage acquisition was associated with 
maternal and household child carriage at one week after delivery, and bed share with the 
newborn and negatively associated with maternal history of dysuria or urinary tract 
infection one week before delivery. Molecular methods may help to identify the source of S. 
aureus in Gambian newborns, but the use of these methods was beyond the scope of this 
study. 
The prevalence of antibiotic resistance was similar in carriage isolates from healthcare and 
















5.2 Implications of study findings for policy, practice and research 
5.2.1 Policy and practice 
Short term 
The work in this thesis highlights some of the factors contributing to the high morbidity and 
mortality of S. aureus disease, especially among neonates. High mortality was associated 
Box 5.1 
Summary of main findings from the studies undertaken for this thesis 
 
Background 
• Preventable infections are still responsible for about 40% of the childhood deaths in sub-
Saharan Africa  
• S. aureus is the most common cause of IBI in newborns and a significant cause in 
childhood. 
• S. aureus carriage is an important risk factor for S. aureus disease.  
• The prevalence of carriage is higher among newborns than other age group, peaking at 
the end of the first week of life. 
The burden of S. aureus disease in Africa 
• An estimated 392,066 staphylococcal cases and 46,467 deaths occurred among children 
aged < 5 years in 2015.  
• One-fifth and over half of the S. aureus septicaemia cases and deaths occurred among 
neonates, respectively.  
• S. aureus isolates were frequently resistant to ampicillin and amoxicillin, but rarely 
resistant to oxacillin or gentamicin. 
• There are limited data on the features of S. aureus disease incidence in Africa. 
The burden of S. aureus bacteraemia in The Gambia  
• The incidence of S. aureus bacteraemia in children aged less than five years was high, 
with the highest rates seen among neonates (3.5 per 1,000 live births). 
• The incidence of S. aureus bacteraemia did not change after the introduction of PCV.  
• The case fatality ratio was substantial (14.1%) and did not vary with age. 
Neonatal acquisition of S. aureus in Gambia  
• The prevalence of carriage at birth was low (9.7%)  
• Carriage at birth was negatively associated with handwashing by midwife or TBAs.  
• The rate of S. aureus carriage acquisition in the first week of life was high (79.5%) and 
associated with maternal carriage at one week, and household child carriage at one week 
and bed share with the newborn. 
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with late presentation. Factors responsible for this late presentation may include the 
inability of parents to identify clinical danger signs, poor healthcare-seeking behaviour of 
the parents, undue financial hardship, lack of social support or inaccessible healthcare 
facilities. Inadequate knowledge of mothers on newborn danger signs delays healthcare-
seeking. Additionally, a number of poor practices were reported including cutting of the cord 
with a non-sterile blade (3.1%), ligation of the cord with a piece of thread (62.0%) and 
application of unhygienic substances to the cord (81.1%); these are likely to have 
contributed to the high rate of umbilical carriage acquisition of S. aureus observed in The 
Gambia. Maternal antenatal education has been demonstrated to improve knowledge of 
essential newborn care.336 Therefore, information, education and communication strategies 
are required to increase awareness among mothers on essential newborn care especially 
the identification of newborn danger signs and effective cord care (for example, daily 
application of chlorhexidine for seven days) and the use of clean delivery kits. The WHO 
recommends the use of chlorhexidine for cord care in settings with high neonatal mortality 
like The Gambia. Periodic monitoring and evaluation of the programme is necessary as well.  
In Africa, although institutional deliveries are encouraged,337 hygienic practices are often 
sub-optimal because a parallel improvement in the health systems or the hospital capacity 
has not increased proportionately, thus increasing the risk of infections. In The Gambia, 
handwashing by the midwife or TBA was negatively associated with newborn S. aureus 
carriage. Clean birth practices, including using hand hygiene and delivery kits, can reduce 
neonatal infections and deaths at home by 15% and in the healthcare facility by 40%.338 
Therefore, low-cost interventions should be introduced or scaled up with regular refresher 
training to improve infection prevention and control (IPC) knowledge and practices. 
Furthermore, monitoring and evaluation of compliance at the workplace are essential to 
identify gaps to be addressed promptly. 
In The Gambia, modification of national guidelines for the treatment of disease is based on 
the prevailing antibiotic susceptibility pattern. Based on the findings of the current study, 
the existing Gambian National guidelines which recommend the use of ampicillin and 
gentamicin for treatment of neonatal sepsis175 requires revision to cloxacillin and 
gentamicin. Susceptibility of S. aureus to oxacillin in both studies of disease (chapter 3) and 
carriage (chapter 4) in The Gambia ranged between 88% and 98%, to gentamicin it was 98% 
while that to penicillin was less than 10% in both studies. The guidelines also recommend 
the use of flucloxacillin in older children if S. aureus is suspected.175 Given the low prevalence 
of resistance to oxacillin observed in both the carriage and bacteraemia studies, this 
recommendation is still valid. In Africa, there are few estimates of the prevalence of 
resistance of S. aureus to amoxicillin. The few studies (including a recent review in sub-
Saharan Africa) that have reported data suggest that the prevalence is high 
(>70%).19,49,262,268 Therefore, the WHO recommendation of amoxicillin for the treatment of 




A major finding of the studies conducted for this thesis is the scarcity of incidence data on 
community-acquired S. aureus disease in Africa even though it is likely to be responsible for 
a substantial burden of disease. The WHO sentinel surveillance for IBI through national and 
regional laboratories should be expanded to include S. aureus to increase awareness of 
stakeholders to this significant contributor to neonatal and childhood mortality (Box 5.2). 
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National governments should establish S. aureus disease surveillance programmes, 
including all hospitals and laboratories where confirmed cases are reported to a central 
database. Annual review of the database is required to inform the modification of the 
existing interventions and to guide the design of new ones if these are necessary. 
Policies on antibiotic use in Africa must balance the effective treatment of S. aureus and other 
infections with overuse of these drugs. Pre-treatment antibiotic use in children is 
common,50,161 because antibiotics can be procured over-the-counter or from community 
drug sellers without prescription in many countries. In addition, antibiotics are 
overprescribed by healthcare professionals who often treat without a microbiology 
laboratory result either due to lack of expertise, laboratory facility or due to the cost of the 
test. Consequently, governments should establish well-equipped laboratories with adequate 
staffing and make possible diagnostic tests at affordable prices. Guidelines for the proper 
collection of samples should be developed nationally and used at facility level since optimal 
sample collection is key to the interpretation of the results. Regular monitoring and 
evaluation of adherence to the guidelines are required. Regular external quality assessments 
of the laboratory processes are required to ensure reliability and comparability of results. 
Additionally, laws should be enacted and enforced to deter the purchase of antibiotics that 
have not been prescribed. 
Governments in Africa should be committed to the establishment of autonomous national 
IPC teams with clearly defined goals, activities, and functions. These teams should have the 
ability to make decisions on IPC-related issues and have a budget to implement their 
recommendations. Furthermore, the national IPC teams should have the responsibility to 
ascertain the training of all healthcare personnel using the team- and task-based strategies 
on locally adapted guidelines, and the provision of necessary infrastructure and supplies to 
safeguard implementation and compliance with the guidelines.  
 
Only six of the 47 countries in the WHO African Region achieved MDG target 4A of reducing 
under-five mortality by two thirds.339 Despite not meeting the MDG, the world has adopted 
the SDGs with even more ambitious health targets. For instance, the newborn mortality in 
the African Region (27 per 1,000 live births) falls significantly short of the interim goals for 
2020 (less than 15 per 1,000 live births). This thesis has identified SAB as a potentially 
significant contributor to this (1.6 cases per 1,000 live births) and enumerated some short- 
and long-term interventions at various levels of the health systems to mitigate against this 
disease and other bacterial diseases. 
 
5.2.2 Implications for future research  
The work undertaken for this thesis has identified a number of research priorities related 
to finding ways for improved management of S. aureus infections in LMIC like The Gambia. 
 
Disease surveillance 
Large scale epidemiological studies to describe the burden and evaluate the risk factors 
associated with S. aureus disease are required to fill the gap in the significant lack of 
surveillance data in Africa. Understanding the role of risk factors in the development of S. 
aureus disease is critical to formulating interventions geared towards the reduction of the 
disease. Although such studies are expensive and time-consuming, they are necessary. The 
least expensive approach will be to set up continuous national surveillance to include all 















Adequate reporting of prior antibiotic use and antimicrobial susceptibility patterns should 
be encouraged for studies describing the burden of bacterial diseases. These will lend 
support to the development and establishment of interventions to reduce the disease 
burden and lead to well-adapted guidelines on drug therapy for infection. 
 
Intrapartum Antibiotics Prophylaxis 
In the carriage study, maternal carriage was the most significant risk factor for neonatal 
carriage acquisition. Consequently, reducing S. aureus carriage in the mother during the 
perinatal period should reduce carriage acquisition in the newborn. A potential way of 
achieving this objective is by administering intrapartum antibiotics prophylaxis (IAP) to the 
Box 5.2 
Summary for the implications of the study findings for policy and practice 
 
Interventions to reduce S. aureus disease 
• Strategies to increase mothers’ awareness to identify early warning signs of deteriorating 
health of newborns and older children 
• Provision and scaling up of chlorhexidine at health posts and postnatal clinics free of 
charge 
• Scale up hand hygiene programmes among HCW and TBAs 
• Modification of national guidelines to change drug of choice for the treatment of neonatal 
sepsis to cloxacillin and gentamicin in The Gambia 
• WHO to include S. aureus among the pathogens under IBI sentinel surveillance 
• National commitment to surveillance of S. aureus disease and AMR 
• Review of guidelines for the treatment of suspected sepsis at the community level 
• Controlled access to antibiotics in Africa 
• Establishment of national and local infection prevention and control (IPC) teams  
 
Tools and Technologies 
• Guidelines for the proper collection of samples to harmonise methods 
• Government to develop and equip regional laboratories 
• Creation of national and local databases to monitor S. aureus diseases and antimicrobial 
resistance 
 
mother to clear S. aureus carriage, which has been shown to reduce both maternal and 
newborn S. aureus carriage by 60% in The Gambia.103 Available strategies are to either 
administer IAP to all pregnant women (non-screening approach) or to screen for S. aureus 
between the 35th and 37th week of pregnancy and treat positive women (screening 
approach). The latter will be similar to the universal screening of pregnant women for GBS 
to prevent disease in their newborns. This approach may not be feasible in Africa because 
of the scarcity of well-equipped and adequately staffed laboratories. 
Given that not all babies born to S. aureus-carrying mothers become infected, another 
strategy would be to reserve IAP for pregnancies with a high risk of infection, especially 
preterm deliveries (risk-based approach). The use of IAP in Africa would need careful 
consideration, in terms of the timing and practicability of screening, cost-effectiveness and 
the emergence of antibiotic resistance. Therefore, a study is required to compare the 
effectiveness of the two (screening and risk-based) approaches in preventing neonatal S. 
aureus carriage and disease. Another research to assess and compare the development of 
antibiotic resistance and the cost-effectiveness of the universal antibiotic administration to 
the screening approach is necessary before a policy can be formulated. If the Gambian 
government were to implement a programme of IAP use, then monitoring for antibiotic 
resistance would be essential.   
 
Cord care  
Chlorhexidine cord cleansing for seven consecutive days post-delivery reduced the risk of 
bacterial carriage, omphalitis and neonatal mortality in South Asia.340 There is no data on 
the effect of chlorhexidine on neonatal mortality in Africa, therefore such trials are required 
in resource-poor settings. However, daily application of chlorhexidine has been associated 
with delayed cord separation, and the risk of poor adherence increases with time, thus 
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increasing the risk of infection. Additionally, it is an easier programmatically intervention to 
implement compared to seven days application. Therefore, RCTs are required to test the 
non-inferiority of the effect of the application of chlorhexidine to the cord once immediately 
post-partum compared to seven days application in Africa.  
 
Evidence of transmission 
Newborns of carrier mothers have similar rates of acquiring both maternal and non-
maternal strains in the early neonatal period.104,105 Therefore, molecular methods to 
determine the genetic relatedness of strains are required to detect the source of 
transmission of S. aureus between contacts and newborns. Spa typing will be a preferred 
method because it is highly discriminatory, reproducible, and not as expensive as other 
sequencing methods. Determination of the source of transmission to the newborn will aid 
the development of interventions to reduce carriage acquisition by the newborn.  
 
Vaccine development 
While IPC measures are necessary, the development of a vaccine against S. aureus is an 
attractive strategy given the success of other vaccines in the reduction of many childhood 
infections as well as the multiplicity of potential sources of the infection. As discussed in 
















efficacy against disease.226 It appears that the key barrier to vaccine development is the lack 
of understanding of the mechanisms of protective immunity to S. aureus.226 Therefore, 
further research is required in this area. Another barrier is that previous vaccine candidates 
have focused on the use of either single or multiple proteins.226 A way forward may be the 
use of the reverse vaccinology approach, which employs computational analysis of the entire 
genome of a bacterium for the prediction and identification of genes.  These genes are likely 
to lead to the expression of proteins that might be expected to elicit to an immune response; 
for example, those likely to be expressed on the surface of a micro-organism. Candidate 
genes are then introduced into an expression system and the recombinant proteins 
produced are tested for their protective effects in animal models. This method has been used 
successfully in the development of vaccines against other diseases.341  
Careful consideration needs to be given to the appropriate vaccination strategies in terms 
of timing and age of administration, given that the burden of disease is highest in newborns. 
Maternal immunisation is a promising strategy because it can protect both the mother and 





• Qualitative studies into the health-seeking behaviour of mothers and cord care practices 
• Effectiveness of chlorhexidine on neonatal mortality 
• Assessment of the efficacy of single use of chlorhexidine for cord care compared to seven 
days 
• Assessment of the effectiveness of maternal screening- and risk-based approaches in 
preventing neonatal S. aureus carriage and disease 
• Assessment of knowledge gaps on IPC among HCW 
 
The African Continent 
• Prospective surveillance studies on the burden of S. aureus disease 
• Clinical development of a vaccine against S. aureus 






workers and vulnerable populations. Such an intervention would not only directly protect 
the newborns, pregnant mothers, and health care workers but would increase the herd 
immunity, thereby further reducing the carriage and burden of disease.  
 
5.3 Overall conclusion 
S. aureus disease is a significant contributor to neonatal and childhood morbidity and 
mortality in Africa yet is under-recognised. S. aureus carriage acquisition by one week of age 
is high; the mother is the primary source of this acquisition. Interventions are required both 
in the community and health facilities to reduce the burden of S. aureus carriage and disease 
among children, especially newborns. There is, also, a need for investment in research and 
continued coordinated population-based surveillance of this disease, strengthening of 
laboratory infrastructures and the promotion of harmonisation of methods. Finally, a 
vaccine against S. aureus remains an attractive, cost-effective option that merits renewed 
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Appendix 1: GATHER Checklist of information in new reports 
of global health estimates 
Item # Checklist item Reported on 
page # 
Objectives and funding 
1 Define the indicator(s), populations (including age, sex, and geographic entities), and 
time period(s) for which estimates were made. 
61-62 
2 List the funding sources for the work. 1 
Data Inputs 
   For all data inputs from multiple sources that are synthesized as part of the study: 
3 Describe how the data were identified and how the data were accessed.  63-64 
4 Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. 61 - 62 
5 Provide information on all included data sources and their main characteristics. For 
each data source used, report reference information or contact name/institution, 
population represented, data collection method, year(s) of data collection, sex and age 
range, diagnostic criteria or measurement method, and sample size, as relevant.  
61-64 
6 Identify and describe any categories of input data that have potentially important 
biases (e.g., based on characteristics listed in item 5). 
64-65 
   For data inputs that contribute to the analysis but were not synthesized as part of the study: 
7 Describe and give sources for any other data inputs.  63, 247-248 
   For all data inputs: 
8 Provide all data inputs in a file format from which data can be efficiently extracted 
(e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 
5. For any data inputs that cannot be shared because of ethical or legal reasons, such 
as third-party ownership, provide a contact name or the name of the institution that 
retains the right to the data. 
Appendix 3, 
Data analysis 
9 Provide a conceptual overview of the data analysis method. A diagram may be helpful.  57 
10 Provide a detailed description of all steps of the analysis, including mathematical 
formulae. This description should cover, as relevant, data cleaning, data pre-
processing, data adjustments and weighting of data sources, and mathematical or 
statistical model(s).  
54 – 60 
11 Describe how candidate models were evaluated and how the final model(s) were 
selected. 
ND 
12 Provide the results of an evaluation of model performance, if done, as well as the 
results of any relevant sensitivity analysis. 
ND 
13 Describe methods for calculating uncertainty of the estimates. State which sources of 
uncertainty were, and were not, accounted for in the uncertainty analysis. 
73 
14 State how analytic or statistical source code used to generate estimates can be 
accessed. 
Appendices 
5 - 11 
Results and Discussion 
15 Provide published estimates in a file format from which data can be efficiently 
extracted. 
Appendices 
5 - 11 
16 Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty 
intervals). 
ND 
17 Interpret results in light of existing evidence. If updating a previous set of estimates, 
describe the reasons for changes in estimates. 
73-102 
18 Discuss limitations of the estimates. Include a discussion of any modelling 
assumptions or data limitations that affect interpretation of the estimates. 
102-113 
Appendix 2: Search strategy and numbers of articles in Medline, Embase and Global 
Health January 1980 - May 2019 
Concept Search Terms Number of 
articles 
African Countries 
 Africa* 288989 
1 Algeria* 4011 
2 Angola* 1494 
3 Benin* 3233 
4 Botswana or Batswana 2090 
5 Burkina* 3782 
6 Burundi*    861 
7 Cameroon* 6585 
8 Cape Verde 468 
9 Chad* 2776 
10 Comoros* 429 
11 Congo* 15060 
12 Cote?d'ivoire OR Ivory?coast OR Ivorian*  146 
13 Djibouti 363 
14 Egypt* 20272 
15 Eritrea* 554 
16 Ethiopia* 13123 
17 Gabon*  2094 
18 Gambia*   7472 
19 Ghana*  8946 
20 Guinea* 157989 
21 Kenya*  18439 
22 Lesotho*  603 
23 Liberia*  1659 
24 Libya* 1516 
25 Madagascar*  4705 
26 Malawi*  6087 
27 Mali OR Malians 3380 
28 Mauritania* 637 
29 Mauritius*  871 
30 Morocco* 6603 
31 Mozambi* 1431 
32 Namibia* 1431 
33 Niger* 44263 
34 Nigeria*  31157 
35 Rwanda*  2782 
36 Sao?tome OR Principe  900 
37 Senegal*  8088 
38 Seychelles* 715 
39 Sierra?leone* 1937 
40 Somali* 2492 
41 South?Africa* 47803 
42 Sudan* 8800 
43 Swazi* OR Eswatini 766 
44 Tanzania* 12451 
45 Togo*  1649 
46 Tunisia OR Tunis* 10170 
47 Uganda* 13449 
245 
 
48 Zambia* 5273 
49 Zimbabwe* 6714 
   
Disease 
50 (Fever* or bacterem* or bacteraem* or septice* or septicae* or 
blood stream infection* or sepsis).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, floating sub-heading word, 
keyword heading word, organism supplementary concept word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
363455 
   
51 (Disease or abscesses or arthritis or brain abscess or burn or 
cellulitis or dermatitis or empyema or endocarditis or 
endophthalmitis or food poisoning or Fournier Gangrene or 
impetigo or laryngitis or lung infection or mastitis or meningitis 
or osteomyelitis or otitis externa or otitis media or paronychia or 
pericarditis or peritonitis or pleural effusion or pneumonia or 
pyelonephritis or pyomyositis or respiratory tract infection or 
scalded skin syndrome or sepsis or septic arthritis or sinusitis or 
skin infections or skin adj3 infection or tonsillitis or toxic shock 
syndrome or pharyngitis or tracheitis or urethritis or urinary 
tract infection or uveitis or vaginitis or vaginosis or wound 
infection).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, 
organism supplementary concept word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
 
4872199 
   
52 Staphylococcus aureus or S aureus or staphylococcal infection* or 
staphylococcal disease* or staphylococc*).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, floating sub-heading 
word, keyword heading word, organism supplementary concept word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms]   
186692 
   
53 (Africa* or Benin or Burkina* or Cape Verde or Cote d'ivoire or 
Ivory coast or Ivorian* or Gambia* or Ghana* or Guinea* or 
Liberia* or Mali or Malians or Mauritania* or Niger* or Nigeria* or 
Senegal* or Sierra leone* or Togo* or Angola* or Botswana* or 
Batswana* or Lesotho* or Malawi* or Mozambi* or Namibia* or 
South Africa* or Swazi* or Zambia* or Zimbabwe* or Burundi* or 
Ethiopia* or Eritrea* or Kenya* or Rwanda* or Somali* or Sudan* 
or Tanzania* or Uganda* or Cameron* or Chad* or Congo* or 
Gabon* or Algeria* or Egypt* or Libya* or Morocco* or Tunisia or 
Tunis* or Sao tome or Principe* or Mauritius* or Madagascar* or 
Comoros* or Seychelles* or Djibouti).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, floating sub-heading word, 
keyword heading word, organism supplementary concept word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
666618 
   
54  




   
55 (54 or 
52) 
 5121044 
   
56 (55 and 
53) 
 149737 




   
Humans  98722 





List of countries by sub-region 
Central 
Burundi, Cameroon, Central African Republic, Chad, Congo Republic, DR Congo, Equatorial 
Guinea, Gabon, São Tomé and Príncipe 
 
East 
Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, Seychelles, 
Somalia, South Sudan, Sudan, Tanzania, Uganda 
 
North 
Algeria, Egypt, Libya, Mauritania, Morocco, Sahrawi, Tunisia 
 
Southern 
Angola, Botswana, Eswatini (Swaziland), Lesotho, Malawi, Mozambique, Namibia, South 
Africa, Zambia, Zimbabwe 
 
West 
Benin, Burkina Faso, Cabo Verde, Côte d’Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, 
Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, Togo 
 
List of countries by mortality stratum 
Stratum 1 
Cape Verde, Libya, Mauritius, Seychelles, Tunisia 
 
Stratum 2 




Benin, Burkina Faso, Burundi, Cameroon, Comoros, Congo, Cote d'Ivoire, Democratic 
Republic of Congo, Djibouti, Eswatini (Swaziland), Gambia, Ghana, Guinea, Kenya, Lesotho, 
Liberia, Malawi, Mali, Mauritania, Mozambique, Niger, Nigeria, Sierra Leone, Somali, 
Equatorial Guinea, South Sudan, Sudan, Togo, Uganda., Zambia,  
 
Stratum 4 
Angola, Central African Republic, Chad, Guinea Bissau
247 
 
Appendix 3: Supplemental Tables and Figures for Chapter 2 
Supplemental Table 2.1: Meta-analysis results by parameter, country, number of 


























Parameter Country Region Mortality 
Stratum 
Number 
of studies  
Effect size (95%CI) 
Pneumonia      % 
   Bacteraemic 
aetiologic fraction 
Pooleda  3 3  6.0 (0.1 – 11.0) 
 Mali West 3 1  0.9 (0.2 – 4.7) 
 Nigeria West 3 1  10.7 (7.2 – 15.7) 
 Uganda East 3 1  5.7 (3.1 – 10.5) 
 Morocco North 2 1 1.3 (0.0 – 7.3) 
      
Meningitis      Cases per 100,000 
population 
All-cause incidenceb Pooled  3 3 85.1 (69.2 – 102.6) 
 Mozambique South 3 1  171.9 (110.4 – 246.3) 
 Mali West 3 1 76.9 (69.0 – 85.4) 
 Togo/Burkina 
Faso 
West 3 1 79.8 (73.0 – 87.0) 
      
    Aetiologic fraction Nigeria West 3 1  7.0 (1.0 – 24.0) 
 Senegal West 2 1 2.3 (0.8 – 5.5) 
      
    All-cause CFRc Nigeria West 3 1  27.0 (18.0 – 37.0) 
      
Septicaemia     Cases per 100,000 
population 
   Incidenceb Pooled  3 6  919.3 (604.5 – 1299.3) 
 Pooled Kenya East 3 2  764.4 (251.6 – 1547.2) 
 Pooled Gambia West 3 2  634.9 (289.9 – 1112.9) 
 Ghana West 3 1  4686.0 (4109.0– 
5300.8) 
 Mozambique South 3 1  782.0 (727.7 – 838.3) 
 Tanzania East 2 1  159.6 (138.4 – 182.2) 
      
   Aetiologic fraction Pooled  3 4 47.0 (40.0 – 54.0) 
 Nigeria West 3 3  48.0 (40.0 – 56.0) 
 Uganda East 3 1  42.0 (28.0 – 58.0) 
 Guinea-Bissau West 4 1  57.0 (41.0 – 71.0) 
         
      
   CFR Pooled  3 2  9.0 (6.0 – 12.0) 
 Gambia West 3 1  14.0 (10.0 – 20.0) 
 Mozambique South 3 1  6.0 (3.0 – 11.0) 
      
a Summary estimate of the meta-analysis of the countries in the same stratum 
b Incidence in cases per 100,000 person-years  
c CFR=Case fatality ratio 
d Incidence in cases per 1,000 live births 
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Parameter Country Region Mortality 
Stratum 
Number 
of studies  
Effect size (95%CI) 
Neonatal 
septicaemia 
    Cases per 1,000 live 
births 
   Incidenced Pooleda  3 2  7.1 (4.1 – 11.0) 
 Gambia West 3 1  9.0 (7.8 – 10.4) 
 Kenya East 3 1  5.5 (4.6 – 6.4) 
      
   Aetiologic 
fraction 
Pooled  3 7  45.0 (27.0 - 63.0) 
 Nigeria (Pooled) West 3 4  40.0 (13.0 – 67.0) 
 Tanzania (Pooled) East 2 3  9.0 (9.0 – 22.0) 
 Uganda (Pooled) East 3 3  52.0 (32.0 – 72.0) 
      
   CFRC Pooled  3 5  20.0 (14.0 – 26.0) 
 Nigeria West 3 4  23.0 (14.0 – 32.0) 
 Gambia West 3 1  18.0 (10.0 – 28.0) 
 Tanzania East 2 1  33.3 (4.0 – 78.0) 
      
a Summary estimate of the meta-analysis of the countries in the same stratum 
b Incidence in cases per 100,000 person-years 
c CFR=Case fatality ratio 






Supplemental Figure 1: Random-effects pooled aetiologic fraction of community-acquired S. 
aureus bacteraemic pneumonia in hospital-based studies in mortality strata 3 in Africa 
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Supplemental Figure 2: Random-effects pooled aetiologic fraction of community-
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Supplemental Figure 3: Random-effects pooled aetiologic fraction of community-acquired 





Supplemental Figure 4: Random-effects pooled case fatality ratio of community-acquired 
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Supplemental Figure 5: Random-effects pooled case fatality ratio of community-
acquired neonatal S. aureus septicaemia in mortality stratum 3 
 
Supplemental Figure 6: Random-effects pooled aetiologic fraction of community-
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Supplemental Figure 7: Random-effects pooled aetiologic fraction of community-
acquired neonatal S. aureus septicaemia in mortality stratum 3 
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Appendix 4: Population size of children aged less than five years by country in 2015 





1 Algeria North 2 4,664,000 2.5 
2 Angola South 4 5,158,000 2.8 
3 Benin West 3 1,739,000 0.9 
4 Botswana South 2 256,000 0.2 
5 Burkina Faso West 3 3,161,000 1.7 
6 Burundi Central 3 1,853,000 1.0 
7 Cameroon Central 3 3,742,000 2.0 
8 Cape Verde West 1 55,000 0.03 
9 Central African Republic Central 4 728,000 0.4 
10 Chad Central 4 2,601,000 1.4 
11 Comoros East 3 117,000 0.1 
12 Congo Central 3 814,000 0.4 
13 Cote d'ivoire  West 3 3,765,000 2.0 
14 Democratic Republic of Congo Central 3 14,099,000 7.5 
15 Djibouti East 3 101,000 0.1 
16 Egypt North 2 12,374,000 6.6 
17 Equatorial Guinea Central 3 176,000 0.1 
18 Eritrea East 2 744,000 0.4 
19 Ethiopia East 2 14,901,000 8.0 
20 Gabon Central 2 267,000 0.1 
21 Gambia West 3 352,000 0.2 
22 Ghana West 3 4,023,000 2.1 
23 Guinea West 3 1,949,000 1.0 
24 Guinea Bissau West 4 285,000 0.1 
25 Kenya East 3 6,997,000 3.7 
26 Lesotho South 3 280,000 0.1 
27 Liberia West 3 705,000 0.4 
28 Libya North 1 630,000 0.3 
29 Madagascar East 2 3,700,000 2.0 
30 Malawi South 3 2,888,000 1.6 
31 Mali  West 3 3,274,000 1.7 
32 Mauritania North 3 640,000 0.4 
33 Mauritius East 1 69,000 0.1 
34 Morocco North 2 3,457,000 1.9 
35 Mozambique South 3 4,844,000 2.6 
36 Namibia South 2 335,000 0.2 
37 Niger West 3 4,066,000 2.2 
38 Nigeria West 3 31,109,000 16.7 
39 Rwanda East 2 1,735,000 0.9 
40 Sao tome and Principe Central 2 31,000 0.02 
41 Senegal West 2 2,493,000 1.3 
42 Seychelles East 1 8,000 0.01 
43 Sierra Leone West 3 1,135,000 0.6 
44 Somali East  3 2,554,000 1.4 
45 South Africa South 2 5,664,000 3.0 
46 South Sudan East 3 1,882,000 1.0 
47 Sudan East 3 5,859,000 3.1 
48 Swaziland/Eswatini South 3 178,000 0.1 
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49 Tanzania East 2 9,419,000 5.0 
50 Togo West 3 1,162,000 0.6 
51 Tunisia  North 1 1,024,000 0.5 
52 Uganda East 3 7,512,000 4.0 
53 Western Sahara North 2 55,000 0.03 
54 Zambia South 3 2,750,000 1.5 
55 Zimbabwe South 2 2,505,000 1.3 
 All countries   186,884,000 100.0 
1 African Union Commission. African Union Handbook: A guide for those working with and  within the African Union. 6th ed. 
Addis Ababa: African Union Commission and New Zealand Ministry  of Foreign Affairs and Trade/Manatū Aorere; 2019. 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, 
UNICEF, 2016. 
3 United Nations Population Fund. World Population Prospects 2017 File POP/7-1: Total population (both sexes combined) 
by five-year age group, region, subregion and country, 1950-2100 (thousands) 2017. 


























Country Region MS1 Population1 Meningitis Pneumonia Septicaemia All cases Incidence2 
Burundi Central 3 1,853,000 252 1,220 2,348 3,821 206 
Cameroon Central 3 3,742,000 510 2,291 4,741 7,541 202 
Central African 
Republic 
Central 4 728,000 99 412 922 1,433 197 
Chad Central 4 2,601,000 354 1,611 3,295 5,260 202 
Congo Central 3 814,000 111 437 1,031 1,580 194 
Democratic 
Republic of Congo 
Central 3 14,099,000 1,920 9,851 17,863 29,634 210 
Equatorial Guinea Central 3 176,000 24 77 223 324 184 
Gabon Central 2 267,000 36 153 338 527 197 
Sao tome or 
Principe 
Central 2 31,000 4 16 39 59 191 
Comoros East 3 117,000 16 92 148 257 219 
Djibouti East 3 101,000 14 51 128 193 191 
Eritrea East 2 744,000 101 502 943 1,546 208 
Ethiopia East 2 14,901,000 2,029 9,073 18,880 29,981 201 
Kenya East 3 6,997,000 953 4,577 3,135 8,664 124 
Madagascar East 2 3,700,000 504 1,865 4,688 7,057 191 
Mauritius East 1 69,000 9 41 87 138 200 
Rwanda East 2 1,735,000 236 667 2,198 3,101 179 
Seychelles East 1 8,000 1 5 10 16 201 
Somali East 3 2,554,000 348 2,347 3,236 5,931 232 
South Sudan East 3 1,882,000 256 0 2,384 2,641 140 
Sudan East 3 5,859,000 798 2,946 7,423 11,167 191 
Tanzania East 2 9,419,000 1,282 6,135 11,934 19,351 205 
Uganda East 3 7,512,000 1,023 4,328 9,518 14,868 198 
1 MS=Mortality Stratum; Population=Population size 
2 Incidence rates of S. aureus disease are per 100,000 children 
 
 
Country Region MSa Populationa Meningitis Pneumonia Septicaemia All cases Incidenceb 
Burundi Central 3 1,853,000 252 1,220 2,348 3,821 206 
Cameroon Central 3 3,742,000 510 2,291 4,741 7,541 202 
Central African 
Republic 
Central 4 728,000 99 412 922 1,433 197 
 Appendix 5: Number of cases by clinical syndrome and incidence of S. aureus disease by country in 2015               











Country Region MS1 Population1 Meningitis Pneumonia Septicaemia All cases Incidence2 
Algeria North 2 4,664,000 635 2,668 5,909 9,212 198 
Egypt North 2 12,374,000 1,685 3,624 15,678 20,987 170 
Libya North 1 630,000 86 244 798 1,128 179 
Mauritania North 3 640,000 87 341 811 1,239 194 
Morocco North 2 3,457,000 471 1,693 4,380 6,544 189 
Tunisia North 1 1,024,000 139 370 1,297 1,807 176 
Western Sahara North 2 55,000 7 0 70 77 140 
Angola South 4 5,158,000 1,419 1,897 6,535 9,851 191 
Botswana South 2 256,000 70 170 324 565 221 
Lesotho South 3 280,000 38 187 355 580 207 
Malawi South 3 2,888,000 393 1,676 3,659 5,728 198 
Mozambique South 3 4,844,000 1,332 3,410 5,730 10,473 216 
Namibia South 2 335,000 92 213 424 729 218 
South Africa South 2 5,664,000 1,558 3,210 7,176 11,944 211 
Swaziland South 3 178,000 24 78 226 328 184 
Zambia South 3 2,750,000 374 2,126 3,484 5,984 218 
Zimbabwe South 2 2,505,000 689 1,267 3,174 5,129 205 
Benin West 3 1,739,000 237 1,342 2,203 3,782 217 
Burkina Faso West 3 3,161,000 405 2,219 4,005 6,629 210 
Cape Verde West 1 55,000 7 30 70 108 196 
Cote d'Ivoire West 3 3,765,000 513 1,214 4,770 6,497 173 
Ghana West 3 4,023,000 548 1,974 25,349 27,870 693 
Guinea West 3 1,949,000 265 1,279 2,469 4,014 206 
1 MS=Mortality Stratum; Population=Population size 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All cases Incidence3 
Guinea Bissau West 4 285,000 39 183 361 583 205 
Liberia West 3 705,000 96 370 893 1,359 193 
Mali West 3 3,274,000 402 2,459 4,148 7,009 214 
Niger West 3 4,066,000 554 3,181 5,152 8,886 219 
Nigeria West 3 31,109,000 4,236 24,009 39,415 67,660 217 
Senegal West 2 2,493,000 339 1,670 3,159 5,168 207 
Sierra Leone West 3 1,135,000 155 614 1,438 2,206 194 
Togo West 3 1,162,000 149 727 1,472 2,348 202 
All countries   186,884,000 27,973 113,368 250,725 392,066   
1 MS=Mortality Stratum; United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2016. 
2  United Nations Population Fund. World Population Prospects 2017 File POP/7-1: Total population (both sexes combined) by five-year age group, region,  
subregion and country, 1950-2100 (thousands) 2017. https://esa.un.org/unpd/wpp/Download/Standard/Population/ (accessed February 02 2018). 



























Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All cases Incidence3 
Burundi Central 3 1,853,000 117 4,195 8,006 12,318 665 
Cameroon Central 3 3,742,000 236 7,874 16,168 24,278 649 
Central African 
Republic 
Central 4 728,000 46 1,415 3,815 5,276 725 
Chad Central 4 2,601,000 164 5,536 13,629 19,329 743 




Central 3 14,099,000 888 33,861 60,918 95,667 679 
Equatorial 
Guinea 
Central 3 176,000 11 264 760 1,036 589 
Gabon Central 2 267,000 9 124 183 316 118 
Sao tome or 
Principe 
Central 2 31,000 1 13 21 35 113 
Comoros East 3 117,000 7 318 506 831 710 
Djibouti East 3 101,000 6 175 436 618 612 
Eritrea East 2 744,000 25 408 511 944 127 
Ethiopia East 2 14,901,000 507 7,371 10,225 18,104 121 
Kenya East 3 6,997,000 441 14,808 25,138 40,387 577 
Madagascar East 2 3,700,000 126 1,516 2,539 4,180 113 
Mauritius East 1 69,000 2 33 47 83 120 
Rwanda East 2 1,735,000 59 542 1,191 1,791 103 
Seychelles East 1 8,000 0 4 5 10 121 
Somali East 3 2,554,000 161 8,068 11,035 19,264 754 
South Sudan East 3 1,882,000 119 0 8,132 8,250 438 
Sudan East 3 5,859,000 369 10,127 25,315 35,811 611 
Tanzania East 2 9,419,000 321 4,985 6,463 11,769 125 
1 MS=Mortality Stratum  
2 Population=Population size 
3 Incidence rates of S. aureus disease are per 100,000 children 
 
 
Country Region MSa Populationa Meningitis Pneumonia Septicaemia All cases Incidenceb 
Burundi Central 3 1,853,000 117 4,195 8,006 12,318 665 
259 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All cases Incidence3 
Uganda East 3 7,512,000 473 15,417 29,004 44,894 598 
Algeria North 2 4,664,000 159 2,168 3,200 5,527 119 
Egypt North 2 12,374,000 421 2,945 8,491 11,857 96 
Libya North 1 630,000 21 199 432 652 104 
Mauritania North 3 640,000 40 1,171 2,765 3,976 621 
Morocco North 2 3,457,000 118 1,376 2,372 3,866 112 
Tunisia North 1 1,024,000 35 300 703 1,038 101 
Western Sahara North 2 55,000 2 0 38 40 72 
Angola South 4 5,158,000 656 6,522 27,028 34,206 663 
Botswana South 2 256,000 18 138 176 332 130 
Lesotho South 3 280,000 18 644 1,210 1,872 669 
Malawi South 3 2,888,000 182 5,762 12,478 18,422 638 
Mozambique South 3 4,844,000 616 11,722 17,804 30,142 622 
Namibia South 2 335,000 23 173 230 426 127 
South Africa South 2 5,664,000 389 2,608 3,887 6,884 122 
Swaziland South 3 178,000 11 269 769 1,049 589 
Zambia South 3 2,750,000 173 7,307 11,882 19,362 704 
Zimbabwe South 2 2,505,000 172 5,359 1,719 7,250 289 
Benin West 3 1,739,000 110 4,613 7,514 12,236 704 
Burkina Faso West 3 3,161,000 187 7,629 13,658 21,474 679 
Cape Verde West 1 55,000 2 25 38 64 117 
Cote d'Ivoire West 3 3,765,000 237 4,174 16,267 20,679 549 
Gambia West 3 352,000 22 779 1,050 1,852 526 
Ghana West 3 4,023,000 253 6,784 88,603 95,641 2,377 
Guinea West 3 1,949,000 123 4,396 8,421 12,940 664 
Guinea Bissau West 4 285,000 18 631 1,493 2,142 752 
1 MS=Mortality Stratum  
2 Population=Population size 
3 Incidence rates of S. aureus disease are per 100,000 children 
 
 
Country Region MSa Populationa Meningitis Pneumonia Septicaemia All cases Incidenceb 
Egypt North 2 12,374,000 421 2,945 8,491 11,857 96 
Libya North 1 630,000 21 199 432 652 104 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All cases Incidence3 
Liberia West 3 705,000 44 1,270 3,046 4,361 619 
Mali West 3 3,274,000 186 1,383 18 1,587 48 
Niger West 3 4,066,000 256 10,934 17,568 28,758 707 
Nigeria West 3 31,109,000 1,959 160,562 137,273 299,793 964 
Senegal West 2 2,493,000 85 1,357 1,711 3,153 126 
Sierra Leone West 3 1,135,000 71 2,110 4,904 7,086 624 
Togo West 3 1,162,000 69 2,499 5,021 7,589 653 
All countries  186,884,000 10,816 376,367 629,334 1,016,516 25,922 
1 MS=Mortality Stratum; United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2016. 
2  Population=Population size; United Nations Population Fund. World Population Prospects 2017 File POP/7-1: Total population (both sexes combined) by five-year 
age group, region, subregion and country, 1950-2100 (thousands) 2017. https://esa.un.org/unpd/wpp/Download/Standard/Population/ (accessed February 02 
2018). 
3  Incidence rates of S. aureus disease are per 100,000 children 
 
 
Country Region MSa Populationa Meningitis Pneumonia Septicaemia All cases Incidenceb 
Liberia West 3 705,000 44 1,270 3,046 4,361 619 
Mali West 3 3,274,000 186 1,383 18 1,587 48 
Niger West 3 4,066,000 256 10,934 17,568 28,758 707 
Nigeria West 3 31,109,000 1,959 160,562 137,273 299,793 964 
Senegal West 2 2,493,000 85 1,357 1,711 3,153 126 
Sierra Leone West 3 1,135,000 71 2,110 4,904 7,086 624 
Togo West 3 1,162,000 69 2,499 5,021 7,589 653 
All countries  186,884,000 10,816 376,367 629,334 1,016,516 25,922 
a MS=Mortality Stratum; Population=Population size 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All deaths MR3 
Burundi Central 3 1,853,000 122 95 211 428 23 
Cameroon Central 3 3,742,000 364 177 427 969 26 
Central African 
Republic 
Central 4 728,000 70 54 83 206 28 
Chad Central 4 2,601,000 258 309 297 863 33 




Central 3 14,099,000 1,196 742 1,608 3,545 25 
Equatorial 
Guinea 
Central 3 176,000 13 7 20 40 23 
Gabon Central 2 267,000 16 6 30 53 20 
Sao tome or 
Principe 
Central 2 31,000 2 1 4 6 19 
Comoros East 3 117,000 10 5 13 28 24 
Djibouti East 3 101,000 4 3 12 18 18 
Eritrea East 2 744,000 61 25 85 171 23 
Ethiopia East 2 14,901,000 1,424 502 1,699 3,625 24 
Kenya East 3 6,997,000 442 180 282 904 13 
Madagascar East 2 3,700,000 317 111 422 850 23 
Mauritius East 1 69,000 3 0 8 11 16 
Rwanda East 2 1,735,000 128 31 198 357 21 
Seychelles East 1 8,000 0 0 1 1 15 
Somalia East 3 2,554,000 283 235 291 809 32 
South Sudan East 3 1,882,000 149 129 215 493 26 
Sudan East 3 5,859,000 465 246 668 1,380 24 
Tanzania East 2 9,419,000 689 230 1,074 1,993 21 
1 MS=Mortality Stratum  
2 Population=Population size  
3 MR=Mortality Rate; Mortality rates of S. aureus disease are per 100,000 children 
 
 
Country Region MSa Populationa Meningitis Pneumonia Septicaemia All deaths MRa 
Burundi Central 3 1,853,000 122 95 211 428 23 
Cameroon Central 3 3,742,000 364 177 427 969 26 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All deaths MR3 
Uganda East 3 7,512,000 380 219 857 1,456 19 
Algeria North 2 4,664,000 295 50 532 877 19 
Egypt North 2 12,374,000 760 134 1,411 2,305 19 
Libya North 1 630,000 22 2 72 96 15 
Mauritania North 3 640,000 59 26 73 158 25 
Morocco North 2 3,457,000 355 36 394 786 23 
Tunisia North 1 1,024,000 70 4 117 191 19 
Western Sahara North 2 55,000 6 1 6 13 23 
Angola South 4 5,158,000 818 474 588 1,880 36 
Botswana South 2 256,000 57 5 29 91 36 
Lesotho South 3 280,000 18 15 32 66 23 
Malawi South 3 2,888,000 151 87 329 568 20 
Mozambique South 3 4,844,000 715 188 344 1,248 26 
Namibia South 2 335,000 39 10 38 87 26 
South Africa South 2 5,664,000 497 114 646 1,257 22 
Swaziland South 3 178,000 12 6 20 38 21 
Zambia South 3 2,750,000 164 84 314 561 20 
Zimbabwe South 2 2,505,000 388 90 286 763 30 
Benin West 3 1,739,000 177 91 198 467 27 
Burkina Faso West 3 3,161,000 225 124 360 710 22 
Cape Verde West 1 55,000 2 1 6 9 16 
Cote d'Ivoire West 3 3,765,000 333 175 429 937 25 
Gambia West 3 352,000 22 12 38 72 21 
1 MS=Mortality Stratum  
2 Population=Population size  
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All deaths MR3 
Ghana West 3 4,023,000 291 104 2,281 2,676 67 
Guinea West 3 1,949,000 174 112 222 509 26 
Guinea Bissau West 4 285,000 26 16 32 75 26 
Liberia West 3 705,000 54 28 80 162 23 
Mali West 3 3,274,000 301 173 373 847 26 
Niger West 3 4,066,000 283 293 464 1,039 26 
Nigeria West 3 31,109,000 2,834 2,137 3,547 8,518 27 
Senegal West 2 2,493,000 198 64 284 546 22 
Sierra Leone West 3 1,135,000 66 60 129 255 22 
Togo West 3 1,162,000 86 48 133 266 23 
All countries   186,884,000 15,977 8,083 22,407 46,467   
1 MS=Mortality Stratum; United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2016. 
2  Population=Population size; United Nations Population Fund. World Population Prospects 2017 File POP/7-1: Total population (both sexes combined) by five-
year age group, region, subregion and country, 1950-2100 (thousands) 2017. https://esa.un.org/unpd/wpp/Download/Standard/Population/ (accessed February 
02 2018). 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All deaths MR3 
Burundi Central 3 1,853,000 112 355 721 1,188 64 
Cameroon Central 3 3,742,000 326 664 1,455 2,445 65 
Central African 
Republic 
Central 4 728,000 62 202 343 608 83 
Chad Central 4 2,601,000 231 1,157 1,227 2,614 100 




Central 3 14,099,000 1,079 2,774 5,483 9,335 66 
Equatorial 
Guinea 
Central 3 176,000 12 25 68 105 60 
Gabon Central 2 267,000 15 5 16 36 14 
Sao tome or 
Principe 
Central 2 31,000 2 0 2 4 13 
Comoros East 3 117,000 9 18 45 73 62 
Djibouti East 3 101,000 4 11 39 54 54 
Eritrea East 2 744,000 55 20 46 121 16 
Ethiopia East 2 14,901,000 1,276 409 920 2,604 17 
Kenya East 3 6,997,000 408 630 2,262 3,301 47 
Madagascar East 2 3,700,000 286 90 229 605 16 
Mauritius East 1 69,000 2 0 4 7 10 
Rwanda East 2 1,735,000 117 25 107 249 14 
Seychelles East 1 8,000 0 0 0 1 10 
Somali East 3 2,554,000 252 880 993 2,125 83 
South Sudan East 3 1,882,000 135 0 732 867 46 
Sudan East 3 5,859,000 422 933 2,278 3,633 62 
Tanzania East 2 9,419,000 628 186 582 1,396 15 
1 MS=Mortality Stratum  
2 Population=Population size  
3 MR=Mortality Rate; Mortality rates of S. aureus disease are per 100,000 children 
 
 
Country Region MSa Population Meningitis Pneumonia Septicaemia All deaths MRa 
Burundi Central 3 1,853,000 112 325 721 1,158 62 
Cameroon Central 3 3,742,000 326 609 1,455 2,390 64 
265 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All deaths MR3 
Uganda East 3 7,512,000 358 779 2,610 3,747 50 
Algeria North 2 4,664,000 272 41 288 601 13 
Egypt North 2 12,374,000 703 109 764 1,576 13 
Libya North 1 630,000 22 2 39 62 10 
Mauritania North 3 640,000 53 97 249 399 62 
Morocco North 2 3,457,000 317 124 213 654 16 
Tunisia North 1 1,024,000 64 13 63 140 13 
Western Sahara North 2 55,000 5 0 3 8 15 
Angola South 4 5,158,000 367 1,623 2,433 4,422 89 
Botswana South 2 256,000 25 17 16 58 18 
Lesotho South 3 280,000 17 53 109 178 65 
Malawi South 3 2,888,000 142 298 1,123 1,563 55 
Mozambique South 3 4,844,000 323 647 1,068 2,038 43 
Namibia South 2 335,000 18 34 21 73 14 
South Africa South 2 5,664,000 236 391 350 976 12 
Swaziland South 3 178,000 11 19 69 100 57 
Zambia South 3 2,750,000 152 331 1,069 1,552 58 
Zimbabwe South 2 2,505,000 175 307 155 636 27 
Benin West 3 1,739,000 158 314 676 1,148 68 
Burkina Faso West 3 3,161,000 218 427 1,229 1,874 61 
Cape Verde West 1 55,000 2 2 3 7 11 
Cote d'Ivoire West 3 3,765,000 299 601 1,464 2,365 64 
1 MS=Mortality Stratum  
2 Population=Population size  
3 MR=Mortality Rate; Mortality rates of S. aureus disease are per 100,000 children 
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Country Region MS1 Population2 Meningitis Pneumonia Septicaemia All deaths MR3 
Gambia West 3 352,000 20 42 147 209 61 
Ghana West 3 4,023,000 265 355 7,974 8,594 214 
Guinea West 3 1,949,000 156 385 758 1,300 68 
Guinea Bissau West 4 285,000 24 57 134 214 77 
Liberia West 3 705,000 49 96 274 419 61 
Mali West 3 3,274,000 298 97 2 396 12 
Niger West 3 4,066,000 259 1,006 1,581 2,846 72 
Nigeria West 3 31,109,000 2,545 14,257 12,355 29,156 94 
Senegal West 2 2,493,000 179 219 154 552 15 
Sierra Leone West 3 1,135,000 61 204 441 707 64 
Togo West 3 1,162,000 83 163 452 697 61 
All countries 
  
186,884,000 13,378 31,568 56,158 101,105 
 
1 MS=Mortality Stratum  
2 Population=Population size 



























Burundi Central 3 1,853,000 76,281 1.6 1,220 5913 1.6 95 
Cameroon Central 3 3,742,000 143,164 1.6 2,291 11071 1.6 177 
Central African 
Republic 
Central 4 728,000 25,731 1.6 412 3368 1.6 54 
Chad Central 4 2,601,000 100,662 1.6 1,611 19275 1.6 308 
Congo Central 3 814,000 27,333 1.6 437 971 1.6 16 
Democratic Republic of 
Congo 
Central 3 14,099,000 615,657 1.6 9,851 46226 1.6 740 
Equatorial Guinea Central 3 176,000 4,806 1.6 77 418 1.6 7 
Gabon Central 2 267,000 9,533 1.6 153 355 1.6 6 
Sao tome or Principe Central 2 31,000 977 1.6 16 35 1.6 1 
Comoros East 3 117,000 5,780 1.6 92 300 1.6 5 
Djibouti East 3 101,000 3,188 1.6 51 184 1.6 3 
Eritrea East 2 744,000 31,388 1.6 502 1551 1.6 25 
Ethiopia East 2 14,901,000 567,035 1.6 9,073 31427 1.6 503 
Kenya East 3 6,997,000 269,243 1.7 4,577 10507 1.7 179 
Madagascar East 2 3,700,000 116,583 1.6 1,865 6951 1.6 111 
Mauritius East 1 69,000 2,562 1.6 41 21 1.6 0 
Rwanda East 2 1,735,000 41,664 1.6 667 1929 1.6 31 
Seychelles East 1 8,000 304 1.6 5 1 1.6 0 
Somali East 3 2,554,000 146,691 1.6 2,347 14669 1.6 235 





Sudan East 3 5,859,000 184,135 1.6 2,946 15551 1.6 249 
Tanzania East 2 9,419,000 383,430 1.6 6,135 14322 1.6 229 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic 
analysis.  Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable  
Development Goals. Lancet 2016; 388: 3027-35 
 
 













Burundi Central 3 1,853,000 76,281 1.6 1,220 5913 1.6 95 
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Uganda East 3 7,512,000 270,471 1.6 4,328 13659 1.6 219 
Algeria North 2 4,664,000 166,754 1.6 2,668 3130 1.6 50 
Egypt North 2 12,374,000 226,501 1.6 3,624 8375 1.6 134 
Libya North 1 630,000 15,280 1.6 244 127 1.6 2 
Mauritania North 3 640,000 21,288 1.6 341 1616 1.6 26 
Morocco North 2 3,457,000 105,827 1.6 1,693 2246 1.6 36 
Tunisia North 1 1,024,000 23,112 1.6 370 234 1.6 4 
Western Sahara North 2 55,000   1.6 0   1.6 0 
Angola South 4 5,158,000 118,577 1.6 1,897 29502 1.6 472 
Botswana South 2 256,000 10,647 1.6 170 307 1.6 5 
Lesotho South 3 280,000 11,717 1.6 187 955 1.6 15 
Malawi South 3 2,888,000 104,755 1.6 1,676 5416 1.6 87 
Mozambique South 3 4,844,000 213,124 1.6 3,410 11757 1.6 188 
Namibia South 2 335,000 13,301 1.6 213 618 1.6 10 
South Africa South 2 5,664,000 200,634 1.6 3,210 7105 1.6 114 
Swaziland South 3 178,000 4,888 1.6 78 354 1.6 6 
Zambia South 3 2,750,000 132,848 1.6 2,126 6020 1.6 96 
Zimbabwe South 2 2,505,000 97,432 1.3 1,267 5582 1.3 73 
Benin West 3 1,739,000 83,873 1.6 1,342 5702 1.6 91 
Burkina Faso West 3 3,161,000 138,710 1.6 2,219 7761 1.6 124 
Cape Verde West 1 55,000 1,898 1.6 30 37 1.6 1 
Cote d'Ivoire West 3 3,765,000 75,899 1.6 1,214 10935 1.6 175 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 
Sustainable Development Goals. Lancet 2016; 388: 3027-35 
in 201510 
 













Uganda East 3 7,512,000 270,471 1.6 4,328 13659 1.6 219 
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 Appendix 7: Number of cases and deaths of S. aureus bacteraemia pneumonia by country in 2015 (population-
































Gambia West 3 352,000 14,165 1.6 227 766 1.6 12 
Ghana West 3 4,023,000 123,352 1.6 1,974 6450 1.6 103 
Guinea West 3 1,949,000 79,935 1.6 1,279 7008 1.6 112 
Guinea Bissau West 4 285,000 11,468 1.6 183 1028 1.6 16 
Liberia West 3 705,000 23,094 1.6 370 1737 1.6 28 
Mali West 3 3,274,000 153,660 1.6 2,459 10766 1.6 172 
Niger West 3 4,066,000 198,793 1.6 3,181 18290 1.6 293 
Nigeria West 3 31,109,000 1,500,575 1.6 24,009 133239 1.6 2,132 
Senegal West 2 2,493,000 104,392 1.6 1,670 3984 1.6 64 
Sierra Leone West 3 1,135,000 38,365 1.6 614 3714 1.6 59 
Togo West 3 1,162,000 45,439 1.6 727 2962 1.6 47 
All countries   186,884,000 7,086,921   113,368 496,427   8,066 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
 systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 




Country Region MSa Populationa All-cause  
pneumonia  
casesb 






AFa S. aureus 
pneumonia 
deaths 
Gambia West 3 352,000 14,165 1.6 227 766 1.6 12 
Ghana West 3 4,023,000 123,352 1.6 1,974 6450 1.6 103 
Guinea West 3 1,949,000 79,935 1.6 1,279 7008 1.6 112 
Guinea Bissau West 4 285,000 11,468 1.6 183 1028 1.6 16 
Liberia West 3 705,000 23,094 1.6 370 1737 1.6 28 
Mali West 3 3,274,000 153,660 1.6 2,459 10766 1.6 172 
Niger West 3 4,066,000 198,793 1.6 3,181 18290 1.6 293 
Nigeria West 3 31,109,000 1,500,575 1.6 24,009 133239 1.6 2,132 
Senegal West 2 2,493,000 104,392 1.6 1,670 3984 1.6 64 
Sierra Leone West 3 1,135,000 38,365 1.6 614 3714 1.6 59 

































Burundi Central 3 1,853,000 76,281 6.0 4,577 5,913 6.0 355 
Cameroon Central 3 3,742,000 143,164 6.0 8,590 11,071 6.0 664 
Central African 
Republic 




Chad Central 4 2,601,000 100,662 6.0 6,040 19,275 6.0 1,157 
Congo Central 3 814,000 27,333 6.0 1,640 971 6.0 58 
Democratic Republic of 
Congo 




Equatorial Guinea Central 3 176,000 4,806 6.0 288 418 6.0 25 
Gabon Central 2 267,000 9,533 1.3 124 355 1.3 5 
Sao tome or Principe Central 2 31,000 977 1.3 13 35 1.3 0 
Comoros East 3 117,000 5,780 6.0 347 300 6.0 18 
Djibouti East 3 101,000 3,188 6.0 191 184 6.0 11 
Eritrea East 2 744,000 31,388 1.3 408 1,551 1.3 20 
Ethiopia East 2 14,901,000 567,035 1.3 7,371 31,427 1.3 409 
Kenya East 3 6,997,000 269,243 6.0 16,155 10,507 6.0 630 
Madagascar East 2 3,700,000 116,583 1.3 1,516 6,951 1.3 90 
Mauritius East 1 69,000 2,562 1.3 33 21 1.3 0 
Rwanda East 2 1,735,000 41,664 1.3 542 1,929 1.3 25 
Seychelles East 1 8,000 304 1.3 4 1 1.3 0 
Somali East 3 2,554,000 146,691 6.0 8,801 14,669 6.0 880 





Sudan East 3 5,859,000 184,135 6.0 11,048 15,551 6.0 933 
Tanzania East 2 9,419,000 383,430 1.3 4,985 14,322 1.3 186 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
 systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 
 Sustainable Development Goals. Lancet 2016; 388: 3027-35 
 
 















 Appendix 7a: Number of cases and deaths of S. aureus bacteraemia pneumonia by country in 2015 (hospital-
































Uganda East 3 7,512,000 270,471 5.7 15,417 13,659 5.7 779 
Algeria North 2 4,664,000 166,754 1.3 2,168 3,130 1.3 41 
Egypt North 2 12,374,000 226,501 1.3 2,945 8,375 1.3 109 
Libya North 1 630,000 15,280 1.3 199 127 1.3 2 
Mauritania North 3 640,000 21,288 6.0 1,277 1,616 6.0 97 
Morocco North 2 3,457,000 105,827 1.3 1,376 2,246 1.3 29 
Tunisia North 1 1,024,000 23,112 1.3 300 234 1.3 3 
Western Sahara North 2 55,000  0 1.3 0  0 1.3 0 
Angola South 4 5,158,000 118,577 6.0 7,115 29,502 6.0 1,770 
Botswana South 2 256,000 10,647 1.3 138 307 1.3 4 
Lesotho South 3 280,000 11,717 6.0 703 955 6.0 57 
Malawi South 3 2,888,000 104,755 6.0 6,285 5,416 6.0 325 
Mozambique South 3 4,844,000 213,124 6.0 12,787 11,757 6.0 705 
Namibia South 2 335,000 13,301 1.3 173 618 1.3 8 
South Africa South 2 5,664,000 200,634 1.3 2,608 7,105 1.3 92 
Swaziland South 3 178,000 4,888 6.0 293 354 6.0 21 
Zambia South 3 2,750,000 132,848 6.0 7,971 6,020 6.0 361 
Zimbabwe South 2 2,505,000 97,432 6.0 5,846 5,582 6.0 335 
Benin West 3 1,739,000 83,873 6.0 5,032 5,702 6.0 342 
Burkina Faso West 3 3,161,000 138,710 6.0 8,323 7,761 6.0 466 
Cape Verde West 1 55,000 1,898 1.3 25 37 1.3 0 
Cote d'Ivoire West 3 3,765,000 75,899 6.0 4,554 10,935 6.0 656 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
 systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 
 Sustainable Development Goals. Lancet 2016; 388: 3027-35 
 
 













Uganda East 3 7,512,000 270,471 5.7 15,417 13,659 5.7 779 
Algeria North 2 4,664,000 166,754 1.3 2,168 3,130 1.3 41 
 Appendix 7a: Number of cases and deaths of S. aureus bacteraemia pneumonia by country in 2015 (hospital-

































Gambia West 3 352,000 14,165 6.0 850 766 6.0 46 
Ghana West 3 4,023,000 123,352 6.0 7,401 6,450 6.0 387 
Guinea West 3 1,949,000 79,935 6.0 4,796 7,008 6.0 420 
Guinea Bissau West 4 285,000 11,468 6.0 688 1,028 6.0 62 
Liberia West 3 705,000 23,094 6.0 1,386 1,737 6.0 104 
Mali West 3 3,274,000 153,660 0.9 1,383 10,766 0.9 97 
Niger West 3 4,066,000 198,793 6.0 11,928 18,290 6.0 1,097 
Nigeria West 3 31,109,000 1,500,575 10.7 160,562 133,239 10.7 14,257 
Senegal West 2 2,493,000 104,392 1.3 1,357 3,984 1.3 52 
Sierra Leone West 3 1,135,000 38,365 6.0 2,302 3,714 6.0 223 








1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
 systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 
 Sustainable Development Goals. Lancet 2016; 388: 3027-35 
 
 













Gambia West 3 352,000 14,165 5.5 779 766 5.5 42 
Ghana West 3 4,023,000 123,352 5.5 6,784 6,450 5.5 355 
Guinea West 3 1,949,000 79,935 5.5 4,396 7,008 5.5 385 
Guinea Bissau West 4 285,000 11,468 5.5 631 1,028 5.5 57 
Liberia West 3 705,000 23,094 5.5 1,270 1,737 5.5 96 
Mali West 3 3,274,000 153,660 0.9 1,383 10,766 0.9 97 
Niger West 3 4,066,000 198,793 5.5 10,934 18,290 5.5 1,006 
Nigeria West 3 31,109,000 1,500,575 10.7 160,562 133,239 10.7 14,257 
Senegal West 2 2,493,000 104,392 1.3 1,357 3,984 1.3 52 
Sierra Leone West 3 1,135,000 38,365 5.5 2,110 3,714 5.5 204 











































Burundi Central 3 1,853,000 76,281 25.0 19,070 5,100 25.0 1,275 
Cameroon Central 3 3,742,000 143,164 25.0 35,791 33 25.0 8 
Central African 
Republic 
Central 4 728,000 25,731 25.0 6,433 3,536 25.0 884 
Chad Central 4 2,601,000 100,662 25.0 25,166 18,839 25.0 4,710 
Congo Central 3 814,000 27,333 25.0 6,833 1,359 25.0 340 
Democratic 
Republic of Congo 
Central 3 14,099,000 615,657 25.0 153,914 49,244 25.0 12,311 
Equatorial Guinea Central 3 176,000 4,806 25.0 1,202 551 25.0 138 
Gabon Central 2 267,000 9,533 25.0 2,383 387 25.0 97 
Sao tome or 
Principe 
Central 2 31,000 977 25.0 244 47 25.0 12 
Comoros East 3 117,000 5,780 25.0 1,445 353 25.0 88 
Djibouti East 3 101,000 3,188 25.0 797 197 25.0 49 
Eritrea East 2 744,000 31,388 25.0 7,847 1,488 25.0 372 
Ethiopia East 2 14,901,000 567,035 25.0 141,759 32,276 25.0 8,069 
Kenya East 3 6,997,000 269,243 25.0 67,311 10,875 25.0 2,719 
Madagascar East 2 3,700,000 116,583 25.0 29,146 6,548 25.0 1,637 
Mauritius East 1 69,000 2,562 25.0 641 19 25.0 5 
Rwanda East 2 1,735,000 41,664 25.0 10,416 1,966 25.0 492 
Seychelles East 1 8,000 304 25.0 76 1 25.0 0 
Somali East 3 2,554,000 146,691 25.0 36,673 18,066 25.0 4,517 
South Sudan East 3 1,882,000 
 
25.0 0 8,179 25.0 2,045 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic 
analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable 
Development Goals. Lancet 2016; 388: 3027-35 
 
 













Burundi Central 3 1,853,000 76,281 25.0 19,070 5,100 25.0 1,275 

































Sudan East 3 5,859,000 184,135 25.0 46,034 12,610 25.0 3,153 
Tanzania East 2 9,419,000 383,430 25.0 95,858 18,029 25.0 4,507 
Uganda East 3 7,512,000 270,471 25.0 67,618 14,992 25.0 3,748 
Algeria North 2 4,664,000 166,754 25.0 41,689 3,130 25.0 783 
Egypt North 2 12,374,000 226,501 25.0 56,625 6,400 25.0 1,600 
Libya North 1 630,000 15,280 25.0 3,820 153 25.0 38 
Mauritania North 3 640,000 21,288 25.0 5,322 1,849 25.0 462 
Morocco North 2 3,457,000 105,827 25.0 26,457 2,255 25.0 564 
Tunisia North 1 1,024,000 23,112 25.0 5,778 232 25.0 58 
Western Sahara North 2 55,000   25.0 0 47 25.0 12 
Angola South 4 5,158,000 118,577 25.0 29,644 17,385 25.0 4,346 
Botswana South 2 256,000 10,647 25.0 2,662 218 25.0 55 
Lesotho South 3 280,000 11,717 25.0 2,929 864 25.0 216 
Malawi South 3 2,888,000 104,755 25.0 26,189 4,785 25.0 1,196 
Mozambique South 3 4,844,000 213,124 25.0 53,281 10,868 25.0 2,717 
Namibia South 2 335,000 13,301 25.0 3,325 562 25.0 141 
South Africa South 2 5,664,000 200,634 25.0 50,159 8,487 25.0 2,122 
Swaziland South 3 178,000 4,888 25.0 1,222 424 25.0 106 
Zambia South 3 2,750,000 132,848 25.0 33,212 5,702 25.0 1,426 
Zimbabwe South 2 2,505,000 97,432 25.0 24,358 4,572 25.0 1,143 
Benin West 3 1,739,000 83,873 25.0 20,968 5,859 25.0 1,465 
Burkina Faso West 3 3,161,000 138,710 25.0 34,678 7,657 25.0 1,914 
Guinea West 3 1,949,000 79,935 25.0 19,984 6,815 25.0 1,704 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
 systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 
 Sustainable Development Goals. Lancet 2016; 388: 3027-35 
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Cape Verde West 1 55,000 1,898 25.0 475 10,754 25.0 2,689 
Cote d'Ivoire West 3 3,765,000 75,899 25.0 18,975 13,515 25.0 3,379 
Gambia West 3 352,000 14,165 25.0 3,541 748 25.0 187 
Ghana West 3 4,023,000 123,352 25.0 30,838 6,179 25.0 1,545 
Guinea Bissau West 4 285,000 11,468 25.0 2,867 1,038 25.0 260 
Liberia West 3 705,000 23,094 25.0 5,774 1,807 25.0 452 
Mali West 3 3,274,000 153,660 25.0 38,415 11,138 25.0 2,785 
Niger West 3 4,066,000 198,793 25.0 49,698 16,132 25.0 4,033 
Nigeria West 3 31,109,000 1,500,575 25.0 375,144 141,912 25.0 35,478 
Senegal West 2 2,493,000 104,392 25.0 26,098 3,993 25.0 998 
Sierra Leone West 3 1,135,000 38,365 25.0 9,591 4,116 25.0 1,029 








1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
2 McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a 
 systematic analysis. Lancet Glob Health 2019; 7: e47-e57  
3 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the 
 Sustainable Development Goals. Lancet 2016; 388: 3027-35 
 
 













Guinea Bissau West 4 285,000 11,468 25.0 2,867 1,038 25.0 260 
Liberia West 3 705,000 23,094 25.0 5,774 1,807 25.0 452 
Mali West 3 3,274,000 153,660 25.0 38,415 11,138 25.0 2,785 
Niger West 3 4,066,000 198,793 25.0 49,698 16,132 25.0 4,033 
Nigeria West 3 31,109,000 1,500,575 25.0 375,144 141,912 25.0 35,478 
Senegal West 2 2,493,000 104,392 25.0 26,098 3,993 25.0 998 
Sierra Leone West 3 1,135,000 38,365 25.0 9,591 4,116 25.0 1,029 








a MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction 
b McAllister et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic 




























Burundi Central 3 1,853,000 85.1 1,577 0.16 252 
Cameroon Central 3 3,742,000 85.1 3,184 0.16 510 
Central African Republic Central 4 728,000 85.1 620 0.16 99 
Chad Central 4 2,601,000 85.1 2,213 0.16 354 
Congo Central 3 814,000 85.1 693 0.16 111 
Democratic Republic of Congo Central 3 14,099,000 85.1 11,998 0.16 1,920 
Equatorial Guinea Central 3 176,000 85.1 150 0.16 24 
Gabon Central 2 267,000 85.1 227 0.16 36 
Sao tome or Principe Central 2 31,000 85.1 26 0.16 4 
Comoros East 3 117,000 85.1 100 0.16 16 
Djibouti East 3 101,000 85.1 86 0.16 14 
Eritrea East 2 744,000 85.1 633 0.16 101 
Ethiopia East 2 14,901,000 85.1 12,681 0.16 2,029 
Kenya East 3 6,997,000 85.1 5,954 0.16 953 
Madagascar East 2 3,700,000 85.1 3,149 0.16 504 
Mauritius East 1 69,000 85.1 59 0.16 9 
Rwanda East 2 1,735,000 85.1 1,476 0.16 236 
Seychelles East 1 8,000 85.1 7 0.16 1 
Somali East 3 2,554,000 85.1 2,173 0.16 348 
South Sudan East 3 1,882,000 85.1 1,602 0.16 256 
Sudan East 3 5,859,000 85.1 4,986 0.16 798 
Tanzania East 2 9,419,000 85.1 8,016 0.16 1,282 
Uganda East 3 7,512,000 85.1 6,393 0.16 1,023 
Algeria North 2 4,664,000 85.1 3,969 0.16 635 
Egypt North 2 12,374,000 85.1 10,530 0.16 1,685 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 














Appendix 9: Number of cases of S. aureus meningitis by country in 2015 


































Libya North 1 630,000 85.1 536 0.16 86 
Mauritania North 3 640,000 85.1 545 0.16 87 
Morocco North 2 3,457,000 85.1 2,942 0.16 471 
Tunisia North 1 1,024,000 85.1 871 0.16 139 
Western Sahara North 2 55,000 85.1 47 0.16 7 
Angola South 4 5,158,000 171.9 8,867 0.16 1,419 
Botswana South 2 256,000 171.9 440 0.16 70 
Lesotho South 3 280,000 85.1 238 0.16 38 
Malawi South 3 2,888,000 85.1 2,458 0.16 393 
Mozambique South 3 4,844,000 171.9 8,327 0.16 1,332 
Namibia South 2 335,000 171.9 576 0.16 92 
South Africa South 2 5,664,000 171.9 9,736 0.16 1,558 
Swaziland South 3 178,000 85.1 151 0.16 24 
Zambia South 3 2,750,000 85.1 2,340 0.16 374 
Zimbabwe South 2 2,505,000 171.9 4,306 0.16 689 
Benin West 3 1,739,000 85.1 1,480 0.16 237 
Burkina Faso West 3 3,161,000 80 2,529 0.16 405 
Cape Verde West 1 55,000 85.1 47 0.16 7 
Cote d'Ivoire West 3 3,765,000 85.1 3,204 0.16 513 
Gambia West 3 352,000 85.1 300 0.16 48 
Ghana West 3 4,023,000 85.1 3,424 0.16 548 
Guinea West 3 1,949,000 85.1 1,659 0.16 265 
Guinea Bissau West 4 285,000 85.1 243 0.16 39 
Liberia West 3 705,000 85.1 600 0.16 96 
Mali West 3 3,274,000 76.8 2,514 0.16 402 
Niger West 3 4,066,000 85.1 3,460 0.16 554 
Nigeria West 3 31,109,000 85.1 26,474 0.16 4,236 
Senegal West 2 2,493,000 85.1 2,122 0.16 339 
Sierra Leone West 3 1,135,000 85.1 966 0.16 155 
Togo West 3 1,162,000 80 930 0.16 149 
All countries  186,884,000  174,831  27,973 
1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 













Libya North 1 630,000 85.1 536 0.16 86 
Mauritania North 3 640,000 85.1 545 0.16 87 
Morocco North 2 3,457,000 85.1 2,942 0.16 471 
Tunisia North 1 1,024,000 85.1 871 0.16 139 
Western Sahara North 2 55,000 85.1 47 0.16 7 
Angola South 4 5,158,000 171.9 8,867 0.16 1,419 

























































Burundi Central 3 63 37 252 159 93 24 90 38 84 122 
Cameroon Central 3 28 72 510 143 367 24 90 34 330 364 
Central African 
Republic 
Central 4 30 70 99 30 69 24 90 7 62 70 
Chad Central 4 26 74 354 92 262 24 90 22 236 258 
Congo Central 3 28 72 111 31 80 24 90 7 72 79 
Democratic 
Republic of Congo 
Central 3 42 58 1,920 806 1,113 24 90 194 1,002 1,196 
Equatorial Guinea Central 3 54 46 24 13 11 24 90 3 10 13 
Gabon Central 2 68 32 36 25 12 24 90 6 10 16 
Sao tome or 
Principe 
Central 2 69 31 4 3 1 24 90 1 1 2 
Comoros East 3 38 62 16 6 10 24 90 1 9 10 
Djibouti East 3 94 6 14 13 1 24 90 3 1 4 
Eritrea East 2 45 55 101 46 56 24 90 11 50 61 
Ethiopia East 2 30 70 2,029 609 1,420 24 90 146 1,278 1,424 
Kenya East 3 66 34 953 629 324 24 90 151 292 442 
Madagascar East 2 41 59 504 207 297 24 90 50 268 317 
Mauritius East 1 96 4 9 9 0 24 90 2 0 3 
Rwanda East 2 54 46 236 128 109 24 90 31 98 128 
Seychelles East 1 96 4 1 1 0 24 90 0 0 0 
Somali East 3 13 87 348 45 303 24 90 11 272 283 
South Sudan East 3 48 52 256 123 133 24 90 30 120 149 
1 MS=Mortality Stratum; CFR=Case Fatality Ratio (obtained from the literature) 
2 The proportion of children under the age of five years with pneumonia in the preceding two weeks and who had access to health used as proxy obtained from United Nations Children’s Fund 
(UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
 
 





































Burundi Central 3 63 37 252 159 93 24 90 38 84 122 
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Sudan East 3 48 52 798 383 415 24 90 92 373 465 
Tanzania East 2 55 45 1,282 705 577 24 90 169 519 689 
Uganda East 3 80 20 1,023 818 205 24 90 196 184 380 
Algeria North 2 66 34 635 419 216 24 90 101 194 295 
Egypt North 2 68 32 1,685 1,146 539 24 90 275 485 760 
Libya North 1 97 3 86 83 3 24 90 20 2 22 
Mauritania North 3 34 66 87 30 58 24 90 7 52 59 
Morocco North 2 22 78 471 104 367 24 90 25 330 355 
Tunisia North 1 60 40 139 84 56 24 90 20 50 70 
Western Sahara North 2 22 78 7 2 6 24 90 0 5 6 
Angola South 4 49 51 1,419 695 724 24 90 167 651 818 
Botswana South 2 14 86 70 10 61 24 90 2 54 57 
Lesotho South 3 63 37 38 24 14 24 90 6 13 18 
Malawi South 3 78 22 393 307 87 24 90 74 78 151 
Mozambique South 3 55 45 1,332 733 600 24 90 176 540 715 
Namibia South 2 72 28 92 66 26 24 90 16 23 39 
South Africa South 2 88 12 1,558 1,371 187 24 90 329 168 497 
Swaziland South 3 60 40 24 15 10 24 90 3 9 12 
Zambia South 3 70 30 374 262 112 24 90 63 101 164 
Zimbabwe South 2 51 49 689 351 338 24 90 84 304 388 
Benin West 3 23 77 237 54 182 24 90 13 164 177 
           1 MS=Mortality Stratum; CFR=Case Fatality Ratio (obtained from the literature) 
  2 The proportion of children under the age of five years with pneumonia in the preceding two weeks and who had access to health used as proxy obtained from United Nations Children’s Fund    































































































Burkina Faso West 3 52 48 405 210 194 24 90 50 175 225 
Cape Verde West 1 96 4 7 7 0 24 90 2 0 2 
Gambia West 3 68 32 48 33 15 24 90 8 14 22 
Ghana West 3 56 44 548 307 241 24 90 74 217 291 
Guinea West 3 37 63 265 98 167 24 90 24 150 174 
Guinea Bissau West 4 34 66 39 13 26 24 90 3 23 26 
Liberia West 3 51 49 96 49 47 24 90 12 42 54 
Mali West 3 23 77 402 93 310 24 90 22 279 301 
Niger West 3 59 41 554 327 227 24 90 78 204 283 
Nigeria West 3 35 65 4,236 1,483 2,753 24 90 356 2,478 2,834 
Senegal West 2 48 52 339 163 177 24 90 39 159 198 
Sierra Leone West 3 72 28 155 111 43 24 90 27 39 66 
Togo West 3 49 51 149 73 76 24 90 17 68 86 
All countries       27,973 13,938 14,035     3,345 12,632 15,977 
1 MS=Mortality Stratum; CFR=Case Fatality Ratio (obtained from the literature) 
2 The proportion of children under the age of five years with pneumonia in the preceding two weeks and who had access to health used as proxy obtained from United Nations Children’s Fund 
(UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
 
 





































Burkina Faso West 3 52 48 405 210 194 24 90 50 175 225 
Cape Verde West 1 96 4 7 7 0 24 90 2 0 2 
Gambia West 3 68 32 48 33 15 24 90 8 14 22 
Ghana West 3 56 44 548 307 241 24 90 74 217 291 
Guinea West 3 37 63 265 98 167 24 90 24 150 174 
Guinea Bissau West 4 34 66 39 13 26 24 90 3 23 26 
Liberia West 3 51 49 96 49 47 24 90 12 42 54 
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Burundi Central 3 1,853,000 85.1 1576.903 0.07 117 
Cameroon Central 3 3,742,000 85.1 3184.442 0.07 236 
Central African Republic Central 4 728,000 85.1 619.528 0.07 46 
Chad Central 4 2,601,000 85.1 2213.451 0.07 164 
Congo Central 3 814,000 85.1 692.714 0.07 51 
Democratic Republic of 
Congo 
Central 3 14,099,000 85.1 11998.25 0.07 888 
Equatorial Guinea Central 3 176,000 85.1 149.776 0.07 11 
Gabon Central 2 267,000 85.1 227.217 0.04 9 
Sao tome or Principe Central 2 31,000 85.1 26.381 0.04 1 
Comoros East 3 117,000 85.1 99.567 0.07 7 
Djibouti East 3 101,000 85.1 85.951 0.07 6 
Eritrea East 2 744,000 85.1 633.144 0.04 25 
Ethiopia East 2 14,901,000 85.1 12680.75 0.04 507 
Kenya East 3 6,997,000 85.1 5954.447 0.07 441 
Madagascar East 2 3,700,000 85.1 3148.7 0.04 126 
Mauritius East 1 69,000 85.1 58.719 0.04 2 
Rwanda East 2 1,735,000 85.1 1476.485 0.04 59 
Seychelles East 1 8,000 85.1 6.808 0.04 0 
Somali East 3 2,554,000 85.1 2173.454 0.07 161 
South Sudan East 3 1,882,000 85.1 1601.582 0.07 119 
Sudan East 3 5,859,000 85.1 4986.009 0.07 369 
                    1 MS=Mortality Stratum; Population=Population size; AF=Aetiology Fraction (obtained from the literature) 
                   2 Incidence rates of S. aureus disease are per 100,000 children (obtained from the literature) 
 
 










Burundi Central 3 1,853,000 85.1 1576.903 0.07 117 
Cameroon Central 3 3,742,000 85.1 3184.442 0.07 236 
Central African Republic Central 4 728,000 85.1 619.528 0.07 46 
Chad Central 4 2,601,000 85.1 2213.451 0.07 164 






























Tanzania East 2 9,419,000 85.1  8015.569 0.04 321 
Uganda East 3 7,512,000 85.1  6392.712 0.07 473 
Algeria North 2 4,664,000 85.1  3969.064 0.04 159 
Egypt North 2 12,374,000 85.1  10530.27 0.04 421 
Libya North 1 630,000 85.1  536.13 0.04 21 
Mauritania North 3 640,000 85.1  544.64 0.07 40 
Morocco North 2 3,457,000 85.1  2941.907 0.04 118 
Tunisia North 1 1,024,000 85.1  871.424 0.04 35 
Western Sahara North 2 55,000 85.1  46.805 0.04 2 
Angola South 4 5,158,000 171.9  8866.602 0.07 656 
Botswana South 2 256,000 171.9  440.064 0.04 18 
Lesotho South 3 280,000 85.1  238.28 0.07 18 
Malawi South 3 2,888,000 85.1  2457.688 0.07 182 
Mozambique South 3 4,844,000 171.9  8326.836 0.07 616 
Namibia South 2 335,000 171.9  575.865 0.04 23 
South Africa South 2 5,664,000 171.9  9736.416 0.04 389 
Swaziland South 3 178,000 85.1  151.478 0.07 11 
Zambia South 3 2,750,000 85.1  2340.25 0.07 173 
Zimbabwe South 2 2,505,000 171.9  4306.095 0.04 172 
Benin West 3 1,739,000 85.1  1479.889 0.07 110 
Burkina Faso West 3 3,161,000 80  2528.8 0.07 187 
    1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic fraction (obtained from the literature) 
     2 Incidence rates of S. aureus disease are per 100,000 children 
 
 










Tanzania East 2 9,419,000 85.1  8015.569 0.04 321 
Uganda East 3 7,512,000 85.1  6392.712 0.07 473 
Algeria North 2 4,664,000 85.1  3969.064 0.04 159 
Egypt North 2 12,374,000 85.1  10530.27 0.04 421 
Libya North 1 630,000 85.1  536.13 0.04 21 
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Cape Verde West 1 55,000 85.1 46.805 0.04 2 
Cote d'Ivoire West 3 3,765,000 85.1 3204.015 0.07 237 
Gambia West 3 352,000 85.1 299.552 0.07 22 
Ghana West 3 4,023,000 85.1 3423.573 0.07 253 
Guinea West 3 1,949,000 85.1 1658.599 0.07 123 
Guinea Bissau West 4 285,000 85.1 242.535 0.07 18 
Liberia West 3 705,000 85.1 599.955 0.07 44 
Mali West 3 3,274,000 76.8 2514.432 0.07 186 
Niger West 3 4,066,000 85.1 3460.166 0.07 256 
Nigeria West 3 31,109,000 85.1 26473.76 0.07 1,959 
Senegal West 2 2,493,000 85.1 2121.543 0.04 85 
Sierra Leone West 3 1,135,000 85.1 965.885 0.07 71 
Togo West 3 1,162,000 80 929.6 0.07 69 
All countries     186,884,000 5,183 174,831   10,816 
    1 MS=Mortality Stratum; Population=Population size; AF=Aetiologic Fraction (obtained from the literature) 
    2 Incidence rates of S. aureus disease are per 100,000 children (obtained from the literature) 
 
 










Cape Verde West 1 55,000 85.1 46.805 0.04 2 
Cote d'Ivoire West 3 3,765,000 85.1 3204.015 0.07 237 
Gambia West 3 352,000 85.1 299.552 0.07 22 
Ghana West 3 4,023,000 85.1 3423.573 0.07 253 
Guinea West 3 1,949,000 85.1 1658.599 0.07 123 
Guinea Bissau West 4 285,000 85.1 242.535 0.07 18 
Liberia West 3 705,000 85.1 599.955 0.07 44 
Mali West 3 3,274,000 76.8 2514.432 0.07 186 
Niger West 3 4,066,000 85.1 3460.166 0.07 256 
Nigeria West 3 31,109,000 85.1 26473.76 0.07 1,959 
Senegal West 2 2,493,000 85.1 2121.543 0.04 85 
Sierra Leone West 3 1,135,000 85.1 965.885 0.07 71 
























































Burundi Central 3 63 37 117 74 43 27 90 20 39 59 
Cameroon Central 3 28 72 236 66 170 27 90 18 153 171 
Central African 
Republic 
Central 4 30 70 46 14 32 27 90 4 29 33 
Chad Central 4 26 74 164 43 121 27 90 11 109 121 
Congo Central 3 28 72 51 14 37 27 90 4 33 37 
Democratic 
Republic of Congo 
Central 3 42 58 888 373 515 27 90 101 463 564 
Equatorial Guinea Central 3 54 46 11 6 5 27 90 2 5 6 
Gabon Central 2 68 32 9 6 3 27 90 2 3 4 
Sao tome or 
Principe 
Central 2 69 31 1 1 0 27 90 0 0 0 
Comoros East 3 38 62 7 3 5 27 90 1 4 5 
Djibouti East 3 94 6 6 6 0 27 90 2 0 2 
Eritrea East 2 45 55 25 11 14 27 90 3 13 16 
Ethiopia East 2 30 70 507 152 355 27 90 41 320 361 
Kenya East 3 66 34 441 291 150 27 90 79 135 213 
Madagascar East 2 41 59 126 52 74 27 90 14 67 81 
Mauritius East 1 96 4 2 2 0 27 90 1 0 1 
Rwanda East 2 54 46 59 32 27 27 90 9 24 33 
Seychelles East 1 96 4 0 0 0 27 90 0 0 0 
Somali East 3 13 87 161 21 140 27 90 6 126 132 
South Sudan East 3 48 52 119 57 62 27 90 15 55 71 
1 MS=Mortality Stratum; CFR=Case Fatality Ratio (obtained from the literature) 
2 The proportion of children under the age of five years with pneumonia in the preceding two weeks and who had access to health used as proxy obtained from United Nations Children’s 
Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
 




































Burundi Central 3 63 37 117 74 43 27 90 20 39 59 
Cameroon Central 3 28 72 236 66 170 27 90 18 153 171 
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Sudan East 3 48 52 369 177 192 27 90 48 173 220 
Tanzania East 2 55 45 321 176 144 27 90 48 130 177 
Uganda East 3 80 20 473 378 95 27 90 102 85 187 
Algeria North 2 66 34 159 105 54 27 90 28 49 77 
Egypt North 2 68 32 421 286 135 27 90 77 121 199 
Libya North 1 97 3 21 21 1 27 90 6 1 6 
Mauritania North 3 34 66 40 14 27 27 90 4 24 28 
Morocco North 2 22 78 118 26 92 27 90 7 83 90 
Tunisia North 1 60 40 35 21 14 27 90 6 13 18 
Western 
Sahara 
North 2 22 78 2 0 1 27 90 0 1 1 
Angola South 4 49 51 656 322 335 27 90 87 301 388 
Botswana South 2 14 86 18 2 15 27 90 1 14 14 
Lesotho South 3 63 37 18 11 7 27 90 3 6 9 
Malawi South 3 78 22 182 142 40 27 90 38 36 74 
Mozambique South 3 55 45 616 339 277 27 90 92 250 341 
Namibia South 2 72 28 23 17 6 27 90 4 6 10 
South Africa South 2 88 12 389 343 47 27 90 93 42 135 
Swaziland South 3 60 40 11 7 4 27 90 2 4 6 
Zambia South 3 70 30 173 121 52 27 90 33 47 79 
Zimbabwe South 2 51 49 172 88 84 27 90 24 76 100 
Benin West 3 23 77 110 25 84 27 90 7 76 83 
1 MS=Mortality Stratum; CFR=Case Fatality Ratio (obtained from the literature) 
2 The proportion of children under the age of five years with pneumonia in the preceding two weeks and who had access to health used as proxy obtained from United Nations Children’s 
Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
 
 

























































































Burkina Faso West 3 52 48 187 97 90 27 90 26 81 107 
Cape Verde West 1 96 4 2 2 0 27 90 0 0 1 
Cote d'Ivoire West 3 38 62 237 90 147 27 90 24 132 157 
Gambia West 3 68 32 22 15 7 27 90 4 6 10 
Ghana West 3 56 44 253 142 111 27 90 38 100 139 
Guinea West 3 37 63 123 45 77 27 90 12 70 82 
Guinea Bissau West 4 34 66 18 6 12 27 90 2 11 12 
Liberia West 3 51 49 44 23 22 27 90 6 20 26 
Mali West 3 23 77 186 43 143 27 90 12 129 140 
Niger West 3 59 41 256 151 105 27 90 41 94 135 
Nigeria West 3 35 65 1,959 686 1,273 27 90 185 1,146 1,331 
Senegal West 2 48 52 85 41 44 27 90 11 40 51 
Sierra Leone West 3 72 28 71 51 20 27 90 14 18 32 
Togo West 3 49 51 69 34 35 27 90 9 32 41 
All countries       10,254 5,270 5,546     1,423 4,992 6,415 
1 MS=Mortality Stratum; CFR=Case Fatality Ratio (obtained from the literature) 
2 The proportion of children under the age of five years with pneumonia in the preceding two weeks and who had access to health used as proxy obtained from United Nations Children’s 
Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
 
 




































Burkina Faso West 3 52 48 187 97 90 27 90 26 81 107 
Cape Verde West 1 96 4 2 2 0 27 90 0 0 1 
Cote d'Ivoire West 3 38 62 237 90 147 27 90 24 132 157 
Gambia West 3 68 32 22 15 7 27 90 4 6 10 
Ghana West 3 56 44 253 142 111 27 90 38 100 139 
Guinea West 3 37 63 123 45 77 27 90 12 70 82 
Guinea Bissau West 4 34 66 18 6 12 27 90 2 11 12 
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Appendix 10: Number of cases and deaths of S. aureus septicaemia by country in 2015                                                     



















Country Region MS1 Population 
Incidence 
Septicaemia2 SAB1 cases CFR1 
S. aureus 
deaths 
Burundi Central 3 1,853,000 126.7 2,348 9 211 
Cameroon Central 3 3,742,000 126.7 4,741 9 427 
Central African 
Republic 
Central 4 728,000 126.7 922 9 83 
Chad Central 4 2,601,000 126.7 3,295 9 297 
Congo Central 3 814,000 126.7 1,031 9 93 
Democratic Republic 
of Congo 
Central 3 14,099,000 126.7 17,863 9 1,608 
Equatorial Guinea Central 3 176,000 126.7 223 9 20 
Gabon Central 2 267,000 126.7 338 9 30 
Sao tome or Principe Central 2 31,000 126.7 39 9 4 
Comoros East 3 117,000 126.7 148 9 13 
Djibouti East 3 101,000 126.7 128 9 12 
Eritrea East 2 744,000 126.7 943 9 85 
Ethiopia East 2 14,901,000 126.7 18,880 9 1,699 
Kenya East 3 6,997,000 44.8 3,135 9 282 
Madagascar East 2 3,700,000 126.7 4,688 9 422 
Mauritius East 1 69,000 126.7 87 9 8 
Rwanda East 2 1,735,000 126.7 2,198 9 198 
Seychelles East 1 8,000 126.7 10 9 1 
Somali East 3 2,554,000 126.7 3,236 9 291 
South Sudan East 3 1,882,000 126.7 2,384 9 215 
Sudan East 3 5,859,000 126.7 7,423 9 668 
Tanzania East 2 9,419,000 126.7 11,934 9 1,074 
Uganda East 3 7,512,000 126.7 9,518 9 857 
Algeria North 2 4,664,000 126.7 5,909 9 532 
Egypt North 2 12,374,000 126.7 15,678 9 1,411 
Libya North 1 630,000 126.7 798 9 72 
 1 MS=Mortality stratum; CFR=Case fatality ratio (obtained from literature); SAB=S. aureus bacteraemia 
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Country Region MS1 Population 
Septicaemia 
Incidence2  SAB1 cases CFR1 
S. aureus 
deaths 
Mauritania North 3 640,000 126.7 811 9 73 
Morocco North 2 3,457,000 126.7 4,380 9 394 
Tunisia North 1 1,024,000 126.7 1,297 9 117 
Western Sahara North 2 55,000 126.7 70 9 6 
Angola South 4 5,158,000 126.7 6,535 9 588 
Botswana South 2 256,000 126.7 324 9 29 
Lesotho South 3 280,000 126.7 355 9 32 
Malawi South 3 2,888,000 126.7 3,659 9 329 
Mozambique South 3 4,844,000 118.3 5,730 6 344 
Namibia South 2 335,000 126.7 424 9 38 
South Africa South 2 5,664,000 126.7 7,176 9 646 
Swaziland South 3 178,000 126.7 226 9 20 
Zambia South 3 2,750,000 126.7 3,484 9 314 
Zimbabwe South 2 2,505,000 126.7 3,174 9 286 
Benin West 3 1,739,000 126.7 2,203 9 198 
Burkina Faso West 3 3,161,000 126.7 4,005 9 360 
Cape Verde West 1 55,000 126.7 70 9 6 
Cote d'Ivoire West 3 3,765,000 126.7 4,770 9 429 
Gambia West 3 352,000 78 275 14 38 
Ghana West 3 4,023,000 630.1 25,349 9 2,281 
Guinea West 3 1,949,000 126.7 2,469 9 222 
Guinea Bissau West 4 285,000 126.7 361 9 32 
Liberia West 3 705,000 126.7 893 9 80 
Mali West 3 3,274,000 126.7 4,148 9 373 
Niger West 3 4,066,000 126.7 5,152 9 464 
Nigeria West 3 31,109,000 126.7 39,415 9 3,547 
Senegal West 2 2,493,000 126.7 3,159 9 284 
Sierra Leone West 3 1,135,000 126.7 1,438 9 129 








  1 MS=Mortality stratum; CFR=Case fatality ratio (obtained from literature); SAB=S. aureus bacteraemia 





































Burundi Central 3 1,853,000 919.3 17034.629 47 8,006 9 721 
Cameroon Central 3 3,742,000 919.3 34400.206 47 16,168 9 1,455 
Central African 
Republic 
Central 4 728,000 919.3 6692.504 57 3,815 9 343 
Chad Central 4 2,601,000 919.3 23910.993 57 13,629 9 1,227 
Congo Central 3 814,000 919.3 7483.102 47 3,517 9 317 
Democratic 
Republic of Congo 
Central 3 14,099,000 919.3 129612.107 47 60,918 9 5,483 
Equatorial Guinea Central 3 176,000 919.3 1617.968 47 760 9 68 
Gabon Central 2 267,000 146 389.82 47 183 9 16 
Sao tome or 
Principe 
Central 2 31,000 146 45.26 47 21 9 2 
Comoros East 3 117,000 919.3 1075.581 47 506 9 45 
Djibouti East 3 101,000 919.3 928.493 47 436 9 39 
Eritrea East 2 744,000 146 1086.24 47 511 9 46 
Ethiopia East 2 14,901,000 146 21755.46 47 10,225 9 920 
Kenya East 3 6,997,000 764.4 53485.068 47 25,138 9 2,262 
Madagascar East 2 3,700,000 146 5402 47 2,539 9 229 
Mauritius East 1 69,000 146 100.74 47 47 9 4 
Rwanda East 2 1,735,000 146 2533.1 47 1,191 9 107 
Seychelles East 1 8,000 146 11.68 47 5 9 0 
Somali East 3 2,554,000 919.3 23478.922 47 11,035 9 993 
South Sudan East 3 1,882,000 919.3 17301.226 47 8,132 9 732 
Sudan East 3 5,859,000 919.3 53861.787 47 25,315 9 2,278 
Tanzania East 2 9,419,000 146 13751.74 47 6,463 9 582 
Uganda East 3 7,512,000 919.3 69057.816 42 29,004 9 2,610 
   1 MS=Mortality Stratum; AF=Aetiologic fraction (obtained from literature); CFR=Case fatality ratio 
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Algeria North 2 4,664,000 146 6809 47 3,200 9 288 
Egypt North 2 12,374,000 146 18066 47 8,491 9 764 
Libya North 1 630,000 146 920 47 432 9 39 
Mauritania North 3 640,000 919.3 5884 47 2,765 9 249 
Morocco North 2 3,457,000 146 5047 47 2,372 9 213 
Tunisia North 1 1,024,000 146 1495 47 703 9 63 
Western Sahara North 2 55,000 146 80 47 38 9 3 
Angola South 4 5,158,000 919.3 47418 57 27,028 9 2,433 
Botswana South 2 256,000 146 374 47 176 9 16 
Lesotho South 3 280,000 919.3 2574 47 1,210 9 109 
Malawi South 3 2,888,000 919.3 26549 47 12,478 9 1,123 
Mozambique South 3 4,844,000 782 37880 47 17,804 6 1,068 
Namibia South 2 335,000 146 489 47 230 9 21 
South Africa South 2 5,664,000 146 8269 47 3,887 9 350 
Swaziland South 3 178,000 919.3 1636 47 769 9 69 
Zambia South 3 2,750,000 919.3 25281 47 11,882 9 1,069 
Zimbabwe South 2 2,505,000 146 3657 47 1,719 9 155 
Benin West 3 1,739,000 919.3 15987 47 7,514 9 676 
Burkina Faso West 3 3,161,000 919.3 29059 47 13,658 9 1,229 
Cape Verde West 1 55,000 146 80 47 38 9 3 
Cote d'Ivoire West 3 3,765,000 919.3 34612 47 16,267 9 1,464 
 1 MS=Mortality Stratum; AF=Aetiologic fraction (obtained from the literature); CFR=Case fatality ratio (obtained from the literature) 


































Gambia West 3 352,000 634.9 2,235 47 1,050 14 147 
Ghana West 3 4,023,000 4686 188,518 47 88,603 9 7,974 
Guinea West 3 1,949,000 919.3 17,917 47 8,421 9 758 
Guinea Bissau West 4 285,000 919.3 2,620 57 1,493 9 134 
Liberia West 3 705,000 919.3 6,481 47 3,046 9 274 
Mali West 3 3,274,000 919.3 30,098 47 18 9 2 
Niger West 3 4,066,000 919.3 37,379 47 17,568 9 1,581 
Nigeria West 3 31,109,000 919.3 285,985 48 137,273 9 12,355 
Senegal West 2 2,493,000 146 3,640 47 1,711 9 154 
Sierra Leone West 3 1,135,000 919.3 10,434 47 4,904 9 441 










 1 MS=Mortality Stratum; AF=Aetiologic fraction (obtained from the literature); CFR=Case fatality ratio (obtained from the literature) 
 2 Incidence rates of S. aureus disease are per 100,000 children (obtained from the literature) 
 
Appendix 11: Number of cases and deaths of neonatal S. aureus septicaemia by country in 2015 (population-




























Burundi Central 3 847,000 1.26 1067.22 21 224 
Cameroon Central 3 167,000 1.26 210 21 44 
Central African Republic Central 4 164,000 1.26 207 21 43 
Chad Central 4 630,000 1.26 794 21 167 
Congo Central 3 3,217,000 1.26 4,053 21 851 
Democratic Republic of 
Congo 
Central 3 29,000 1.26 37 21 8 
Equatorial Guinea Central 3 266,820 1.26 336 21 71 
Gabon Central 2 51,000 1.26 64 33.3 21 
Sao tome or Principe Central 2 6,000 1.26 8 33.3 3 
Comoros East 3 26,000 1.26 33 21 7 
Djibouti East 3 22,000 1.26 28 21 6 
Eritrea East 2 175,000 1.26 221 33.3 73 
Ethiopia East 2 3,176,000 1.26 4,002 33.3 1,333 
Kenya East 3 1,571,000 0.44 691 21 145 
Madagascar East 2 831,000 1.26 1,047 33.3 349 
Mauritius East 1 14,000 1.26 18 33.3 6 
Rwanda East 2 363,000 1.26 457 33.3 152 
Seychelles East 1 2,000 1.26 3 33.3 1 
Somali East 3 471,000 1.26 593 21 125 
South Sudan East 3 446,000 1.26 562 21 118 
Sudan East 3 1,319,000 1.26 1,662 21 349 
1 MS=Mortality stratum; NN=Neonatal; NNS=Neonatal septicaemia; CFR=Case fatality ratio (obtained from the literature) 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 









NNSa cases CFRa 
S. aureus 
NNSa deaths 
Burundi Central 3 847,000 1.26 1067.22 21 224 
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Appendix 11: Number of cases and deaths of neonatal S. aureus septicaemia by country in 2015                                             



























Tanzania East 2 2,064,000 1.26 2,601 33.3 866 
Uganda East 3 1,665,000 1.26 2,098 21 441 
Algeria North 2 936,000 1.26 1,179 33.3 393 
Egypt North 2 2,488,000 1.26 3,135 33.3 1,044 
Libya North 1 129,000 1.26 163 33.3 54 
Mauritania North 3 134,000 1.26 169 21 35 
Morocco North 2 699,000 1.26 881 33.3 293 
Tunisia North 1 202,000 1.26 255 33.3 85 
Western Sahara North 2 478,898 1.26 603 33.3 201 
Angola South 4 1,128,000 1.26 1,421 21 298 
Botswana South 2 55,000 1.26 69 33.3 23 
Lesotho South 3 61,000 1.26 77 21 16 
Malawi South 3 665,000 1.26 838 21 176 
Mozambique South 3 1,087,000 1.26 1,370 21 288 
Namibia South 2 72,000 1.26 91 33.3 30 
South Africa South 2 1,111,000 1.26 1,400 33.3 466 
Swaziland South 3 38,000 1.26 48 21 10 
Zambia South 3 645,000 1.26 813 21 171 
Zimbabwe South 2 539,000 1.26 679 33.3 226 
Benin West 3 388,000 1.26 489 21 103 
Burkina Faso West 3 717,000 1.26 903 21 190 
Cape Verde West 1 11,000 1.26 14 33.3 5 
1 MS=Mortality stratum; NN=Neonatal; NNS=Neonatal septicaemia; CFR=Case fatality ratio (obtained from the literature) 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 












Appendix 11: Number of cases and deaths of neonatal S. aureus septicaemia by country in 2015 (population-

























NNS1 cases CFR1 
S. aureus 
NNS1 deaths 
Cote d'Ivoire West 3 838,000  1.26 1,056 21 222 
Gambia West 3 83,000  3.5 291 18 52 
Ghana West 3 884,000  1.26 1,114 21 234 
Guinea West 3 460,000  1.26 580 21 122 
Guinea Bissau West 4 68,000  1.26 86 21 18 
Liberia West 3 156,000  1.26 197 21 41 
Mali West 3 758,000  1.26 955 21 201 
Niger West 3 983,000  1.26 1,239 21 260 
Nigeria West 3 7,133,000  1.26 8,988 23 2,067 
Senegal West 2 567,000  1.26 714 33.3 238 
Sierra Leone West 3 229,000  1.26 289 21 61 
Togo West 3 256,000  1.26 323 21 68 
All countries  41,521,718   51,215  13,091 
1 MS=Mortality stratum; NN=Neonatal; NNS=Neonatal septicaemia; CFR=Case fatality ratio (obtained from the literature) 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
3 Incidence rates of S. aureus disease are per 1,000 live births (obtained from the literature) 
 
 





NNSa cases CFRa 
S. aureus 
NNSa deaths 
Cote d'Ivoire West 3 838,000  1.26 1,056 21 222 
Gambia West 3 83,000  3.5 291 18 52 
Ghana West 3 884,000  1.26 1,114 21 234 
Guinea West 3 460,000  1.26 580 21 122 
Guinea Bissau West 4 68,000  1.26 86 21 18 
Liberia West 3 156,000  1.26 197 21 41 
Mali West 3 758,000  1.26 955 21 201 
Niger West 3 983,000  1.26 1,239 21 260 
Nigeria West 3 7,133,000  1.26 8,988 23 2,067 
Senegal West 2 567,000  1.26 714 33.3 238 
Sierra Leone West 3 229,000  1.26 289 21 61 
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Burundi Central 3 266,820 7.1 1,894 45 852 21 179 
Cameroon Central 3 847,000 7.1 6,014 45 2,706 21 568 
Central African 
Republic 
Central 4 164,000 7.1 1,164 45 524 21 110 
Chad Central 4 630,000 7.1 4,473 45 2,013 21 423 
Congo Central 3 167,000 7.1 1,186 45 534 21 112 
Democratic 
Republic of Congo 
Central 3 3,217,000 7.1 22,841 45 10,278 21 2,158 
Equatorial Guinea Central 3 29,000 7.1 206 45 93 21 19 
Gabon Central 2 51,000 7.1 362 22 80 33.3 27 
Sao tome or 
Principe 
Central 2 6,000 7.1 43 22 9 33.3 3 
Comoros East 3 26,000 7.1 185 45 83 21 17 
Djibouti East 3 22,000 7.1 156 45 70 21 15 
Eritrea East 2 175,000 7.1 1,243 22 273 33.3 91 
Ethiopia East 2 3,176,000 7.1 22,550 22 4,961 33.3 1,652 
Kenya East 3 1,571,000 5.46 8,578 45 3,860 21 811 
Madagascar East 2 831,000 7.1 5,900 22 1,298 33.3 432 
Mauritius East 1 14,000 7.1 99 22 22 33.3 7 
Rwanda East 2 363,000 7.1 2,577 22 567 33.3 189 
Seychelles East 1 2,000 7.1 14 22 3 33.3 1 
Somali East 3 471,000 7.1 3,344 45 1,505 21 316 
1 MS=Mortality stratum; NN=Neonatal; NNS=Neonatal septicaemia; NN AF=Neonatal aetiological fraction (obtained from the literature); CFR=Case fatality ratio (obtained 
from the literature) 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
3 Incidence rates of S. aureus disease are per 1,000 live births (obtained from the literature) 
 
 














Burundi Central 3 266,820 7.1 1894.422 45 852 21 179 





































South Sudan East 3 446,000 7.1 3,167 45  1,425 21 299 
Sudan East 3 1,319,000 7.1 9,365 45  4,214 21 885 
Tanzania East 2 2,064,000 7.1 14,654 22  3,224 33.3 1,074 
Uganda East 3 1,665,000 7.1 118,212 52  6,147 21 1,291 
Algeria North 2 936,000 7.1 6,646 22  1,462 33.3 487 
Egypt North 2 2,488,000 7.1 17,665 22  3,886 33.3 1,294 
Libya North 1 129,000 7.1 916 22  201 33.3 67 
Mauritania North 3 134,000 7.1 951 45  428 21 90 
Morocco North 2 699,000 7.1 4,963 22  1,092 33.3 364 
Tunisia North 1 202,000 7.1 1,434 22  316 33.3 105 
Western Sahara North 2 478,898 7.1 3,400 22  748 33.3 249 
Angola South 4 1,128,000 7.1 8,009 45  3,604 21 757 
Botswana South 2 55,000 7.1 391 22  86 33.3 29 
Lesotho South 3 61,000 7.1 433 45  195 21 41 
Malawi South 3 665,000 7.1 4,722 45  2,125 21 446 
Mozambique South 3 1,087,000 7.1 7,718 45  3,473 21 729 
Namibia South 2 72,000 7.1 511 22  112 33.3 37 
South Africa South 2 1,111,000 7.1 7,888 22  1,735 33.3 578 
Swaziland South 3 38,000 7.1 270 45  121 21 25 
Zambia South 3 645,000 7.1 4,580 45  2,061 21 433 
Zimbabwe South 2 539,000 7.1 3,827 22  842 33.3 280 
Benin West 3 388,000 7.1 2,755 45  1,240 21 260 
1 MS=Mortality stratum; NN=Neonatal; NNS=Neonatal septicaemia; NN AF=Neonatal aetiological fraction (obtained from the literature); CFR=Case fatality ratio (obtained 
from the literature) 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 
3 Incidence rates of S. aureus disease are per 1,000 live births (obtained from the literature) 
 















Tanzania East 2 2,064,000 7.1 14654.4 22  3,224 33.3 1,074 
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Burkina Faso West 3 717,000 7.1 5,091 45 2,291 21 481  
Cape Verde West 1 11,000 7.1 78 22 17 33.3 6 
Cote d'Ivoire West 3 838,000 7.1 5,950 45 2,677 21 562 
Gambia West 3 83,000 9 747 45 336 18 61 
Ghana West 3 884,000 7.1 6,276 45 2,824 21 593 
Guinea West 3 460,000 7.1 3,266 45 1,470 21 309 
Guinea Bissau West 4 68,000 7.1 483 45 217 21 46 
Liberia West 3 156,000 7.1 1,108 45 498 21 105 
Mali West 3 758,000 7.1 5,382 45 2,422 21 509 
Niger West 3 983,000 7.1 6,979 45 3,141 21 660 
Nigeria West 3 7,133,000 7.1 50,644 40 20,258 23 4,659 
Senegal West 2 567,000 7.1 4,026 22 886 33.3 295 
Sierra Leone West 3 229,000 7.1 1,626 45 732 21 154 










1 MS=Mortality stratum; NN=Neonatal; NNS=Neonatal septicaemia; NN AF=Neonatal aetiological fraction (obtained from the literature); CFR=Case fatality ratio 
(obtained from the literature) 
2 United Nations Children’s Fund (UNICEF). The State of the World's Children New York, USA: Division of Communication, UNICEF, 2017. 

















Cape Verde West 1 11,000 7.1 78.1 22 17 33.3 6 
Cote d'Ivoire West 3 838,000 7.1 5949.8 45 2,677 21 562 
Gambia West 3 83,000 9 747 45 336 18 61 
Ghana West 3 884,000 7.1 6276.4 45 2,824 21 593 
Guinea West 3 460,000 7.1 3266 45 1,470 21 309 





















































Appendix 15: PARTICIPANT INFORMATION SHEET 
 
Version   1.0 Date 06 Aug 2016 
 
Study Title: Transmission of Staphylococcus aureus to neonates in rural Gambia 
SCC: 1510 Protocol: 
Transmission of Staphylococcus aureus to 
neonates in rural Gambia 
 
Sponsor & Funder: Medical Research Council Unit, The Gambia 
 
What is informed consent?  
You are invited to take part in a research study. Participating in a research study is not the same as 
getting regular medical care. The purpose of regular medical care is to improve one’s health. The 
purpose of a research study is to gather information. It is your choice to take part and you can stop 
any time. 
Before you decide you need to understand all information about this study and what it will involve. 
Please take time to read the following information or get the information explained to you in your 
language. Listen carefully and feel free to ask if there is anything that you do not understand. Ask for 
it to be explained until you are satisfied. You may also wish to consult your spouse, family members 
or others before deciding to take part in the study. 
 
If you decide to join the study, you will need to sign or thumbprint a consent form saying you agree 
to be in the study.  
 
Why is this study being done?  
A leading cause of death of newborns in Gambia is severe infection. Studies have shown the bacteria 
Staphylococcus aureus is the major cause of these infections. S. aureus infections are difficult to treat, 
and children often stay in hospital some time. The S. aureus bacteria inhabits the nose, umbilicus, 
hands and groin of children and adults, from where it is spreads to other parts of the body to cause 
disease. How do these newborn babies get to carry the bugs? Babies are free of this and other 
organisms at birth but quickly acquire this organism within hours of delivery. It is thought that they 
get it from the birth canal during delivery, the person who conducts delivery, equipment used 
during delivery or from other family members. We do not know which of these is the most 
important source of S. aureus being spread to newborns. This study plans to find out the main 
source of S. aureus being spread to newborns. If we know how the babies get this bug, then we can 
plan to block the route through which they get it and therefore reduce infections due to this bug. 
 
The results of the study will be made available to you. 
 
What does this study involve? 
To take part in this study, one of our field staff will approach and tell you the details of the study. If 
you agree to take part in the study, you will be asked to sign/thumbprint the consent form in the 
presence of a witness who will also sign the same form. When you are in labour, the nurse will 
insert a soft cotton swab into your vagina (vagina swab) and another one into your nose (nasal 
swab) for a few seconds and remove. Nasal swabs will also be taken from your baby, one the other 
caregiver of your baby and two of the under-five children in your house at birth. One week after 
birth, nasal swabs will be taken from your baby. The field staff will ask you questions about you and 
your child(ren) and s/he will document your answers in a questionnaire. To take the nasal swabs 
the field staff will insert a soft cotton swab into your or your child/ward’s nose for a few seconds 
and then remove. To take vaginal swab, the nurse will insert a soft cotton swab into your vagina, 
rotate and remove. Thereafter, the swab will be put in a small container with liquid and taken to the 
MRC   laboratory for testing. 
 
In case the investigator discovers you or your child(ren) is(are) sick and decides that you or your 
child(ren) cannot participate in the study because of that,  you or your child(ren) will be sent to the 
appropriate health facility to receive immediate care. 
 
If the research study needs to be stopped, you will be informed, and you and your child will have the 
normal medical care. 
 
What will happen to the samples taken in this study? 
All swabs taken will be transported to the MRC laboratory where they will be processed. Some of 
bacteria we get from the swabs will be sent to the United Kingdom for further tests which cannot be 
done here in MRC. 
 
What harm or discomfort can you expect in the study? 
This process should not cause you or your child(ren) any harm but you will experience some 
temporary discomfort when the swab is inserted into the nose.  
 
What benefits can you expect in the study?  
Although there may be no direct benefit to the child but result of the study may help us plan ways of 
reducing the transmission and carriage of the organism by newborns. Also, all newborns will be 
examined during each home visit and if any sign of illness is noticed the baby will be referred to the 
clinic if required.  
 
Will you be compensated for participating in the study? 
You will not get paid for participation, but you will get either transport by MRC or get the costs for 
the transport reimbursed.  
 
What happens if you refuse to participate in the study or change your mind 
later? 
You are free to participate or not in the study and you have the right to stop participating at any 
time without giving a reason. This will not affect the medical care that you would normally receive.  
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In case you decide to withdraw your participation during the study, any information already 
generated from the samples until the time of withdrawal will be used and samples already collected, 
for which you have given consent, will also be analysed and data used. The study doctor may also 
ask for tests for your safety.  
Should any new information become available during the study that may affect your participation, 
you will be informed as soon as possible. 
 
If you are injured in the study what compensation will be available?  
We will be responsible to provide for treatment caused by procedures of the research study.  
If medical treatment is required as an emergency, please refer to your health centre or clinic and 
contact the field worker who gave his/her telephone number to you or contact Dr Aderonke 
Odutola on 5668751 Ext 130 or Demba Njie 7628945.  
 
How will personal records remain confidential and who will have access to it? 
All information that is collected about you in the course of the study will be kept strictly 
confidential. Your personal information will only be available to the study team members and might 
be seen by some rightful persons from the Ethics Committee, Government authorities and sponsor. 
 
Who should you contact if you have questions? 
If you have any queries or concerns, you can contact Dr Aderonke Odutola on 5668751 Ext 130 or 
Demba Njie 7628945 and you can always call the personal numbers of the study staff given to you.  
Please feel free to ask any question you might have about the research study. 
 
Who has reviewed this study?  
This study has been reviewed and approved by a panel of scientists at the Medical Research Council 
and the Gambia Government/MRC Joint Ethics Committee, which consists of scientists and lay 
persons to protect your rights and wellbeing. 
CONSENT FORM 
Participant Identification Number: |__|__|__|__|__|__|__|__|__|__|__|__| 
  
 (Printed name of participant) 
 I have read the written information OR 
 I have had the information explained to me by study personnel in a language that I 
understand, 
and I 
• confirm that my choice to participate is entirely voluntarily, 
• confirm that I have had the opportunity to ask questions about this study and I am 
satisfied with the answers and explanations that have been provided, 
• understand that I grant access to data about me to authorised persons described in 
the information sheet, 
• have received sufficient time to consider taking part in this study,  
• agree to take part in this study.  
 
Tick as appropriate 
I agree for my samples to be shipped outside of 
The Gambia  
 
          Yes        No  
I agree to further research on my samples as described  
in the information sheet 




    
   Date (dd/mmm/yyyy)
 
Time (24hr) 
    
Printed name of witness*  
 
Printed name of person 
obtaining consent  
I attest that I have explained the study information accurately in 
______________________ to and was understood to the best of my knowledge by, the 
participant. He/she has freely given consent to participate *in the presence of the 
above-named witness (where applicable).  
Signature of person 
obtaining consent    
   Date (dd/mmm/yyyy)
 
Time (24hr) 





Appendix 16: Supplemental tables for Chapter 4 


























Characteristics n (%) 
Age group in years  
       17-24 64 (28.2) 
       25-30 109 (48.0) 
       >31 54 (23.8) 
  
Ethnic group   
       Sarahule 105 (46.3) 
       Fula 57 (25.1) 
       Othersa 65 (28.6) 
 
 
Educational level  
       None 80 (35.2) 
       Arabic school 94 (41.4) 
       Primary and above 53 (23.4) 
  
Occupation  
       Unemployed 200 (88.1) 
       Employedb 27 (11.9) 
  
Marital status  
       Married 227 (100.0) 
  
Number of newborn’s siblings   
       0-3 101 (44.5) 
       4-5 87 (38.3) 
       >5 39 (17.2) 
  
Hospitalised in the past six months  
       Yes 12 (5.3) 
  
Antibiotic use within the previous six months  
       Yes 12 (5.3) 
       No 205 (90.3) 
       Unsure 10 (4.4) 
  
Smoking status  
       Yes 2 (0.9) 
  
Nose picking  
       Yes 121 (53.3) 
  
Current skin disease, e.g. dermatitis or skin 
ulcers  
 
       Yes 10 (4.4) 
  
Daily contact with animals  
       Yes 147 (64.8) 
a Other ethnic groups include Mandinka, Wollof, Jola 
b Teacher, farmer, childcare attendant, accountant 
 
 
Characteristics n (%) 
Age group in years  
       17-24 64 (28.2) 
       25-30 109 (48.0) 



















Characteristics n (%) 
Mode of delivery  
       Vaginal delivery 227 (100.0) 
  
Rupture of membranes ≥18 hours  
       Yes 0 (0.0) 
  
History of dysuria or UTI1 one week before delivery  
       Yes 12 (5.3) 
  
History of vaginal discharge one week before 
delivery 
 
       Yes 12 (5.3) 
  
History of vaginal bleeding one week before delivery  
       Yes 14 (6.2) 
  
Peri-partum fever within one week of delivery  
       Yes 95 (41.9) 
  
Foul-smelling liquor  
        Yes 35 (15.4) 
  
Place of delivery  
       Home 41 (18.1) 
       Health Centre 186 (81.9) 
  
Health care talk on cord care  
       Yes 90 (39.7) 
  
Admitted during this pregnancy  
       Yes 14 (6.2) 
  
Nurse/TBA1 washed hands before taking delivery  
       Yes 198 (87.2) 
       No 11 (4.9) 
       Don’t know 18 (7.9) 
  
Nurse/TBA wore gloves before taking delivery  
       Yes 203 (89.4) 
       No 21 (9.3) 
       Don’t know 3 (1.3) 
1 UTI=Urinary tract infection; TBA=traditional birth attendant 
 
 
Characteristics n (%) 
Mode of delivery  
       Vaginal delivery 227 (100.0) 
  
Rupture of membranes ≥18 hours  
       Yes 0 (0.0) 
  
History of dysuria or UTIa one week before delivery  
       Yes 12 (5.3) 
  
History of vaginal discharge one week before 
delivery 
 
       Yes 12 (5.3) 
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Travelled in the previous two weeks    
      No 31/41 (75.6) 142/186 (76.3)  
      Yes 10/41 (24.4) 44/186 (23.7) 0.92 
    
Nose picking    
      No 11/41 (35.7) 71/186 (38.2)  
      Yes 30/41 (64.3) 115/186 (61.8) 0.18 
    
Hands washed before delivery     
     No 5/41 (12.2) 5/186 (2.7)  
     Yes 36/41 (87.8) 181/186 (97.3) 0.01 
    
Current episode of cough or cold    
      No 26/41 (36.6) 139/186 (74.7)  
      Yes 15/41 (63.4) 47/186 (25.3) 0.15 
    
Current skin lesion    
      No 41/41 (100.0) 185/186 (99.5)  
      Yes 0/41 (0.0) 1/186 (0.5) - 
    
Antibiotic use in the past six months     
       No 35/41 (85.3) 132/186 (71.0)  
      Yes 6/41 (14.7) 54/186 (29.0) 0.07 
1 Logistic regression with robust standard error was used to determine the p-value. Clustering was by 








Travelled in the previous two weeks    
      No 31/41 (75.6) 142/186 (76.3)  
      Yes 10/41 (24.4) 44/186 (23.7) 0.92 
    
Nose picking    
      No 11/41 (35.7) 71/186 (38.2)  
      Yes 30/41 (64.3) 115/186 (61.8) 0.18 
    
Hands washed before delivery     
     No 5/41 (12.2) 5/186 (2.7)  
     Yes 36/41 (87.8) 181/186 (97.3) 0.01 
    
Current episode of cough or cold    
      No 26/41 (36.6) 139/186 (74.7)  
      Yes 15/41 (63.4) 47/186 (25.3) 0.15 











 Characteristics n/N (%)1  
Age (months)   
       Median (IQR) 2 38 (29, 50)  
   
Sex   
       Male 233/438 (53.2)  
   
Bed shared with newborn   
       Yes 32/434 (7.4)  
   
Cough or cold since day 0 visit   
       Yes 54/434 (12.4)  
   
Antibiotic use since day 0 visit   
       Yes 10/434 (2.3)  
1 Data for 18 children were missing  




 Characteristics n/N (%)a  
Age (months)   
       Median (IQR) b 38 (29, 50)  
   
Sex   
       Male 233/438 (53.2)  
   
Bed shared with newborn   
       Yes 32/434 (7.4)  
   
Cough or cold since day 0 visit   
       Yes 54/434 (12.4)  
   
Antibiotic use since day 0 visit   
       Yes 10/434 (2.3)  
a Data for 18 children were missing  






























Characteristics n/N (%) 
Age (years)  
        Median (IQR) 1 54.5 (44, 65) 
  
Sex  
       Female 208/219 (95.0) 
  
Ethnic group  
       Sarahule 94/213 (44.1) 
       Fula 57/213 (26.8) 
       Others 2 62/213 (29.1) 
  
Residence  
        Same house as newborn 124/212 (58.5) 
       Another house 88/212 (41.5) 
  
Bed shared with newborn  
       Yes 8/212 (3.8) 
  
Cough or cold since day 0 visit  
       Yes 29/212 (13.7) 
  
Antibiotic use since day 0 visit  
       Yes 7/212 (3.3) 
1 IQR=Interquartile range 















































History of dysuria or UTI1 one week 
before delivery 
    
          No 20/215 (9.3) 1  1  
          Yes 2/12 (16.7) 1.95 (0.40 – 9.53) 0.44 1.78 (0.34 – 9.22) 0.51 
      
History of vaginal discharge one week 
before delivery 
    
          No 1/12 (8.3) 1  1  
          Yes 21/215 (9.8) 0.84 (0.10 – 6.83) 0.87 0.79 (0.10 – 6.57) 0.82 
      
History of vaginal bleeding one week 
before delivery 
    
          No 21/213 (9.9) 1  1  
          Yes 1/14 (7.1) 0.70 (0.09 – 5.65) 0.73 0.77 (0.09 – 6.32) 0.80 
      
Peri-partum fever within one week of 
delivery 
    
          No 9/132 (6.8) 1  1  
          Yes 13/95 (13.7) 2.17 (0.89 – 5.30) 0.09 2.26 (0.91 – 5.61) 0.08 
      
Foul-smelling liquor      
          No 17/192 (8.9) 1  1  
          Yes 5/35 (14.3) 1.72 (0.59 – 5.00) 0.34 1.54 (0.51 – 4.71) 0.46 
      
Place of delivery      
          Home 5/41 (12.2) 1  1  
          Health Centre 17/186 (9.1) 0.72 (0.25 – 2.09) 0.56 0.78 (0.26 – 2.31) 0.66 
      
Health care talk on cord 
care 
     
          No 11/137 (8.0) 1  1  
          Yes 11/90 (12.2) 1.60 (0.66 – 3.85) 0.30 1.82 (0.72 – 4.60) 0.21 
      
Admitted during this 
pregnancy 
     
          No 22/213 
(10.3) 
- - - - 
          Yes 0/14 (0.0)     
      
Nurse/TBA1 washed hands before taking 
delivery 
    
          No 3/11 (27.3) 1  1  
          Yes 18/198 (9.1) 0.27 (0.06 – 1.10)  0.34 (0.05 – 1.04)  
          Don’t know 1/18 (5.6) 0.16 (0.01 – 1.75) 0.20 0.13 (0.01 – 1.56) 0.16 
      
Nurse/TBA wore gloves before taking 
delivery 
    
          No 4/21 (19.1) 1  1  
          Yes 17/203 (8.4) 0.39 (0.12 – 1.29)  1.72 (0.52 – 5.63)  
          Don’t know 1/3 (33.3) 2.13 (0.15 – 29.7) 0.19 1.87 (0.59 – 5.92) 0.21 

















Age group in years      
       17-24 48/64 (75.0) 1  1  
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Supplemental Table 4.7: Maternal demographic factors associated with S. aureus carriage acquisition in 










































Age group in years      
       17-24 48/64 (75.0) 1  1  
       25-30 74/109 (67.9) 0.71 (0.35 – 1.41)  0.70 (0.33 – 1.39)  
       >31 41/54 (75.9) 1.05 (0.45 – 2.44) 0.45 1.09 (0.42 – 2.44) 0.42 
      
Ethnic group       
       Sarahule 77/105 (73.3) 1  1  
       Fula 40/57 (70.2) 0.86 (0.42 – 1.75)  0.90 (0.44 – 2.17)  
       Others2 46/65 (70.8) 0.88 (0.44 – 1.75) 0.89 0.84 (0.46 – 2.09) 0.96 
      
Educational level      
       None 52/80 (65.0) 1  1  
       Arabic school 71/94 (75.5) 1.66 (0.86 – 3.21)  1.67 (0.81 – 3.35)  
       Primary and above 40/53 (75.5) 1.66 (0.76 – 3.60) 0.25 1.74 (0.71 – 3.64) 0.25 
      
Occupation      
       Unemployed 143/200 (71.5) 1  1  
       Employed3 20/27 (74.1) 1.14 (0.46 – 2.84) 0.78 0.98 (0.43 – 3.17) 0.98 
      
Number of children excluding 
newborn 
    
       0-3 79/101 (78.2) 1  1  
      4-5 55/87 (63.2) 0.48 (0.25 – 0.91)  0.45 (0.20 – 1.02)  
       >5 29/39 (74.4) 0.81 (0.34 – 1.91) 0.07 0.67 (0.22 – 2.06) 0.13 
      
Hospitalised in the past six months     
       No 154/215 (71.6) 1  1  
       Yes 9/12 (75.0) 1.19 (0.31 – 4.54) 0.80 1.22 (0.31 – 4.75) 0.78 
      
Antibiotic use within the previous six 
months 
    
       Yes 146/205 (71.2) 1  1  
       No 9/12 (75.0) 1.21 (0.32 – 4.64)  1.18 (0.30 – 4.66)  
       Unsure 8/10 (80.0) 1.62 (0.33 – 7.84) 0.80 1.64 (0.33 – 8.14) 0.81 
      
Nose picking      
       No 76/106 (71.7) 1  1  
       Yes 87/121 (71.9) 1.01 (0.57 – 1.80) 0.97 1.06 (0.59 – 1.92) 0.85 
      
Current skin disease      
       No 156/217 (71.9) 1  1  
       Yes 7/10 (70.0) 0.91 (0.23 – 3.64) 0.90 0.97 (0.24 – 3.97) 0.97 
      
Daily contact with animals     
       No 62/80 (77.5) 1  1  
       Yes 101/147 (68.7) 0.64 (0.34 – 1.20) 0.16 0.65 (0.34 – 1.25) 0.19 
1 Adjusted for maternal age, maternal educational status, and ethnicity 
2 Other ethnic groups include Mandinka, Wollof, Jola 








Supplemental Table 4.8: Characteristics of household children potentially associated with S. 





























Bed shared with newborn     
          No 144/195 (73.9) 1  1  
          Yes 18/29 (62.1) 0.58 (0.26 – 1.31) 0.20 0.57 (0.25 – 1.32) 0.20 
      
Cough or cold since 
the last visit 
     
          No 126/179 (70.4) 1  1  
          Yes 36/45 (80.0) 1.68 (0.76 – 3.74) 0.19 1.67 (0.73 – 3.81) 0.21 
      
Antibiotic use since 
the last visit 
     
          No 154/215 (71.6) 1  1  
          Yes 8/9 (88.9) 3.17 (0.39 – 25.90) 0.22 3.23 (0.39 – 27.04) 0.22 


















Bed shared with newborn     
          No 144/195 (73.9) 1  1  
          Yes 18/29 (62.1) 0.58 (0.26 – 1.31) 0.20 0.57 (0.25 – 1.32) 0.20 
      
Cough or cold since 
the last visit 
     
          No 126/179 (70.4) 1  1  
          Yes 36/45 (80.0) 1.68 (0.76 – 3.74) 0.19 1.67 (0.73 – 3.81) 0.21 
      
Antibiotic use since 
the last visit 
     
          No 154/215 (71.6) 1  1  
          Yes 8/9 (88.9) 3.17 (0.39 – 25.90) 0.22 3.23 (0.39 – 27.04) 0.22 
a Adjusted for maternal age, maternal educational status, and ethnicity 
 
 
